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Abstract 
Osteoarthritis (OA) is a debilitating joint disease that increases in prevalence with age. As a result of 
the ageing population, the latest figures show that almost four million Australians are affected by 
arthritis, with around 60% of these suffering from OA. There are currently no disease-modifying 
drugs available for OA and the majority of patients are not satisfied with their disease management. 
As a result of the poor management options the number of joint replacement surgeries, the majority 
being done for OA, is increasing by nearly 10% per annum in Australia. The clinical features of OA are 
pain and loss of joint function, due to the gradual degeneration of joint tissues. Of these, cartilage is 
the most widely studied as the most serious degradation manifests in the cartilage, particularly in 
weight-bearing areas. Cartilage acts as a smooth, low-friction articulating surface in the joint with 
significant compressive properties. These properties are largely due to the extracellular matrix 
(ECM), comprised mainly of collagen type II and proteoglycans, which surrounds and protects 
chondrocytes, the sole cell type in cartilage. Chondrocytes are responsible for maintenance of the 
ECM; in OA, chondrocytes shift to a catabolic state, producing increased numbers of the enzymes 
(MMPs and ADAMTS) that degrade collagen and proteoglycans. 
 
S100A8 and S100A9 calcium-binding proteins are expressed by immune cells and are involved in 
inflammatory situations, where they act as danger signals, attracting more cells to the site. They are 
present in the body preferentially as a heterodimer (S100A8/S100A9) or less commonly as 
homodimers. S100A8 and S100A9 are also heavily involved in inflammatory diseases such as 
rheumatoid arthritis, where there is an increase in circulating and local (synovial fluid) levels of 
S100A8 and S100A9. Recently, S100A8 and S100A9 have been found in bone and cartilage cells, 
however their roles in these tissues are still unknown. S100A8 and S100A9 can be up-regulated by 
inflammatory stimuli such as Interleukin-1 (IL-1) in mouse femoral head cultures and chondrocyte 
cultures. Chondrocyte cultures stimulated with S100A8 or S100A9 up-regulate catabolic enzymes, 
suggesting they may be involved in cartilage degradation. In addition to this, S100A8 and S100A9 
mRNA was found to be up-regulated at early time points after surgically-induced OA in mice, further 
suggesting a role in OA. The possible role of S100A8 and S100A9 in cartilage and OA has not yet been 
determined. The aim of this research therefore is to determine the role(s) of S100A8 and S100A9 in 
cartilage degeneration and OA. 
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This study showed that stimulation of cartilage explants with S100A8 or S100A9 (but not the 
heterodimer) shifted the chondrocytes to a catabolic gene expression profile, however, this did not 
translate into enzyme activation, and therefore there was no biochemical breakdown of the 
cartilage. This study also showed that biochemical breakdown could be achieved when cartilage was 
co-treated with S100A8 or S100A9 and IL-1, co-cultured with synovium, or when human OA cartilage 
was stimulated with S100A8 or S100A9. 
 
An in vitro model of cartilage degeneration was utilised with healthy full-thickness cartilage explants 
from normal ovine knee joints using IL-1α as a positive control for biochemical degradation. Cartilage 
explants were treated with S100A8, S100A9 or the heterodimer, and analysed for gene expression 
changes, enzyme activation and biochemical matrix degradation. Stimulation with S100A8 or S100A9 
homodimers, in agreement with chondrocyte monolayer studies, led to up-regulation of MMPs and 
ADAMTS and down-regulation of ECM components aggrecan and collagen type II with no change in 
TIMPs, the endogenous inhibitors of MMPs. A novel positive feedback loop was also identified, with 
S100A9 mRNA up-regulated by both S100A8 and S100A9 stimulation. S100A8 and S100A9 were not 
capable of activating MMP-2, MMP-9 or MMP-13, and as a consequence, were not capable of 
inducing ECM breakdown, as evidenced by a lack of aggrecan or collagen release. This was found to 
be the case regardless of treatment time, with cultures up to 14 days showing no cartilage 
breakdown compared to non-treated controls. Further studies into the mechanisms of action of 
S100A8 and S100A9 in cartilage explants were performed by the addition of synthetic small-
molecule inhibitors to the explant cultures to determine which signalling pathways were being 
activated. Addition of MAPK inhibitors to cartilage explant cultures were able to block all of the gene 
expression changes induced by S100A8 and S100A9, suggesting that multiple MAPK pathways (ERK, 
p38) were being activated. Addition of TLR4 inhibitors to cartilage explant cultures were also able to 
block up-regulation of MMPs and ADAMTS, suggesting that S100A8 and/or S100A9 may be binding 
to TLR4, a known binding partner of S100A8/A9 in immunity. 
 
We hypothesised that S100A8 and S100A9 were priming the cartilage towards degradation, and that 
a second messenger (or co-stimulus) was required to act synergistically with S100A8 and S100A9 to 
cause biochemical breakdown of the cartilage. To explore this hypothesis, a number of methods 
were utilised: co-treatment of S100A8 or S100A9 with IL-1α; S100A8 or S100A9 stimulation of 
cartilage and synovium co-cultures; and S100A8 or S100A9 stimulation of human OA cartilage. The 
xiv 
 
results showed that whilst cartilage breakdown was achieved when cartilage was co-treated with 
S100A8 or S100A9 and IL-1α, there was no significant difference compared to cultures treated with 
IL-1α alone, suggesting that IL-1α was the instigator of cartilage breakdown. Similarly, the addition of 
synovium to cartilage cultures had a catabolic effect on the cartilage, however this was enhanced in 
the presence of S100A9, suggesting that S100A9 was working synergistically with the synovium. 
Stimulation of human OA cartilage explants with S100A8 or S100A9 had a similar effect compared to 
healthy ovine cartilage; however, there was evidence of MMP activation and biochemical cartilage 
breakdown in S100A9-treated cultures, presumably due to pre-existing degeneration, which again 
suggests a synergistic effect.    
 
In order to more clearly define the role of S100A8 and S100A9 in OA, expression of these proteins 
was determined in human OA cartilage, a surgically-induced mouse model of OA and a spontaneous 
genetic mouse model of OA. In human OA joints from 18 patients, almost all chondrocytes stained 
positive for S100A8 but not S100A9, and abundant S100A8 staining was observed at joint margins, 
areas of invading pannus and in osteophyte formation, with sporadic cells in these areas also 
staining positive for S100A9. In contrast, S100A8 and S100A9 did not appear to be heavily involved in 
murine OA. Mice that had undergone surgically-induced OA showed positive staining for S100A8 in 
chondrocytes only at one day after surgery, with no positive staining for S100A8 or S100A9 seen at 
any other time in the 12 weeks post-surgery. Similarly, in a spontaneous model of OA (Coll11a1+/- 
mice), no S100A8 or S100A9 staining was observed in wild type or Coll11a1+/- mice at three months 
of age, with weak S100A8 staining observed in chondrocytes of both genotypes at nine months of 
age, together suggesting that S100A8 and S100A9 may not play a role in non-inflammatory murine 
OA. 
 
Finally, this study sought to determine if S100A8 and S100A9 played a role in chondrogenesis, due to 
the abundant staining observed in osteophytes in human OA cartilage. Levels of S100A8 and S100A9 
were first determined in mesenchymal stem cells (MSCs) derived from the bone marrow of OA 
patients, and during osteogenic, chondrogenic and adipogenic differentiation of these cells. 
Expression of S100A9 decreased during all three differentiation processes, however, S100A8 
significantly increased during chondrogenic differentiation. We therefore stimulated chondrogenic 
MSC pellet cultures with S100A8 and S100A9, and found that there was significant variation in 
patient response to S100A8: in one patient chondrogenesis was decreased in response to S100A8 
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treatment, whereas two patients showed no differences in chondrogenic potential between non-
treated and S100A8-treated cultures.    
 
These results have provided insight into the role(s) of S100A8 and S100A9 in cartilage and in OA. 
S100A8 and S100A9 act as primers of cartilage degradation, through TLR4 and MAPK signalling 
pathways, but require a second messenger in order to achieve full biochemical breakdown. S100A8 
is abundant in chondrocytes of human OA joints, but does not appear to be involved in non-
inflammatory mouse models. S100A8, and to a lesser degree S100A9, are also abundant at joint 
margins and in osteophytes from human OA patients, and may play a role in chondrogenesis. The 
results presented in this thesis have determined some of the mechanisms of action of S100A8 and 
S100A9 in cartilage, however, the exact role of S100A8 and S100A9 in OA remain unclear, and 
further work will need to be performed to fully determine the significance of S100A8 and S100A9 in 
OA. 
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Chapter 1  Literature Review 
1.1 Cartilage Biology 
1.1.1  Introduction 
The skeleton provides a locomotive system for the body, protecting soft tissue, allowing complex 
movement and acting as a reservoir for mineral storage [1]. The complex movements facilitated by 
the skeleton requires articulations (joints), whose normal function requires a specialised tissue 
(cartilage) to line the two articulating bones. Cartilage is found in a variety of anatomical sites in 
mature animals, including the trachea, nasal septum, and joints [2]. Appendicular joints such as the 
knee and hip are synarthroses or synovial joints, with the knee shown as an example in Figure 1.1. 
 
Figure 1.1: A typical synovial joint, the knee joint (adapted from [3]) 
The synovial joint is made up of multiple tissue types, including articular cartilage, bone, meniscus, 
tendons and ligaments, synovium and its secretory product synovial fluid, and the joint capsule. 
Hyaline cartilage, about 2-4mm thick in human adults, covers the end of long bones in synovial joints 
and provides a smooth surface for articulation. One side of the hyaline cartilage faces the synovial 
space, while the other connects to the subchondral bone via a thin layer of calcified cartilage [4]. 
Subchondral bone is an important tissue in the joint as it can attenuate around 30% of joint load, 
supplies nutrients to the deep layers of cartilage, and facilitates removal of waste. Evidence suggests 
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that there is cross-talk between subchondral bone and articular cartilage through both mechanical 
and humoral/soluble signals [5]. Articular cartilage is aneural, avascular, does not contain any other 
connective tissue types and has no inflammatory cell populations [6]. The articular cartilage contains 
only one cell type, the chondrocyte, and these cells are embedded within the extracellular matrix 
(ECM), which is primarily made up of two types of proteins in terms of weight; collagens and 
proteoglycans with their attached glycosaminoglycans (GAGs). 
 
1.1.2 Extracellular Matrix 
The ECM of normal articular cartilage contains around 60-80% water, and of the solid component of 
cartilage, collagen makes up around 70-75%, whilst around 10-20% is made up of proteoglycan [7]. 
Collagen is the most plentiful protein in the body, being the major protein of the ECM of all tissues. 
The main role of collagen is to provide tough reinforcement and definition to the tissue shape, whilst 
proteoglycans and associated GAGs in cartilage provide a negatively charged hydrated matrix to 
resist compression via their osmotic pressure [8]. The cartilage ECM can be considered as a fibre-
reinforced composite material, consisting of a network of collagen fibrils embedded in a high 
concentration of proteoglycans. In articular cartilage it is designed primarily to resist compressive 
forces (that predominant in appendicular joints), achieved by the balance between the swelling 
pressure of the proteoglycan GAGs and the tension in the collagen fibrils, as shown in Figure 1.2 [9].  
 
The major proteoglycan by weight in cartilage is aggrecan; however other proteoglycans such as 
biglycan, decorin, fibromodulin and versican exist at lower weight percentages [10]. Aggrecan 
contains an extended protein core with 20-30 keratan sulphate side chains, and then a longer 
extended region containing up to 150 chondroitin sulphate side chains [11]. Multiple aggrecan 
molecules bind non-covalently to a hyaluronan molecule via the G1 globular domain, immobilising 
the aggrecan in the matrix and allowing the formation of multi-molecular aggregates stabilised by 
link proteins [12]. Collagen type II is the main collagen constituent in articular cartilage ECM, with 
smaller concentrations of collagen type IX and XI also present. Collagen type II forms a right-hand 
triple helical structure with three identical chains held together by hydrogen bonds, making these 
molecules resistant to most proteinases [13]. Type II, IX and XI collagens in cartilage form 
heterotypic fibrils with collagen type XI forming the core, type II surrounding the core and forming 
the bulk of the fibril, and type IX at the surface [14]. It is likely that the collagen and proteoglycans 
bind to strengthen the matrix, and it has been proposed that this occurs through the keratan 
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sulphate-rich region, with studies showing a significant collagen binding affinity in vitro [15]. The 
area directly surrounding the chondrocytes is called the pericellular matrix. The composition of the 
pericellular matrix differs from the bulk of the ECM, containing type VI and IX collagens, fibronectin, 
decorin, fibromodulin, biglycan, cartilage oligomeric matrix protein (COMP), matrilin 3 and aggrecan 
[16]. 
Figure 1.2: Proteoglycans in cartilage swell with water, causing osmotic pressure, which is restrained by the 
collagen fibrils which provide tension, resulting in the ability to withstand high compressive pressure [9] 
 
1.1.3 Chondrocytes 
1.1.3.1 Biology and Function 
Chondrocytes, the only cell type in human adult articular cartilage, are derived from mesenchymal 
stem cells (MSCs), as is the case with all connective tissue cells [2]. Chondrocytes are generally 
rounded or polygonal, except at the surface of the cartilage (see Section 1.1.3.3), and have 
intracellular deposition of glycogen. A typical human chondrocyte is shown in Figure 1.3. The role of 
chondrocytes is to synthesise and maintain the cartilage ECM. They do this by synthesising both the 
constituents of the ECM and the proteinases that degrade it [2]. There is a very low ratio of cells to 
matrix (cells make up less than 10% of the total tissue volume), and due to this, chondrocytes are 
considered largely not to be in direct physical contact with each other. This, in addition to the lack of 
vascularisation in cartilage, means that the cells: 1) must rely on diffusion through the articular 
surface of nutrients and metabolites; and 2) must function at very low oxygen levels, with the 
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majority of the cell’s energy requirements met by glycolysis [2]. In vivo, cells divide very infrequently, 
and individual cells therefore have a long residence time in the cartilage [17].   
 
Figure 1.3: Electron micrograph of a typical chondrocyte [2] 
 
1.1.3.2 Origin of Chondrocytes 
Mature chondrocytes are derived from MSCs, adult stem cells that originate from the mesoderm 
that can turn into various cell types, such as bone, tendon, muscle or cartilage cells, depending on 
the physical and chemical cues in the local area [18]. In vivo, chondrogenesis occurs when MSCs 
condense, and a favourable chemical environment allows the cells to begin their commitment to a 
chondrocytic lineage. This process can be recapitulated in vitro with adult MSCs, as originally 
described by Johnstone et al. in 1998 [19]. This has become the standard in vitro procedure, using a 
pellet culture system where cells are in close proximity at a high density, and the appropriate culture 
conditions are utilised to provide the necessary chemical cues for chondrogenesis including 
transforming growth factor (TGF)-β, ascorbic acid and dexamethasone. Other factors that are 
favourable to chondrogenesis include hypoxia [20-22], compressive strain [23], and hydrostatic 
pressure [24]. It is generally accepted that successful chondrogenesis has been achieved where 
expression of aggrecan, sox9, and type II collagen, is present, without expression of collagen type I 
[25].  
 
1.1.3.3 Cartilage Structure 
Adult articular cartilage has four zones: superficial, middle, deep, and calcified, progressing from the 
surface of the articular cartilage towards the bone (Figure 1.4). Whilst the superficial, mid, and deep 
zones merge without clear boundaries, the calcified cartilage is separated by a mineralisation line 
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called the tidemark. There are differences between these zones in cell density and orientation, 
nature, content and distribution of proteoglycans and organisation of the fibrillar collagen network 
[26]. Chondrocytes generally become bigger in deeper zones of the cartilage, and change shape from 
flatter, ellipsoidal-like to spherical cells. In the superficial zone, they tend to be separate, however, in 
the mid and deep zones, chondrocytes are often grouped together in columns of three or four cells 
[4]. Collagen fibrils in the superficial zone are tightly packed and arranged tangentially to the surface, 
and in the mid and deep zones the collagen fibrils form an interlacing network, becoming denser and 
more radially aligned as depth increases. Proteoglycan content increases with increasing depth [27].  
 
Figure 1.4: Structure of cartilage from the surface to subchondral bone in terms of: A) chondrocyte 
morphology; and B) collagen orientation [28] 
 
1.1.3.4 Cartilage Metabolism 
In healthy cartilage the rate of turnover of ECM is very slow as opposed to the constant remodelling 
in other tissues, such as is the case in bone [6, 29]. Various anabolic and catabolic stimuli are present 
in the local area of the cartilage matrix, produced by chondrocytes themselves, or by cells from the 
surrounding joint tissues. Anabolic factors are those that promote production of matrix proteins, 
including TGF-β, which counteracts Interleukin (IL)-1 and promotes collagen type II and proteoglycan 
synthesis; bone morphogenetic proteins (BMPs), which are involved in homeostasis; and insulin-like 
growth factors (IGFs), which promote production of matrix proteins [30]. Catabolic factors promote 
the degradation of cartilage through the action of enzymes including matrix metalloproteinases 
(MMPs, specific members being responsible for cleaving collagen fibrils) and A Disintegrin and 
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Metalloproteinase with a Thrombospondin Motifs (ADAMTSs, in particular ADAMTS-4 and -5, also 
termed aggrecanases, the principle enzymes responsible for degradation of aggrecan molecules), 
which are known to be up-regulated by various cytokines such as IL-1 and Tumour Necrosis Factor α 
(TNFα) [30, 31]. MMPs play a major role in normal cartilage matrix turnover, with MMP-3 considered 
to be the most prominent MMP involved [6, 32]. The activity of these metalloproteinases is 
regulated by Tissue Inhibitors of Metalloproteinases (TIMPs); their roles in cartilage pathology are 
discussed in detail in Section 1.2.3. 
 
1.1.3.5 Age-Related Cartilage Changes 
The process of ageing has an effect on all tissues of the body where, over time, the ability of cells to 
proliferate and synthesise new proteins diminishes, compromising their ability to repair and 
regenerate the damaged tissue. Senescence is the term used to describe the deterioration of cells 
and tissues with age, and many changes occur in the cartilage in this senescent period. Biochemical 
changes in ageing include an increase in non-collagenous proteins, changes in glycosaminoglycan 
composition, increased levels of hyaluronic acid, as well as accumulation of Advanced Glycation End 
Products (AGEs) [33]. AGEs are the result of the spontaneous reaction of reducing sugars with 
proteins within the body, and greater accumulation is seen in tissues with slower turnover rates [33, 
34]. For example, a study on the accumulation of AGEs in cartilage and skin tissue showed that a 
linear increase could be seen between AGE accumulation and age in both tissues, with the rate being 
higher in cartilage. Collagen has a longer residence time in cartilage than in skin, with an estimated 
half-life in cartilage of 117 years [35].  
 
The accumulation of AGEs has been shown to correlate with impaired biomechanical properties of 
the tissue, making it more brittle with increasing stiffness, more susceptible to fatigue failure, and 
increasing the deposition of calcium-containing crystals [36]. In vitro studies showed that increased 
AGE levels promote a decrease in the rate of proteoglycan synthesis and decreased chondrocyte-
mediated degradation, suggesting the AGEs can hamper both the removal of damaged tissue and 
the replacement of this tissue [37]. Changes in mechanical properties that occur with AGE 
accumulation could be related to enzymatic cross-linking, which occurs normally during 
development of the cartilage in order to stabilise the structure. In ageing, however, AGE 
accumulation triggers non-enzymatic cross-linking, which, over time, leads to decreased solubility of 
the cartilage, greater resistance to enzymatic activity and reduced flexibility of the tissue. Glycation 
can also modify the side-chains of aggrecan, potentially interfering with the cell-matrix and collagen-
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matrix interactions. Additionally, AGEs have been shown to be chemotactic (recruiting factor) for 
macrophages, and capable of inducing the secretion of pro-inflammatory cytokines, suggesting a 
regulatory system in which macrophages selectively remove AGE-modified proteins [38]. The 
Receptor for Advanced Glycation End Products (RAGE) is expressed in many cell types, including 
chondrocytes, and, like AGEs, has been shown to increase in aged tissue [34]. 
 
The expression profile of chondrocytes changes during senescence, leading to altered MMP and 
TIMP profiles [39] and increased expression of cytokines and growth factors [40]. Turnover of 
collagen and aggrecan stabilises at around 20-30 years of age in humans, after which time catabolic 
cleavage of aggrecan and collagen occurs at a faster rate with increasing age [41, 42]. Indeed it has 
been shown that there is an age-related decline in the ability of chondrocytes to respond to anabolic 
stimulus [29, 33, 43]. There is still much debate as to whether cells undergo higher levels of 
apoptosis (programmed cell death) in senescent compared to mature cartilage, and whether their 
ability to synthesise matrix proteins is decreased. Various animal studies have shown increased 
levels of apoptosis in aged cartilage compared to mature cartilage [44], and chondrocyte numbers 
were found to be decreased by Bobacz et al. [45] in aged human (healthy) cartilage compared to 
mature cartilage, although others [33] reported no change in DNA content between aged and 
mature human cartilage. This latter study found that in vitro accelerated ageing of human articular 
cartilage caused a decrease in the synthesis of proteoglycans, whereas Bobacz et al. [45] found no 
significant changes in biosynthetic activity in aged and mature cartilage. Others reported that 
aggrecan synthesis correlated inversely with age and differences were observed in the aggregates 
formed, with younger cartilage synthesising aggregates consisting of more aggrecan molecules per 
hyaluronan molecule [46]. These findings demonstrate an age-related change not only in the ability 
to synthesise aggrecan aggregates but also the quality of the aggregates formed, suggesting a 
reduced ability in ageing to adequately repair tissue or respond to altered compressive loading [46].  
 
1.2 Arthritis 
1.2.1 Biology of Osteoarthritis 
Osteoarthritis (OA) is a multi-factorial joint disease that, while involving all tissues of the joint (Figure 
1.5), is characterised by a progressive loss of articular cartilage, impairing joint movement and 
causing disability [47]. The exact mechanism(s) of onset and progression of OA are unknown, but 
due to the localisation of cartilage degradation to the weight-bearing joint regions, OA was 
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previously assumed to be primarily due to repetitive mechanical injury and tissue disruption. While 
biomechanics is certainly a critical signal for initiation and progression of the disease, it is now 
commonly accepted that cartilage erosion in OA is an active biological process and the chondrocyte 
plays a vital role [48]. The progressive loss of articular cartilage ECM alters the material properties of 
the tissue by causing an increase in water content, allowing water and other molecules to flow in 
and out of the tissue, leading to a decrease in tensile strength [48, 49]. The damage often occurs first 
in the pericellular matrix, before macroscopic changes can be observed on the surface, suggesting 
that chondrocytes are the source of matrix-degrading proteins [50].  
 
The increased prevalence of OA with age could be due to the diminished capability of ageing cells to 
repair damaged tissue, as discussed in Section 1.1.3.5, and their significant decline in anabolic 
response mechanisms, however ageing is not sufficient on its own to induce OA i.e. not all aged 
individuals or joints are affected [29, 40]. Due to the significant correlation of age with OA, it was 
hypothesised that chondrocytes may become senescent in the disease, with a study by Price et al 
showing senescent cells localised in osteoarthritic legions, whereas none were observed in control or 
distal samples [39]. These cells also had shorter telomere length, suggesting increased levels of 
proliferation in these areas [39]. Murine models of experimental arthritis provided evidence for a 
link between chondrocyte terminal or hypertrophic differentiation and matrix catabolism in 
osteoarthritic cartilage [51]. As in ageing, increased apoptosis of chondrocytes in osteoarthritic 
tissue has been reported, which would further decrease the ability of cartilage to repair damage or 
respond to physiological challenges such as load-bearing, by decreasing the number of functional 
chondrocytes [52-56]. Apoptosis has been linked with changes in hydrostatic pressure, which 
suggests that chondrocytes could undergo apoptosis in response to increased mechanical loading of 
joints [50]. Aigner et al. [57] suggest that the inconsistent reporting of apoptosis in OA is due in part 
to the fact that the apoptosis process is difficult to quantify based on the fast rate of the process and 
the slow, chronic nature of OA, and in part to the fact that due to the avascular nature of cartilage, 
normal apoptosis involving phagocytic digestion is impossible. They therefore propose a new term 
“chondroptosis” as the primary method of cell death, involving auto-digestion of cellular debris; 
however the debate still continues whether this is a primary or secondary event in OA. The reported 
increase in chondrocyte apoptosis may be associated with reduced autophagy, a process in which 
aberrant cytosolic cell material is destroyed, which negates the need for the whole cell to be 
destroyed. Reduced chondrocyte autophagy has been demonstrated in human cartilage and mouse 
models [56], and pharmacologic activation of autophagy reduces experimental OA in mice [58]. Risk 
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factors for OA other than age include obesity, joint abnormalities causing atypical biomechanics, 
previous joint trauma, repetitive use or injury, genetics, joint infection, and crystal deposition [3, 59, 
60].  
 
Figure 1.5: Osteoarthritis affects the whole joint. a) Healthy joint; b) Early focal degeneration and fibrillation of 
cartilage are seen, as well as osteophyte development and changes in synovium, joint capsule, subchondral 
bone and meniscus [3]. 
 
OA not only affects the cartilage, but all tissues in and distant from the synovial capsule (Figure 1.5). 
Osteophyte formation (bony outgrowths at joint margins), inflammation and fibrosis of the 
synovium, changes in composition of synovial fluid, weakened and frayed tendons, ligaments and 
muscles, thickening of the capsule, subchondral bone changes and sclerosis are all observed in 
osteoarthritic joints [3, 61, 62]. Subchondral bone reportedly thickens in OA, reducing the shock 
absorbing ability of bone and reducing the ability to spread the load and distribute strain effectively, 
both of which would accelerate overlying cartilage damage [63, 64]. Lajeunesse et al. [65] suggest 
that the subchondral bone itself releases cytokines and growth factors that seep into the cartilage 
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via micro-cracks that form in aged tissue, leading to increased production of catabolic enzymes by 
chondrocytes. Osteoarthritic chondrocytes, when co-cultured with subchondral osteoblasts, cause 
differentiation of osteoblasts, a phenomenon that does not occur with healthy chondrocytes. This 
suggests that subchondral bone remodelling may be a secondary event to osteoarthritic changes in 
the cartilage [66], and emphasises the potential cross-talk and interaction of these tissues.  
 
Many studies have linked osteoarthritic progression with hypertrophic differentiation of 
chondrocytes, with some groups believing this change is one of the driving factors of OA [12, 54]. 
The change in phenotype leads to differential expression of genes such as increased MMP-13 [67]; a 
change from production of collagen type II to collagen type X [68]; and expression of osteonectin 
(not expressed in healthy chondrocytes) [6]. These changes promote the mineralisation of cartilage, 
similar to that in the formation of the epiphyseal growth plate [55]. Human articular chondrocytes 
were found to up-regulate genes associated with chondrogenic differentiation in and adjacent to 
early focal lesions, suggesting that chondrocyte hypertrophy is an early event in cartilage 
degeneration [69]. Conversely, a surgically induced OA rat model showed that swelling of 
chondrocytes in the superficial region was an early event, however, these cells did not up-regulate 
collagen type X so were deemed not to be differentiating into hypertrophic chondrocytes [70]. 
Increases in collagen type X, however, may be an event that occurs later than the timeline of this 
experiment. Using knockout mice, it was shown that ablation of MMP-13 activity did not alter 
articular chondrocyte hypertrophy and type X collagen expression, suggesting this activity is 
downstream of rather than driving hypertrophic changes, with hypertrophy itself not shown to cause 
cartilage damage [71].  
 
1.2.2 Osteoarthritis and Inflammation 
OA is generally not considered to be an “inflammatory arthropathy”; however local inflammatory 
symptoms and synovitis are often present in the joint in both human patients and animal models, 
with increased levels of inflammatory cytokines seen in synovial fluid even when no other 
inflammatory symptoms are observed [48]. This idea of inflammation being a critical feature of OA is 
gaining more attention, with supporting evidence that OA involves low-grade systemic inflammation 
[72], coupled with expression of adipokines (inflammatory molecules released from fat cells) linking 
obesity with OA [73]. In addition, synovitis (inflammation and thickening of the synovial lining) has 
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been shown to be one of the few symptoms that correlates with osteoarthritic pain, particularly in 
the knee [74], and is predictive of progression of cartilage degradation in human knees [75, 76].  
 
The existing paradigm suggests that synovial inflammation is a secondary response, with some 
authors arguing that OA is always initiated by mechanical factors [77, 78]. The cause of inflammation 
is most likely the release of cartilage breakdown products into synovial fluid, resulting in an increase 
in inflammatory cytokines and inflammatory cells [79]. For example, fibronectin fragments released 
into the synovial fluid and cartilage matrix during cleavage have been shown to induce an 
inflammatory response [80]. It is likely that the cytokines are released by cells in the synovial lining 
and diffuse into the cartilage through the synovial fluid, stimulating chondrocytes to produce matrix-
degrading factors [79]. However, chondrocytes themselves are also capable of producing these 
cytokines, and could be contributing to the inflammatory environment in the joint [77]. The 
inflammatory component of OA, unlike that of rheumatoid arthritis (RA), is not classically systemic, 
but is restricted to the affected joint [81]. The issue of whether inflammation or mechanical factors 
are the primary cause of OA is still under debate, with evidence for and against each viewpoint [73, 
78]. Nevertheless, once the osteoarthritic disease process is initiated, it is clear that all joint tissues 
are affected and synovitis plays a role in the progression of the disease. 
 
1.2.3 Cartilage Anabolic and Catabolic Activity in Osteoarthritis 
In OA there is an increase in chondrocyte metabolic activity, resulting finally in an imbalance 
between the anabolic (synthesis of complex molecules from more simple ones) and catabolic 
(breakdown of complex molecules to more simple ones) activity, in favour of catabolic events [6, 12]. 
An increase in anabolic activity has been reported in OA, presumably as an attempt to repair the 
damaged cartilage, but ultimately catabolic activity overwhelms the reparative efforts [41, 48, 82]. 
While all classes of catabolic enzymes are up-regulated in osteoarthritic chondrocytes [83], two 
major families have been implicated in cartilage degradation, MMPs and ADAMTSs, as they are key 
to proteolysis of collagen and aggrecan, the two major structural proteins in cartilage [61]. These 
two metalloproteinase families are discussed in further detail below. In OA, chondrocytes were also 
found to produce abnormally high levels of reactive oxygen species (ROS) compared with normal 
cartilage [84], and female patients with knee OA were found to have higher ROS metabolites in 
serum compared to healthy volunteers [85]. It is believed that reactive oxygen species exert their 
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role in OA through mechanical stress or inflammation [86], which can trigger catabolic and inhibit 
anabolic factors [87], as well as inducing cell death [79], reviewed by Loeser in [88].  
 
1.2.3.1 Proteinases in Osteoarthritis 
Due to the high abundance of collagen and aggrecan in cartilage, the cleavage of these two matrix 
proteins is considered a major proteinase-mediated event in cartilage degradation. The loss of 
aggrecan is thought to be an early and reversible process, however, once the collagen starts to 
degrade, the damage becomes irreversible [47, 89]. The major groups of MMPs involved in OA are 
the collagenases (MMP-1, -8, and -13), the gelatinases (MMP-2 and -9) and stromolysin (MMP-3). 
Although various MMPs have been shown to be up-regulated in osteoarthritic tissue, perhaps the 
MMP of most significance is MMP-13 [90], with the highest activity of all the MMPs for degrading 
collagen type II. MMPs are synthesised in an inactive (pro-) form, with a cysteine residue that binds 
to zinc, requiring removal of this region (the pro-domain) in order to be activated. This can be 
performed by a variety of proteins, with MMP-3, which is up-regulated in OA, able to activate pro-
collagenases and pro-MMP-9 [62] and MMP-14 (which is secreted in its active form) able to activate 
pro-MMP-2 and pro-MMP-13 [32]. Immunostaining of osteoarthritic cartilage for MMP activity 
shows that collagenases and MMP-9 were present and localised to the superficial zones, in areas 
where fibrillation and matrix destruction was observed [91], in agreement with the hypothesis that 
cartilage destruction starts at the surface and works its way down through the cartilage layers. 
Inhibition of MMPs in cartilage explants via a general MMP inhibitor neutralised the degradation of 
both collagen and proteoglycans, which could reflect activity of MMPs against proteoglycans, or 
inhibition of aggrecanases by the inhibitor [92]. There is evidence that MMP gene expression is 
regulated primarily at the transcriptional level, through MMP promoters [93]. 
 
MMP-13 has been shown to be up-regulated in late-stage human OA [6, 94, 95] but is not found in 
healthy cartilage tissue [47, 94]. Furthermore, over-expression of MMP-13 in cartilage in transgenic 
mice induced joint abnormalities similar to those seen in OA, highlighting its important role in OA 
[96]. MMP-13 deficient mice showed no differences compared to wild type controls in early stage 
OA (4 weeks post-op after surgically-induced OA), however even those MMP-13 deficient mice with 
focal aggrecan loss did not lose cartilage structure, suggesting a vital role for MMP-13 in collagen 
cleavage [71]. Collagenases cleave collagen through sequential hydrolysis of a single peptide bond in 
each of the three collagen fibrils, yielding characteristic one-quarter and three-quarter fragments 
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[97]. Chung et al. showed, using MMP-1 and collagen type I, that the collagenases must first bind to 
the collagen and unwind the three fibrils before cleaving each fibril in turn [13].  
 
Of the ADAMTS family, ADAMTS-4 and -5 in particular have been shown to be involved in OA. These 
enzymes can cleave aggrecan at multiple sites, but do not cleave collagen fibrils. The aggrecanases 
were discovered when fragments of aggrecan which showed a different N-terminal sequence than 
previously discovered fragments generated by the action of MMPs were found to be in abundance in 
synovial fluid from OA and knee injury patients [98]. Like MMPs, ADAMTS are synthesised in an 
inactive form, and require proteolytic removal of the pro-domain to become activated [62], which is 
classically mediated by furin-like serine proteinases [99] and has been shown to also be possible via 
autocatalysis [100]. At least two groups have found that ADAMTS-5 is the main aggrecanase involved 
in aggrecan cleavage in mice both in vitro when cartilage is stimulated with catabolic agents such as 
IL-1 and in vivo in models of both OA and inflammatory arthritis [90, 101, 102]. In contrast studies in 
ADAMTS-4 knockout mice suggest that ADAMTS-4 is not involved in OA pathology in this species 
[103]. In contrast to these studies, the same group found that ADAMTS-4 and ADAMTS-5 both 
contribute to the structural damage seen in human OA, but not ADAMTS-1 (another family member 
with significant “aggrecanase” activity), using siRNA transfection on osteoarthritic samples [104]. 
Likewise, ADAMTS-1 has been shown not to play a critical role in normal cartilage growth or 
experimental inflammatory arthritis, as shown by ADAMTS-1 knockout mice [105]. 
 
TIMPs are endogenous inhibitors of MMPs and ADAMTSs [77, 95]. They provide a metabolic balance 
within cartilage tissue, by binding (in a 1:1 ratio) and inhibiting the activity of MMPs, and therefore 
could be involved in OA through an imbalance with MMPs [95]. TIMP levels are elevated in 
osteoarthritic cartilage, albeit lower than those of MMPs, rendering them unable to neutralise all the 
catabolic activity [77]. All four TIMPs have been detected in cartilage [97], with TIMP-1 reported to 
completely inhibit collagen breakdown in vitro [106], and TIMP-3 capable of blocking MMPs, 
ADAMTS-4 and ADAMTS-5 [77]. TIMP-3 has been shown to be chondroprotective in mice, with 
Timp3-/- mice developing increased cartilage degradation upon ageing [107]. Interestingly, mRNA 
levels of Timp3 are not greatly altered in OA, however as TIMP-3 protein can be endocytosed and 
degraded by chondrocytes; this suggests possible post-transcriptional regulation [108-111]. 
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The order of catabolic events in OA has been investigated, with the findings suggesting that early OA 
involves aggrecan cleavage by the aggrecanases, followed by collagen cleavage; a process mediated 
by MMPs [112]. Aggrecan cleavage is thought to be necessary for the subsequent proteolysis of 
collagen fibrils; the prevention of aggrecan loss inhibits collagen loss [89]. The mechanism for this 
could be that MMPs cannot be activated while aggrecan is intact [62], or that there is steric 
hindrance preventing access of MMPs to the cleavage site in collagen [112]. A depth-wise study of 
cartilage damage in early and late OA showed that in early OA, collagen fibrils in the superficial layer 
change their orientation, potentially allowing proteoglycans in both the superficial- and mid-zones to 
migrate out to the surface [49]. While it is suggested that MMPs do not play a major role in cartilage 
degradation until later stages, Milner et al. [106] showed, using cartilage explants, that high levels of 
pro-MMPs are expressed by chondrocytes during early stages of cartilage degradation in vitro, and it 
is their activation in later stages that is critical.  
 
Our understanding of the process of aggrecan cleavage has been greatly enhanced by the discovery 
of antibodies to identify the new N- and C-terminal epitopes in collagen and aggrecan exposed by 
proteolysis at specific sites. These “neoepitope” antibodies are able to detect both cleaved 
fragments released from, and fragments still contained in the cartilage as a result of cleavage. Two 
major cleavage sites on aggrecan have been identified, one corresponding to MMP activity, and the 
other site corresponding to aggrecanase activity [113]. All MMPs tested can cleave aggrecan at the 
Asn341-Phe342 position, corresponding to neo-epitopes VDIPEN341, the C-terminal sequence of the 
fragment remaining in cartilage, and 342FFGVG, which is the N-terminal sequence on the fragment 
released from the cartilage (Figure 1.6). The most widely recognised cleavage point of aggrecanases 
on aggrecan is at Glu373-Ala374, corresponding to neo-epitopes NITEGE373, remaining in cartilage, and 
374ARGSV, released from cartilage. Aggrecanases can also cleave aggrecan at the following sequences 
in the core protein: GELE1480 – 1481GRGT; KEEE1667 – 1668GLGS, and in the COOH-terminal: TAQE1771 – 
1772AGEG; and VSQE1871 – 1872LGQR [114]. Whilst it has been shown that sites within the chondroitin 
sulphate 2 (CS2) domain are preferentially cleaved, cleavage at the Glu373-Ala374 would be more 
deleterious due to the resulting release of the entire CS-containing portion of the aggrecan. Using a 
genetic mutation of the aggrecan gene rendering the IGD domain only resistant to ADAMTS, mice 
subjected to either surgically-induced OA or inflammatory experimental arthritis showed diminished 
aggrecan loss and cartilage erosion, demonstrating the importance of the Glu373-Ala374 cleavage site 
[115]. The first evidence that MMPs could degrade cartilage was found in 1996, using neoepitope 
antibodies to identify aggrecan fragments that corresponded with the MMP cleavage site in human 
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synovial fluid [116], followed closely by similar results by Billinghurst et al., where they showed both 
up-regulation of collagenases and identification of collagen fragments in human cartilage [117].  
Another study by Lark et al. [42] provided evidence for both MMP-mediated and aggrecanase-
mediated aggrecan cleavage using neo-epitopes, and based on the fragments seen, hypothesised 
one of two scenarios: aggrecan is first cleaved by aggrecanase, then MMPs process some of the 
fragments remaining in the cartilage leading to both ARGSV- and FFGVG-positive interglobular-
domain fragments in synovial fluid, as well as both VDIPEN- and NITEGE-positive fragments in 
cartilage (later proven to be possible by Little et al. [118]); or the two act independently of each 
other. A recent study confirmed that both MMP and aggrecanase cleaved aggrecan fragments in 
cartilage explants, using highly sensitive ELISA methods with neo-epitopes, supporting the latter 
scenario [119].  
 
Figure 1.6: MMP and ADAMTS cleavage sites on aggrecan (adapted from [114]). 
 
1.2.3.2 Inflammatory Cytokines in Osteoarthritis 
Although the importance of inflammation in OA remains controversially reported, there is evidence 
that cytokines are involved in the pathogenesis of the disease. IL-1β and TNF-α, widely reported to 
be increased in chondrocytes in osteoarthritic cartilage, are present in the synovial fluid of 
osteoarthritic patients [31, 77, 91], and have been shown to mediate up-regulation of MMP 
expression [30, 120]. Additionally, other pro-inflammatory cytokines such as IL-6, IL-8 and IL-17 are 
also up-regulated in OA [120], with IL-17 able to induce the release of chemokines and IL-1β by 
chondrocytes and synovial fibroblasts. These cytokines are all potentially involved in promoting 
functional alterations of cartilage, subchondral bone and synovium, and have been shown to 
decrease the compensatory synthetic pathways that attempt to repair cartilage damage [120]. 
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Additionally to these prominent pro-inflammatory cytokines, anti-inflammatory cytokines have been 
reported to be differentially expressed in OA. Anti-inflammatory cytokines IL-4, IL-10, and IL-13 have 
been reported in OA [120], in addition to anabolic (growth) factors such as TGF-β and IGF which 
promote synthesis of collagen II and proteoglycans and down-regulate catabolic protein synthesis, 
suggesting mechanisms of attempted repair [30, 50]. Chondrocytes however, are either unable to 
respond adequately to these stimuli due to age-related changes, or the levels of these proteins are 
not sufficient enough to counteract enhanced degradation. TGF-β is known to be involved in 
chondrocyte differentiation at all stages, of particular relevance in OA in inhibition of hypertrophic 
differentiation of chondrocytes [121]. The natural antagonist of IL-1 receptors, IL-1Ra is decreased in 
OA, allowing IL-1 signalling to occur more readily [120].  
 
1.2.4 Experimental Osteoarthritis Methods 
OA mechanisms can be experimentally studied in vivo in a number of species with different 
induction mechanisms. Animal models generally fall under one of three categories: spontaneous; 
chemically-induced; or surgically induced OA. Various animal species and specific genotype 
abnormalities are susceptible to spontaneous onset of OA, with age-related changes similar to that 
of human OA. One example of such a spontaneous OA model is the Col11a1+/-, or chondrodysplasia 
(cho) mouse, in which disorganisation of the collagen network leads to cartilage matrix instability 
and progressive OA [122]. The disadvantages of spontaneous compared with induced models are 
that it is a slower process, and therefore more costly, and onset of OA is more variable [123]. 
Chemically-induced models such as collagenase-induced arthritis, involving intra-articular injection 
of collagenase are faster and less variable; however they involve a significant inflammatory 
component which may not accurately reflect human OA disease progression. Surgically-induced 
models of OA are the most commonly used animal models to study OA, and involve damage to 
either ligaments or meniscus in order to induce instability and/or alter joint biomechanics [124]. The 
advantages of using surgical methods are that it is faster and less variable than spontaneous OA 
models, there is a known onset and time course of disease, and there is a decreased dependency on 
specific alterations in genetic background and thus a more robust translation to humans [124]. One 
of the most common surgical models is Anterior Cruciate Ligament Transection (ACLT), mimicking 
post-traumatic OA, with similar pathology as seen in humans with the same injury although much 
more rapid, occurring as early as four weeks post-surgery in some species, particularly rodents [44, 
64, 67]. The disadvantage of this model in mice is that the joint damage is very severe making the 
opportunity for studying progressive change and amelioration with treatment difficult [124]. The 
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most common surgical model in mice is destabilisation of the medial meniscus (DMM) through injury 
to the ligaments anchoring the meniscus to the tibia. This method leads to more slowly progressive 
OA with moderate to severe OA change in all animals at eight weeks after the operation [101, 103, 
124].  
 
While not modelling the interactions between different joint tissues, the effect of mechanical 
loading, or the time course of disease development in patients, in vitro methods can provide very 
useful information on the pathophysiological cellular and molecular mechanisms in specific joint 
tissues. In particular, a great deal has been learned about the signalling pathways and enzymes 
responsible for cartilage degradation using cell (chondrocyte) and tissue (explant) cultures. 
Cytokines are extensively used as a means of stimulating catabolic activity in vitro in either 
chondrocytes or cartilage explants. IL-1, TNF-α, and oncostatin M (OSM) all have the ability to induce 
catabolic changes, with the combination of IL-1 and OSM being the most potent inducer reported 
[31, 89, 92, 106, 118, 125]. All of these studies have shown up-regulation of MMPs and ADAMTSs in 
a variety of species (including human), as well as up-regulating a repair response; however this 
response is overwhelmed by the catabolic effect [126]. Collagen and aggrecan loss can be blocked by 
inhibitors allowing the role of specific enzymes to be elucidated [31, 47, 112, 127-130], or addition of 
compounds that modulate the cellular signalling pathways to define the key mechanisms. Cartilage 
explants may be superior to monolayer chondrocyte cultures due to the cartilage ECM being present 
and cells retaining a differentiated phenotype. When cultured with the above-mentioned cytokines, 
cartilage explants represent the most physiologically relevant in vitro model of cartilage degradation 
[12, 119]. A study by Lafeber et al. [131], into the viability of using human cartilage explants showed 
that areas of healthy tissue from osteoarthritic patients with focal cartilage degradation were 
comparable in terms of proteoglycan content, release and DNA content, showing that they are 
suitable as controls, and that parameters such as these correlated linearly with wet weight, proving 
this to be a reliable parameter to normalise results to. This study also found that culture times of at 
least four days were necessary for additives to penetrate the explant and have an effect. Use of in 
vitro cartilage explant systems with cytokine stimulus has added weight to the theory of aggrecanase 
activity occurring in early stages of OA with collagen loss occurring later due to MMP activity; 
proteoglycan loss occurring in bovine explants over the first seven to nine days of culture; collagen 
degradation occurring from fourteen days (another bovine explant study reported 10-17 days, using 
OSM and TNF-α [89]), and complete digestion occurring after 31 days of culture [92].  
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1.2.5 Current Treatment Methods and Therapeutic Targets in 
Osteoarthritis 
There is currently no cure for OA, and no drugs have yet been registered as “disease-modifying” for 
clinical use. Treatment methods therefore attempt to relieve pain, reduce inflammation, protect 
joints from further damage and maintain joint function [132]. Treatment programs may include one 
or more of the following: exercise, which is not always possible due to pain and joint function, 
weight loss to reduce joint loading, non-surgical realignment, analgesic/anti-inflammatory 
medications, or, in severe cases where no other options are available, surgical intervention such as 
arthroscopy (minimally-invasive diagnosis and repair of small problems within the joint), arthrodesis 
(fusing together of bones), and arthroplasty (replacement with artificial joint). Recent 
recommendations from OARSI on treatment methods are summarised in [133]. Unfortunately, most 
drugs that target pain do not help joint structure, and those that target joint structure do not have 
any effect on pain, so as a consequence, the majority of OA patients report that they are unsatisfied 
with their disease treatment [134], and as a result of the poor management options the number of 
joint replacement surgeries, the majority being done for OA, is increasing by nearly 10% per annum 
in Australia [135]. 
 
Current research aims to identify key contributors to OA pathogenesis and create disease-modifying 
drugs that inhibit the activity of these key mediators. Theoretically, there are a number of ways to 
achieve this, based on the different tiers of regulation present in the complex system that is the 
human body. Inhibition could be targeted at any of the following processes: gene transcription, 
synthesis, secretion, pro-enzyme activation, or could involve enzyme inhibition through synthetic or 
endogenous inhibitors or substrate hydrolysis [97]. Obvious therapeutic targets are MMPs, 
ADAMTSs and cytokines, however due to the differential expression of these proteins at various 
stages of disease; it may be that multiple therapies are required to address these temporal 
differences [89]. 
 
Over 50 compounds have been trialled as direct MMP inhibitors, for arthritis or cancer treatment, 
with only one having been approved (as of 2008) for use in periodontal disease. The reason for the 
discontinuation of many of these compounds in clinical trials has been due to low efficacy [97]. 
Many of these compounds showed promising in vitro and in vivo results, however, due to minimal 
knowledge of the physiological roles of MMPs in the body, many broad spectrum MMP inhibitors 
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resulted in side effects including musculoskeletal syndrome [47], thought now to be due to inhibition 
of MMP-1, which is believed to be involved in normal tissue turnover [136]. Early broad spectrum 
MMP inhibitors targeted the zinc-binding site that is present on all MMPs. Newer MMP inhibitors 
are attempting to target unique sites on MMPs that are now known to be highly active in OA, such 
as MMP-13, thus providing a more specific inhibition, and hopefully eradicating musculoskeletal 
side-effects [137, 138]. Another consideration when designing MMP inhibitors is the physiochemical 
properties - cartilage offering a unique challenge with some drugs unable to penetrate the cartilage 
matrix to the site of enzyme activity [129]. Other MMPs currently being directly targeted include 
MMP-3 [139] and MMP-2 [140]. ADAMTS provide another attractive target for drug development, 
and whilst many of the broad spectrum MMP inhibitors that act via zinc chelation may also act on 
ADAMTS, this would not be specific, and they have, on the majority, not been tested against 
ADAMTS [97]. Several specific ADAMTS inhibitors have been developed [127, 128, 130], and have 
thus far been shown to inhibit aggrecan release both in vitro in cartilage explant cultures, and in vivo 
in mouse models. Alternatively, up-regulation or exogenous addition of natural inhibitors of MMPs, 
TIMPs, could provide a new therapeutic approach. The capacity of TIMPs in vivo in OA cartilage to 
counteract overproduction of MMPs does not appear to be sufficient [141]; however attempts to 
boost the capacity of TIMPs via exogenous delivery have had little success in terms of efficacy [142-
144]. Similarly to this, targeting the growth factors that stimulate anabolic pathways could be an 
alternative approach. Growth factors such as TGF-β, IGF-1 and Fibroblast Growth Factor (FGF)-2 
have been shown to have anabolic effects on cartilage matrix synthesis in vitro [145]. Intra-articular 
injection of TGF-β1 into the temporomandibular joint of rabbits with surgically-induced OA led to 
increased proteoglycan content in the cartilage and normal subchondral bone structure compared to 
vehicle-treated controls which showed typical OA features [146]. Some caution, however must be 
used, as TGF-β1 signalling has also been reported to enhance OA progression [147], with one study 
by Zhen et al. providing evidence that TGF-β is involved in abnormal bone remodelling and cartilage 
degeneration in OA [148].  
 
In contrast to directly targeting the catabolic enzymes themselves, the factors that promote their 
increased synthesis and activity, including cytokines and signalling molecules have also been 
suggested as therapeutic options for OA. IL-1β and TNFα are two major cytokines involved in OA 
[149-151], and are therefore prime targets for inhibitory therapeutics. The IL-1 receptor (IL-1R) has 
been proposed as a target by using an IL-1R antagonist (IL-1Ra), or inhibitors against IL-1R. In vitro 
studies, as well as animal studies (summarised in [152]) have shown a protective effect of inhibition 
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of IL-1R, and some human clinical trials have been conducted [153, 154], but despite good tolerance, 
there was no statistical differences in WOMAC scores or pain compared to placebo. Few clinical 
studies have evaluated anti-TNFα therapy, and those that have gave mixed results. A small open 
study [155] on patients with inflammatory hand OA showed trends of improvement of various 
outcome measures with no statistical significance, but this study is hard to interpret as there was no 
control group. Successful treatment was described in a case study [156] of one patient with knee OA 
using a TNFα antibody, with improvements in symptoms and MRI findings such as synovitis, synovial 
effusion and bone marrow edema.  
 
Signalling pathways are extensively studied in vitro as a method to develop targeted therapies; 
however, these may act differently in vivo, between species, or with different catabolic stimuli. For 
instance, MAP kinase proteins are highly active in OA signalling; however differing activation 
pathways have been reported by different groups. Goldring et al. [86] demonstrated activation of 
MAP kinase cascade elements ERK1/2, p38 MAPK, JNK, and NF-κB in human osteoarthritic cartilage, 
especially in the superficial zone. Similarly, Liacini et al. found that MMP-13 expression by human 
osteoarthritic chondrocytes stimulated with TNF-α was mediated by ERK, p38 and JNK [157]. Ovine 
cartilage explants stimulated with OSM+TNF showed a large increase in matrix destruction, with 
subsequent signalling pathway studies revealing that blocking of p38 or p44/42 inhibited MMP 
activity, whereas aggrecanase activity could only be inhibited by blocking p44/42, suggesting that 
these two proteinase families contribute to cartilage degradation via different pathways [158]. In a 
rabbit model of surgically-induced OA (sectioning of the ACL), inhibition of MEK1/2, an upstream 
component of the ERK pathway, partially decreased development of cartilage erosion [159]. 
Conversely, in human articular chondrocytes, fibronectin fragments caused an inflammatory 
response via NF-κB requiring the activation of both the p38 and JNK MAPK pathways but not ERK 
[80]. Osteoarthritic human chondrocytes co-cultured with subchondral bone osteoblasts led to 
osteoblastic differentiation, mediated by ERK1/2 [66].  
 
In addition to the involvement of classical adaptive inflammatory pathways, the innate immune 
system has also been implicated in OA. Toll-Like receptors (TLR) have been shown to play a role in 
OA; TLR4 expression is up-regulated in osteoarthritic cartilage, which is directly related to the 
disease severity, but decreased in very severe cases [160]. Lipopolysaccharide (LPS) can directly 
activate articular chondrocytes in vitro to express IL-1β and inhibit biosynthetic activity, with 
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inhibition of p38 resulting in increased GAG synthesis, whilst blocking of ERK had no effect. TLR4-
deficient mice stimulated with LPS, however, show no response in GAG synthesis or IL-1β 
expression, suggesting this pathway is necessary only for LPS-mediated cartilage destruction [161]. 
In 2008, Zhang et al. [162] showed that activation of TLR3 could increase human chondrocyte MMP-
13 expression to levels above those seen with IL-1+OSM treatment. Proteoglycan loss was seen with 
stimulation of TLR1/2 or TLR2/6, and all three combinations activated the NF-κB pathway, leading to 
JNK, p38 and ERK phosphorylation, whilst TLR4 was not found to have any significant effects. In 
human osteoarthritic articular cartilage chondrocytes and explants, TLR2 and TLR4 were found to be 
up-regulated compared to non-osteoarthritic human samples [160]. In the same study, stimulation 
with peptidoglycan or LPS further up-regulated TLR2 or TLR4 respectively, phosphorylated p38, ERK, 
JNK and activated NF-κB. Since NF-κB is present in a large number of systems in the human body, 
inhibition of this transcription factor is likely to cause side effects in unwanted areas. However, it 
may be of therapeutic value to target downstream molecules of the NF-κB pathway [163, 164]. 
Whilst these methods of stimulation, using inflammatory cytokines, are often referred to as OA 
models, they better resemble inflammatory arthritis; therefore the role of TLR4 in OA has not yet 
been elucidated. Various mouse models have shown the important role of TLR4 in inflammatory 
arthritis. In immune complex mediated arthritis (ICA), TLR4 mediates early onset inflammation and 
cartilage destruction [86], and is an essential component of the signalling pathway in the initiation 
and progression of auto-antibody or LPS induced arthritis [165]; however TLR2 is not involved in ICA 
[166]. Similarly, MyD88-/- mice did not develop arthritis after serum transfer, whilst control animals 
developed severe arthritis, again suggesting involvement of TLRs in this inflammatory arthropathy 
[167]. IL-17 treatment in collagen-induced arthritis mouse models can up-regulate expression of 
synovial TLR2, TLR4 and TLR9 compared to normal mice, suggesting that joint inflammation and 
destruction caused by this pro-inflammatory cytokine is mediated by the TLR signalling cascade also 
[168]. The ERK MAPK pathway is involved in a large number of pathways involving growth factor 
signalling, cell proliferation and tissue homeostasis; therefore its inhibition may cause toxic effects. 
JNK and p38 are activated by inflammatory events, which may present better therapeutic targets 
due to the potentially fewer side effects [169]. Several p38 inhibitors have been trialled in 
experimental animal models of RA, with all demonstrating reduced disease severity and 
maintenance of joint integrity with a reduction in loss of cartilage and bone, rendering it a 
potentially viable therapeutic for OA [170-172].  
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1.2.6 Rheumatoid Arthritis 
RA is an autoimmune disease that targets the joints, with the hand being most commonly affected 
[132]. Unlike OA, RA is a systemic disease that can affect multiple organs, leading in some cases to 
heart, respiratory, nervous system or eye problems [132]. It is estimated that around 1% of the 
world’s population are affected by RA, and the disease can affect any age group; however those 
between the ages of 35-55 are the most common. Females are also more susceptible to the disease 
than males, with oestrogen thought to play a role due to the higher incidence of RA in menopausal 
and post-natal women, and lower incidence in pregnant women. There is also a genetic component 
to the disease, with genetic factors contributing to about 50% of the risk of having RA [173]; 
however it is thought to also require a trigger such as an infection. Another recognised risk factor is 
smoking, with increased risk with increased smoking duration [132].  
 
The disease is characterised by inflammation of the synovium (the lining of the joint capsule, Figure 
1.7), causing hyperplasia of the synovial cells and angiogenesis, leading to infiltration of immune 
cells into the joint capsule, and subsequent cartilage destruction mediated by destructive enzymes 
released from the pannus [174]. Virtually all types of immune cells are recruited to the synovium in 
RA, leading to production of pro-inflammatory cytokines such as TNF-α and IL-6 [175]. Whereas 
cartilage degradation is localised to the surface and pericellular areas in OA, in RA cartilage 
degradation occurs at the cartilage-pannus junction and in the deeper zones of the cartilage. The 
mechanism of cartilage degradation in RA however, is not due to differences in MMP expression 
between cartilage-pannus junction and other areas of the joint [176]. Chondrocytes in RA do not 
show an attempted repair response, with a shift to a catabolic response being more pronounced 
than in OA [86]. While apoptosis of chondrocytes is apparent in RA, it is suggested that apoptosis of 
synovial cells and immune cells is decreased due to the presence of proliferation-inducing cytokines 
and growth factors such as IL-1β and TGF-β [62]. Apoptosis rates are not able to keep up with the 
increased proliferation rates of these cells, leading to an excess of these cells and therefore an 
excessive response [177]. Mouse transgenic models coupled with inflammatory arthritis models such 
as collagen type II- or antigen-induced arthritis have revealed the importance of TNF-α and IL-1, with 
TNF-α thought to drive acute inflammation, and IL-1 thought to sustain the cartilage erosion [178].  
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Figure 1.7: Changes occurring in joint tissues of patients with rheumatoid arthritis (adapted from [179]). 
 
Unlike OA, treatments for RA are starting to have some success in reducing the severity of disease. 
Whilst conventional disease-modifying anti-rheumatic drugs (DMARDS) are commonly used in RA, 
the main limitation of a number of the drugs of this type (e.g. methotrexate, cyclosporine A, 
cyclophosphamide) is the compromise between effective doses and adverse side-effects, leading to 
the cessation of many treatment regimens [180]. Similarly, glucocorticoids, which are routinely given 
to patients who present with early but non-definitive signs of RA, have been shown to provide no 
significant benefits in the delay of progression, nor any effects on remission [181]. The biological 
DMARDs currently in clinical use fall under one of two broad categories: monoclonal antibodies such 
as TNF-α inhibitors, interleukin family inhibitors, inhibitors of osteoclastogenesis or apoptosis, T-cell 
and B-cell inhibitors; or small molecules targeting cytokines, chemokines or signalling molecules 
[182]. Anti-TNF-α therapies have been shown to be efficacious in most patients and recently, B-cell 
depletion drugs have shown to be efficacious and relatively safe, highlighting the importance of 
inflammation and the adaptive immune system in this form of arthritis [86, 180, 183, 184]. The most 
effective treatment method is thought to be early DMARD treatment as a preventative measure to 
avoid further joint function loss, rather than targeting patients with advanced disease status [185]. 
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As is evident from the above literature review on cartilage, OA and RA, synovial joints are complex 
organs, and their health is dependent on normal functioning of a number of tissues and body 
systems. In both OA and RA, cartilage breakdown is a central feature of disease, and whilst we have 
learned a great deal about the mechanisms of cartilage degradation in disease, such as the role of 
key proteinases like ADAMTS and MMPs, it is clear in inflammatory arthropathies that adaptive 
immunity and inflammation plays a role in pathogenesis, and there is a growing awareness that 
these same pathways along with aspects of the innate immune system are involved in OA. Despite 
our growing knowledge of OA, there are no disease modifying drugs available, but data from RA 
suggests that with improved understanding of the molecular pathogenesis specific and effective 
disease modifying therapies for OA can be developed. In this regard, recent studies from our and 
other laboratories have suggested there may be a role for S100 proteins in cartilage/chondrocyte 
biology and in the pathogenesis of OA [186-189]. In the following section, the biology of S100 
proteins, the role of S100 proteins in RA and the evidence that S100 may be involved in cartilage 
and/or OA is explored.  
 
1.3 S100 Proteins 
1.3.1 The S100 Protein Family 
1.3.1.1  Discovery and Structure 
S100 proteins were first discovered in 1965, with analysis of bovine brain fractions giving rise to two 
novel proteins that were 100% soluble in saturated ammonium sulphate at neutral pH (hence the 
name S100) and these were named S100B and S100A1 [190, 191]. The S100 protein family now 
consists of over 20 calcium-binding proteins that are exclusively expressed in vertebrates, and have a 
multitude of intracellular and extracellular roles [192]. Generally speaking, they are all of a low 
molecular weight, between 9 and 14 kDa, and most form homodimers linked by non-covalent bonds, 
although some are able to form heterodimers or oligomers with other members of the family [192, 
193].  
 
The S100 proteins are highly conserved, and all have a similar structure and the same intron/exon 
organisation [194]. The structure is that of two distinct helix-loop-helix motifs, called EF hands, one 
of which is a “classical” EF hand, consisting of twelve amino acids, and the second one being a 
variation on the classical version that is unique to S100 proteins, located at the N-terminus, and 
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consisting of 14 amino acids. These EF hands are flanked at each end by hydrophobic regions, and 
joined via a central hinge region, where the majority of divergence between different members 
occurs. Each EF-hand has a calcium-binding region, with the C-terminus having a higher affinity than 
the N-terminus for calcium [195]. In humans, the S100-encoding genes are clustered on region 1q21 
of human chromosome 1, with similar clustering of a number of the S100 protein-coding genes in 
mice (chromosome 3f2) and rats (chromosome 2q34). Orthologous sequences have been described 
from various mammalian species, however they are absent from most invertebrates, and cell- and 
tissue-specific gene expression patterns are also highly conserved between species [196]. The 
exon/intron structure of S100 proteins is identical, as mentioned above, with the exception of 
S100A5, and consists of three exons of different lengths separated by two introns of different 
lengths, the protein being encoded by exons 2 and 3, depicted below in Figure 1.8 [194, 195]. Upon 
calcium binding, usually due to high intracellular levels of Ca2+, S100 proteins change shape, with the 
monomers opening up to expose a target protein-binding site [192, 197]. Apart from calcium 
binding, many S100 proteins have a high affinity for zinc or copper ions, which could regulate 
important homeostatic intracellular or extracellular functions, such as the antiparasitic and 
antifungal properties of S100A12 and S100A9 [198].  
 
Figure 1.8: General gene, mRNA and protein structure of S100 proteins, blue shows protein coding exons 
(adapted from [194]). 
 
1.3.1.2  Roles of S100 Proteins 
S100 proteins have a variety of intracellular roles, including regulation of calcium homeostasis, 
protein phosphorylation, energy metabolism, enzyme activities, cytoskeletal arrangement and 
transcriptional activities [199]. Several S100 proteins are also capable of being secreted into the 
extracellular space and can act as cytokine-like molecules, including S100B, S100A4, S100A6, 
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S100A7, S100A8, S100A9, S100A12 and S100A13 [196, 197]. Unlike some other calcium-binding 
proteins, S100 proteins are not ubiquitous, and tend to be tissue or cell specific. Differential 
expression of S100 proteins is particularly prevalent in diseases, with S100A1 associated with 
cardiomyopathies, S100A7 associated with psoriasis, S100A8, S100A9 and S100A12 associated with 
inflammatory diseases, S100B associated with neurodegeneration, and most S100 proteins 
associated with at least one type of cancer [196, 200]. The functions of S100 proteins may also be 
affected by post-translational modifications through mechanisms such as phosphorylation, 
methylation, acetylation or oxidation [199].  
 
Family members S100A8 and S100A9 are associated with inflammation, which is a common feature 
of arthropathies. There is evidence that S100A8 and S100A9 are involved in cartilage/chondrocyte 
biology, so these family members were chosen as the focus of this thesis, and will be discussed in 
detail in the following sections.  
  
1.3.2 S100A8 and S100A9 
1.3.2.1  The Calgranulin Sub-Family 
The human calgranulin sub-family consists of three distinct S100 proteins: S100A8, S100A9 and 
S100A12. These three proteins are positioned next to each other in the human gene, and have high 
homology. Human S100A8 and S100A9 were originally discovered in 1987 by Odink et al. [201], 
isolated from myeloid cells. The relative molecular masses of S100A8 and S100A9 were found to be 
8kDa and 14kDa respectively, using SDS-PAGE. The S100A8 cDNA was shown to have 279 
nucleotides, corresponding to 93 amino acids, and S100A9 cDNA to have 352 nucleotides, 
corresponding to a length of 114 amino acids. In the same year, S100A8 was also isolated from 
serum of cystic fibrosis patients [202], and more recently, S100A12 was included in this sub-family, 
although rodents do not have an orthologous gene [203]. The murine form of S100A8 (also known as 
CP-10) was first discovered and purified in 1992 [204]. These three proteins are referred to in 
literature by a number of names, as per Table 1.1 below [198].  
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Table 1.1: Alternative names for S100A8, S100A9 and S100A12 
Alternative names for Calgranulin Sub-Family Members 
S100A8 S100A9 S100A12 
Calgranulin A Calgranulin B Calgranulin C 
Myeloid-related protein 8 
(MRP8) 
Myeloid-related protein 14 
(MRP14) 
Myeloid-related protein 6 
(MRP6) 
p8 p14 p6 
B8Ag B8Ag Calgranulin-related protein 
L1Ag L1Ag CaBP in amniotic fluid (CAAF-1) 
60B8Ag 60B8Ag Cornea-associated antigen 
(CoAg) 
L1 light chain L1 heavy chain Extracellular Newly Identified 
RAGE-Binding protein (EN-
RAGE) 
p7 (bovine A8) p23 (bovine A9)  
CP-10 (murine A8) BEE22  
Cystic Fibrosis Antigen [202, 
205] 
Calprotectin (A8/A9 complex)  
Calprotectin (A8/A9 complex)   
 
S100A8 and S100A9 are preferentially found in the body as a heterodimer, with trimers and 
tetramers also reported to be present in humans. The reason for the heterodimerisation of these 
two proteins could be that the complex has a high resistance to protease attack, whereas the 
homodimers are readily degraded by proteases [206]. The higher-order oligomers can only be 
induced in vitro in the presence of calcium (some studies also report formation in the presence of 
zinc [207]) and in this environment, the tetramer is the most abundant form [208, 209]. Oxidation 
may play a role in the function of the proteins as S100A8 and S100A9 both contain a cysteine residue 
which may be oxidised, leading to changes that can be either reversible, after mild oxidation, or 
irreversible, after strong oxidation, potentially affecting the binding sites on these proteins [199]. 
The properties of mouse S100A8 (CP-10) differ from those of human S100A8, and have some 
commonality with human S100A12, suggesting that the human S100A8 gene may have duplicated 
and diverged such that these two proteins split the functions of murine S100A8 [198].  
 
1.3.2.2  S100A8 and S100A9 in Immunity  
S100A8 and S100A9 have both intracellular and extracellular roles in the immune system. They are 
highly abundant in heterodimeric form in some cells of the immune system, such as neutrophils, 
monocytes and activated but not resting macrophages [193, 210]. The S100A8/A9 heterodimer is 
also referred to as a damage associated molecular pattern (DAMP); a molecule that is primarily 
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involved in intracellular activity but acts as an extracellular danger signal when released as a result of 
cell damage or is secreted by activated cells [211, 212]. In neutrophils, S100A8 and S100A9 make up 
around 40% of the soluble cytosolic protein content [213]. S100A9 has been found in two different 
isoforms in neutrophils, one being truncated (lacking the first four amino acids), and differences 
occur in both these proteins upon phosphorylation, which could be a regulatory mechanism of 
intracellular activity [214]. In neutrophils, S100A8 and S100A9 have been found to translocate to the 
membrane during activation of these cells in the presence of high levels of calcium [215, 216]. The 
heterodimer also aids in the formation of microtubules in the cytoskeleton of neutrophils; a process 
necessary for many cellular activities including cell division and motility [209].  
 
Despite the abundance of the heterodimer (S100A8/A9) in neutrophils and its affinity for zinc and 
calcium ions, it does not appear to regulate calcium or zinc homeostasis in these cells [217]. The 
heterodimer is highly abundant in acute inflammation, in monocytes and macrophages, however, in 
chronic conditions, the heterodimer is far less abundant and appears to dissociate into monomers 
[218, 219]. Extra-cellular S100A8 and S100A9 have also been found to be necessary co-factors for 
induction of auto-reactive CD8 T-cells, and systemic auto-immunity [220]. The heterodimer, though 
highly active in inflammation, appears not to be indispensable. S100A9-null mice are healthy and 
viable, with no change in number or morphology of immune cells, and an immune response was still 
seen in these animals. In S100A9-null mice despite having S100A8 mRNA in immune cells, no S100A8 
protein was detectable, suggesting post-transcriptional loss, probably due to the absence of its 
binding partner and the susceptibility of the homodimer to degradation [221]. The heterodimer can 
be expressed on the surface of neutrophils, and can assist in the trafficking of leukocytes by binding 
to activated endothelial cells via carboxylated N-glycans [222]. Alternatively, the heterodimer can 
bind to heparan sulphate proteoglycans on endothelial cells [211], and this binding occurs on the 
S100A9 end of the dimer. Binding can be blocked by heparin, heparan sulphate and chondroitin 
sulphate B, and binding cannot occur in glycosaminoglycan negative cell lines. This study also proved 
that the S100A8/A9 was not expressed by the endothelial cells [223]. Further to this, S100A8/A9 
does not bind to resting endothelium, as shown by a co-culture of stimulated monocytes and 
endothelial cells, and high intracellular calcium levels in monocytes were required for binding [224]. 
S100A8 and S100A9 homodimers can bind to activated endothelial cell line HMEC-1 in addition to 
the complex, in the order of affinity S100A8<S100A9<S100A8/A9 [225]. 
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The S100A8/A9 heterodimer can be secreted from neutrophils via a novel secretion method 
involving microtubules and activation of protein kinase C, induced by inflammatory stimuli such as 
cytokines or bacteria, and through elevation of intracellular calcium levels, which can be induced 
when phagocytes are in contact with activated endothelial cells [226, 227]. In the extracellular space, 
S100A8/A9 has strong chemotactic activity (ability to stimulate and attract neutrophils) [228], as well 
as anti-bacterial properties, being able to suppress the growth of yeast and fungi; properties which 
may be regulated by zinc binding [210]. Regulation of the chemotactic ability of the complex could 
be via oxidation, at least in murine systems, as oxygen metabolites are present at inflammatory 
sites, at the S100A8 end, leading to conversion to a covalent homodimer, usually inactive in 
chemotaxis [229]. S100A8/A9 has been shown to induce a thrombogenic, inflammatory response in 
endothelial cells by increasing the synthesis of pro-inflammatory chemokines and adhesion 
molecules, and down-regulating the genes involved in endothelial cell-cell interactions [230]. This 
breakdown of cell-cell interactions leads to apoptotic and necrotic death of the endothelial cells, 
impairing the integrity of the endothelium [231]. Interestingly, anti-inflammatory properties have 
been reported for S-nitrosylated S100A8 (modification by nitric oxide) by suppressing in vitro 
leukocyte adhesion and extravasation [232]. NF-κB, p38 MAPK, and ERK1/2, have been implicated in 
inflammatory effects through stimulation of endothelial cells [233], and monocytes [234] with 
S100A8/A9. In the immune system, the heterodimer has been shown to be modulated by 
intracellular calcium levels and/or signalling via the p38 MAPK cascade [235]. Inhibition of p38 can 
also inhibit phosphorylation of S100A9 in human neutrophils [236]. S100A8 is vital in embryonic 
development, possibly in prevention of maternal rejection of embryos by protecting the embryo 
from immune attack by maternal cells. Deletion of the S100A8 gene in mice results in embryonic 
absorption at 8.5-9.5 days, with no abnormalities seen until this point. In normal mice, S100A8 is 
expressed in large mononuclear cells following initial attachment and implantation of the embryo, 
but is no longer expressed after 8.5 days [237].   
 
1.3.2.3  S100A8 and S100A9 Signalling Pathways 
The most common receptor associated with S100 proteins is the receptor for advanced glycation 
end products (RAGE). RAGE has been reported to bind to S100B, S100A4, S100A6, S100A7, S100A11, 
S100A12 with controversial reports for the binding of RAGE to S100P [238], S100A8 and S100A9 
[197, 239]. S100A12 binds RAGE and plays a role in the inflammatory process, where blocking of 
RAGE suppresses both acute and chronic inflammation, and decreases activation of NF-κB and 
expression of pro-inflammatory cytokines [240]. Whether the S100A8/A9 heterodimer binds to 
RAGE remains unclear, with some studies reporting that it does [239, 241], while others suggest that 
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S100A8/A9 does not bind to RAGE [234, 242]. This discrepancy in the literature may be associated 
with differences between cell types or species studied. The binding of S100A8/A9 to RAGE in tumour 
cell lines led to the phosphorylation of MAPK pathways p38 and p44/42, as well as NF-κB without 
significant phosphorylation of JNK [241]. Other documented receptors for S100A8/A9 include CD36 
[243], NADPH oxidase [244] and TLR4 [211]. TLRs are intimately involved in the innate immune 
system, recognising pathogenic micro-organisms by specific molecular patterns present in microbes 
[245]. The TLRs are transmembrane receptors with an intracellular domain very similar to the IL-1R 
family, and an extracellular receptor domain [245]. After ligand binding, TLRs dimerise and undergo 
conformational changes which allow them to recruit downstream signalling molecules [245]. The 
signalling cascade includes proteins MyD88, the IRAK family, and TRAF6, and is able to activate both 
the MAPK and NF-κB pathways [245]. Different TLRs, however, activate slightly different signalling 
pathways. Two separate signalling pathways have been identified: a MyD88-dependent pathway; 
and a MyD88-independent pathway, and whilst most TLRs activate one or the other, TLR4 can 
activate both [246]. The different TLR pathways are shown in Figure 1.9, with TLR1, -2, -4, -5, -6, -7, 
and -9 activating the MyD88-dependent pathway, and TLR3 and -4 activating the MyD88-
independent pathway [245]. Major ligands of TLR4 are LPS, produced by bacteria, and cause septic 
shock. LPS signals through both the MyD88-dependent and MyD88-independent pathways, with the 
former being an early response leading to activation of NF-κB and MAPK pathways p38 and JNK, 
while the latter is a late response that activates NF-κB [247]. 
 
Figure 1.9: MyD88-dependent and MyD88-independent pathways involved in TLR activation [245]. 
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1.3.2.4  S100A8 and S100A9 in Pathology 
S100A8 and S100A9 are up-regulated in many pathologies; particularly those with an inflammatory 
component. A novel but very rare inflammatory disease has been reported in a handful of patients in 
which very high levels of S100A8 and S100A9 are present systemically (referred to as 
hypercalprotectinaemia). The symptoms of the disease include hyperzincaemia, recurrent infections, 
cutaneous vasculitis (inflammation of bold vessels in the skin) and arthritis. High levels of the 
heterodimer appear at the onset of this disease, possibly due to a deficiency in catabolism or 
excessive synthesis, as it is not related to an increase in the number of immune cells [213, 248, 249]. 
The heterodimer is also present in monocytes involved in acute kidney allograft rejection, however, 
in chronic kidney allograft rejection, the two proteins are differentially expressed, supporting the 
increased role of S100A8/A9 in acute inflammation [250]. Persistent pain due to hypersensitivity of 
neurons in the spinal cord after tissue damage was shown to correlate with higher levels of S100A8 
and S100A9 localised to this area, expressed by infiltrating neutrophils [251]. S100A9 is expressed by 
keratinocytes in skin, and the heterodimer has been implicated in wound repair by reorganisation of 
the keratin skeleton [192, 200, 252, 253]. Similarly, S100A8 but not S100A9 expression can be 
induced in fibroblasts by IL-1β or heparin/FGF-2, and is implicated in fibroblast growth and 
differentiation at sites of wound healing [254]. The heterodimer is present in infiltrating immune 
cells in inflammatory myopathies, regulating the regeneration of myoblasts by inhibiting 
proliferation and differentiation and increasing apoptosis of affected cells [255].  
 
Recently, S100A8 and S100A9 have been shown to be up-regulated in cardiac tissue exposed to LPS 
stimulation, suggesting a role in cardiac dysfunction [239]. The dual role of S100A8 and S100A9 in 
cancer is becoming increasingly apparent. Many groups have reported the up-regulation of these 
two proteins in various skin cancers, adenocarcinomas, cervical carcinomas, and breast cancer cells 
[200, 252, 256, 257]. These proteins (released by immune cells) have been associated with increased 
apoptosis in various tumour cells, such as colon cell lines [258], and have therefore been proposed 
as highly cancer-specific therapeutics. Zinc binding to colon cancer cell lines resulted in partial 
inhibition of apoptosis of these cells [258]. Conversely, S100A8 and S100A9 have also been 
implicated in tumour development, cancer invasion and metastasis [259]; clearly more research is 
needed to establish how the different roles are regulated.  
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1.3.2.5  S100A8 and S100A9 in Rheumatoid Arthritis 
The infiltration of immune cells to the synovium in RA is led by activated phagocytes that express the 
S100A8/A9 heterodimer. The highest levels of the heterodimer are at the cartilage-pannus junction, 
where the majority of cartilage destruction occurs, and elevated levels are found in the synovial fluid 
and serum of RA patients [213]. Levels of the S100A8/A9 heterodimer, and S100A12, are elevated in 
the synovial fluid and serum of active RA patients compared to non-erosive RA patients, healthy 
volunteers and osteoarthritic patients [174, 260-262], with the heterodimer being approximately 
1000 times more prevalent than either the S100A8 or S100A9 homodimer. Whilst lower than RA 
patients, levels of the heterodimer in synovial fluid from OA patients are still significant, generally 
around 5µg/ml [234]. Similarly, S100A8, S100A9 and S100A12 are differentially expressed in RA 
compared to other inflammatory arthritides, and it has been suggested therefore they could be used 
as specific biomarkers with high accuracy at early stages of the disease [263]. The heterodimer also 
correlates well with currently used clinical biomarkers such as rheumatoid factor and C-reactive 
protein, as well as clinical markers such as joint damage and pain, acting as a good measure of 
disease activity [264, 265]. A 10-year study found that S100A8/A9 was consistently found to predict 
radiographic and clinical measures of joint damage [266], however another group found the 
heterodimer to be a poor predictor of joint damage and functional impairment at a five-year follow-
up [264]. The DMARD drugs based on cytokine targeting do not interfere with this prediction, so the 
heterodimer only reflects leukocyte activation during inflammation [266]. Levels of S100A8/A9 do 
not directly relate to neutrophil number, as opposed to the correlation in other inflammatory 
arthritides, suggesting that the heterodimer could also be expressed by the synovial cells [263], with 
in vitro evidence of this shown through the spontaneous production of the complex by isolated RA 
synovial tissue cells [234]. Interestingly, S100A4 has also been reported to be expressed by a number 
of immune cells infiltrating human RA synovial tissue, with a large increase detected in synovial fluid 
and plasma, although its role in disease pathogenesis is unclear [267]. 
 
Juvenile Idiopathic Arthritis (JIA) is a general term for inflammatory arthritis in children and 
teenagers (<16 years of age). S100A8/A9 has been detected at high levels in the serum and synovial 
fluid of JIA patients with active disease [224] being about 120 times higher than healthy controls 
[268], with levels decreasing to near normal in remission [269]. The symptoms of JIA are often hard 
to distinguish from other inflammatory pathologies, however, the heterodimer has been shown to 
be differentially expressed in JIA compared to other inflammatory pathologies (around 12 times 
higher in JIA), again making it a potential highly specific, highly accurate biomarker [268, 270]. In a 
recent clinical trial, S100A8/A9 levels were able to accurately predict whether patients in remission 
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would suffer a flare in the following three months [271]. S100A8/A9 was also found to be expressed 
by leukocytes and keratinocytes in skin samples of rashes from early stage patients, representing a 
potential, non-invasive testing procedure [268]. It has been suggested that the heterodimer 
represents a novel feedback mechanism in systemic-onset JIA [269]. 
 
1.3.3 S100 Proteins in Joint Tissues and Osteoarthritis 
The previous section clearly shows a role for S100A8 and S100A9 in inflammatory arthropathies, but 
there is emerging data suggesting these proteins may also play a role in OA. Several S100 proteins 
have been shown to be expressed by chondrocytes or bone cells, as reviewed in [272]. S100A2, 
S100A4 and S100A11 are expressed by healthy chondrocytes, with levels of S100A4 and S100A11 up-
regulated in osteoarthritic cartilage compared to healthy cartilage [273-275]. Addition of S100A4 to 
chondrocytes in vitro up-regulated the expression of MMP-13 [274]. S100A1, S100B and S100A11 
are all linked with terminally differentiating chondrocytes, with S100A1 and S100B suggested to be 
involved in inhibition of terminal differentiation [276], whereas S100A11 induced chondrocyte 
hypertrophy [275]. In addition, S100A2 and S100A4 were found to be expressed by bone cells [272, 
273, 277].  
 
Studies into the relationship of S100A8/A9 to RA have thus far focused on expression of these 
proteins in immune cells and, to a lesser extent, synovial cells; however it is now known that 
chondrocytes also express S100A8 and S100A9 [186]. In mice, S100A8 was localised in growth plate 
mature and degenerating hypertrophic chondrocytes and in and near hypertrophic chondrocytes in 
calcifying areas of the epiphyseal cartilage. S100A8 was also localised in human hypertrophic 
chondrocytes [186]. Abundant positive staining for S100A8 was found close to articular 
chondrocytes and in areas of proteoglycan loss in human osteoarthritic articular cartilage, 
correlating with expression of proteases such as MMPs [188]. Unsurprisingly, strong 
immunolocalisation of S100A8 and S100A9 is seen in murine bone marrow (a major source of 
immune cells), particularly in neutrophils, but S100A8 was also present in osteoblasts, and both 
S100A8 and S100A9 were present in osteoclasts in certain areas, including at sites of rapid 
remodelling in human bones [186]. S100A8 staining was found to be strongest in pre-osteoblastic 
cells, and weakened with maturity. IL-1 stimulation of murine femoral head cartilage explants and 
over-expression of IL-17 or TNF in murine knee joints leads to both increased mRNA expression and 
cellular staining of S100A8 and S100A9, suggesting that these proteins are involved in the 
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inflammatory component of OA [187, 278]. Using chondrocyte monolayer cultures, two groups have 
shown that stimulation by S100A8 can increase mRNA levels of ADAMTS-4 and -5, as well as MMP-3 
and -13, with one group also finding increased levels of MMP-2 and -9 (in a murine chondrocyte cell 
line) [279], and the other additionally finding increased levels of ADAMTS-1, MMP-1 as well as a 
down-regulation of aggrecan and collagen type II, all of which could also be stimulated by S100A9 
but not S100A8/A9 (in primary ovine articular chondrocytes) [187, 280]. Human monolayer cultures 
and explants have also been stimulated with S100A8, S100A9 or the heterodimer (short term 
cultures only), with similar gene expression changes seen to those reported in chondrocyte 
monolayers [188]. 
 
S100A8 and S100A9 have been widely studied in the context of experimental mouse models of 
arthritis, particular via the use of the S100A9-/- mice. These arthritis models can be categorised into 
those mimicking inflammatory arthropathies, and those modelling post-traumatic OA, with 
interesting differential effects observed based on the degree of inflammation. Experimental 
inflammatory arthritis models in mice showed S100A8 and S100A9 were abundantly expressed in 
and around chondrocytes [279], as well as in synovium [189]. Lack of S100A9 was protective in 
inflammatory models, such as antigen-induced arthritis (AIA) and collagen-induced arthritis (CIA). 
Decreased cartilage destruction, MMP expression [281], synovial activation [189] and bone erosion 
[282] in AIA has been shown in S100A9-/- compared to controls, whilst intra-articular injection of 
S100A8 to wild type and S100A9-null mice led to joint inflammation, depletion of proteoglycans and 
up-regulation of cytokines, MMPs and ADAMTSs in synovium, suggesting a role for S100A8 in the 
instigation of inflammatory arthritis [281]. Neutralisation of S100A9 using a specific antibody 
improved clinical scores, diminished immune cell infiltration, reduced inflammatory cytokines, both 
in serum and in the joints, and preserved bone/collagen integrity in a murine LPS-synchronized CIA 
model, suggesting that S100A9 enhances the immune response seen in this inflammatory arthritis 
model [283]. A second group, however, found no differences in regard to joint damage or bony 
erosions of S100A9-/- mice compared to wild type littermates in CIA or K/BxN serum transfer models, 
representing a chronic and acute form of inflammatory arthritis respectively [284]. The reason for 
this inconsistency is unclear. 
 
The post-traumatic surgery model of OA, however, does not appear to have the same involvement 
of S100A8 and S100A9. An increase in S100A8 and S100A9 gene expression was observed in cartilage 
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in early (one or two weeks post-operatively) surgically-induced OA (DMM model) in mice, however 
mRNA for both proteins were decreased at late stages (six weeks post-operatively) [187]. In contrast 
to this, S100A8 cellular staining in non-calcified cartilage was decreased at weeks two, eight and 16 
in sections taken from the same mice, perhaps suggesting secretion from the cells. These results 
were in contrast with antigen-induced-arthritis (AIA), in which cellular staining of S100A8 and 
S100A9 increases. Van Lent et al. [189] had similar findings, in which mRNA levels of S100A8 and 
S100A9 were only increased at day seven in synovium, along with an increase in protein levels in the 
synovium, mostly seen in macrophages. There was no protective effect in the S100A9-/- mice in this 
surgically-induced model, while in collagenase-induced arthritis (CiOA – representing instability-
induced arthritis with a profound inflammatory component), ablation of S100A9 was protective. 
Whilst both RAGE and TLR4 can be expressed by chondrocytes [272], TLR4 is the dominant signalling 
pathway in the context of in vitro chondrocyte experiments and experimental murine models. In 
monolayer chondrocyte cultures, blocking TLR4 with a synthetic inhibitor decreased S100-induced 
gene expression changes by up to 80%, where blocking of RAGE or carboxylated glycans had no 
effect [188]. Blocking TLR4 has been shown to partially reverse the stimulatory action of S100A8 in 
both mice and humans, but does not completely block it, pointing to the possible involvement of 
other pathways being activated by S100A8 [220]. 
 
It is clear that S100A8 and S100A9 are heavily involved in inflammatory arthritides, both in human 
disease (RA) and in experimental mouse models (AIA, CIA, CiOA); however their role(s) in OA are less 
clear. Further to this, the reason for S100A8 and S100A9 to be expressed by cartilage cells has not 
been determined; these proteins are classically involved in inflammation and immunity, and 
therefore have no obvious role in cartilage. The effect of exogenous S100A8 and S100A9 on 
chondrocyte monolayer cultures has been briefly examined, with results showing a shift to a 
catabolic gene expression profile, however, only one study has looked at the mechanisms behind 
this (binding partners, signalling pathways), and none have looked into the implications of this to the 
cartilage itself (i.e. physical breakdown of cartilage).  
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1.4 Summary of Literature Review and Research Aims 
From the literature it is clear that: 
 OA is a complicated disease, and whilst the body of knowledge on the mechanisms involved 
in OA has increased rapidly, there is still much that is unknown, and this is hindering the 
development of disease-modifying drugs; 
 OA, whilst not classically described as an inflammatory disease, has an inflammatory 
component and involves the adaptive immune system; 
 S100A8 and S100A9 are well known to play a role in inflammation and inflammatory 
arthritis, but emerging evidence suggests they may be involved in cartilage and the 
pathogenesis of OA. 
  
To date the role of S100A8 and S100A9 in cartilage and OA pathology has not been determined. 
Therefore the aim of this research is to determine the potential role of S100A8 and S100A9 in 
cartilage, in particular cartilage breakdown, a central feature of OA; with a hypothesis that S100A8 
and S100A9 are active players in the mechanisms involved in cartilage degradation due to 
osteoarthritis. 
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Chapter 2 General Methodology 
The methods described in this chapter are those commonly used throughout the course of this 
thesis. Methods and techniques specific to a particular study, or that differ significantly from that 
described below are presented in detail in the Methods section of the relevant chapter. Details of all 
reagents used are outlined in Table 2.5. 
2.1 Tissue Culture Methods 
2.1.1 Articular Cartilage Explant Cultures 
Ovine articular cartilage was obtained from the joints of 6-12 month old sheep within 24 hours of 
sacrifice (generous gift from Peare Meats Australia). Human articular cartilage was obtained from 
the knee joints of patients undergoing total knee replacement surgery (with patient consent and 
approval of NSCCAH Human Research Ethics Committee). Under sterile conditions, ovine knee joints 
were opened to expose the trochlear groove, and all excess material cut away using a scalpel blade. 
Small pieces (approximately 8mmx5mm) of full-thickness cartilage were harvested from the 
trochlear groove (ovine and human), and placed in PBS containing 50µg/ml gentamycin. Cartilage 
explants were then left to equalise at 37oC for 48 hours in Dulbecco’s modified Eagle medium 
(DMEM) buffered with 3.7g/L sodium carbonate, containing 10% Fetal Calf Serum (FCS), 2mM 
Glutamine and 50µg/ml gentamycin. Cultured explants were then washed three times for at least 10 
minutes in serum-free media to remove FCS, and then cultured in a variety of different conditions. 
Typically, explants were cultured in 24-well plates in 1ml serum-free media, for four days, with 
added S100A8, S100A9, S100A8/S100A9 or IL-1 (IL-1α for ovine, IL-1β for human) at the following 
concentrations: S100A8, S100A9 and S100A8/S100A9 at 0.1µM; IL-1 at 10ng/ml. At the end of the 
culture period, conditioned media was collected. Media from longer cultures (up to 14 days) was 
changed every 3-4 days, pooled and stored at -20oC for biochemical analysis to give cumulative 
results over the total time period studied.  
 
2.1.2 Isolation and culture of chondrocytes 
Full thickness cartilage was dissected and pooled from the trochlear groove, femoral condyles and 
tibial plateau. Cartilage was placed in a petri dish with PBS containing 50µg/ml gentamycin, and, 
using two small scalpel blades, was finely diced, transferred to a 50ml tube, and centrifuged at 
2000rpm (870 x g) using a Beckman Bench Centrifuge. Cartilage was washed in PBS, and then 
centrifuged at 2000rpm, before incubation at 37oC for 90-120 minutes in 0.1% Pronase in 
DMEM/F12 containing 10% FCS, 2mM Glutamine and 25µg/ml gentamycin. Cartilage was then 
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centrifuged and washed in media, then incubated at 37oC overnight in 0.05% Collagenase in 
DMEM/F12 containing 10% FCS, 2mM Glutamine and 25µg/ml gentamycin. Collagenase digest was 
then centrifuged and washed in media, then filtered through a 70µm cell sieve to remove any un-
digested particles. Isolated chondrocytes were counted using Trypan blue and a haemocytometer, 
and cells seeded at 500,000 cells/well in 6-well plates containing 2ml media (DMEM/F12 containing 
10% FCS, and 2mM Glutamine) per well. Cells were left to attach for at least 48 hours, then media 
was refreshed every two days until cells reached approximately 90% confluence, at which point they 
were incubated in serum-free media for four hours at 37oC. Chondrocyte monolayer cultures were 
then treated for 24 hours with serum-free media ± 0.01µM S100A8, S100A9 or S100A8/S100A9, or 
IL-1α at a concentration of 1ng/ml. 
 
2.1.3 Human Bone-Marrow derived Mesenchymal Stem Cells 
2.1.3.1 Isolation of Human Bone-Marrow derived Mesenchymal Stem Cells 
Isolation and culture of mesenchymal stem cells (MSCs) was performed as part of a Boerhinger 
Ingleheim Fonds Travel Grant for a three-month collaborative project at Saarland University, 
Germany to undertake research training at Prof Henning Madry’s Laboratory. Bone marrow 
aspirates (10-15 ml) were obtained from the distal femurs of patients undergoing total knee 
arthroplasty. All patients provided informed consent prior to inclusion in the study and all 
procedures were in accordance with the Helsinky Declaration. Aspirates were washed multiple times 
in DMEM, red blood cells were lysed by adding red cell lysis buffer for 1-2 minutes, and the cell-
containing fractions were centrifuged at 800xg for 30 minutes at room temperature. The nucleated 
cell fraction at the interface was collected, washed, and resuspended in DMEM containing 10% FCS, 
100 U/ml penicillin and 100 ml/ml streptomycin (pen-strep) (basal media) and rFGF-2 (10 ng/ml, only 
after the fourth day of culture). MSCs were plated at a density of 200,000 cells/cm2 in T-75 flasks and 
maintained at 37°C in a humidified atmosphere with 5% CO2. The medium was changed after 48 
hours and every 2-3 days thereafter. Cells were detached and replated for further experiments at 
appropriate densities. All experiments were performed with cells at no more than passage three. 
 
2.1.3.2 Chondrogenic Differentiation of Mesenchymal Stem Cells 
Confluent flasks of MSCs were trypsinised and washed, then aggregate cultures (200,000 cells) were 
prepared in 1.5ml tubes by centrifugation at 1500rpm for five minutes, and kept in 300µl high 
glucose DMEM (4.5 g/l), pen-strep, ITS+ Premix (insulin 6.25 mg/ml, transferrin 6.25 mg/ml, 
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selenous acid 6.25 mg/ml, linoleic acid 5.35 mg/ml, bovine serum albumin 1.25 mg/ml), pyruvate (1 
mM), ascorbate 2-phosphate (37.5 mg/ml), dexamethasone (10-7 M), and TGF-β3 (10 ng/ml) at 37°C 
in a humidified atmosphere with 5% CO2. The cells formed a free-floating mass within 24 hours that 
was kept in defined medium for up to 21 days, with media changed every 2-3 days. 
 
2.1.3.3 Osteogenic Differentiation of Mesenchymal Stem Cells 
Confluent flasks of MSCs were trypsinised and washed, then plated into 6-well plates at a density of 
45,000 cells per well, in 2ml basal media (defined in Section 2.1.3.1) for 1-2 days. Basal media was 
then removed and replaced with StemPro osteogenic differentiation media for up to 21 days, with 
media changed every 2-3 days.  
 
2.1.3.4 Adipogenic Differentiation of Mesenchymal Stem Cells 
Confluent flasks of MSCs were trypsinised and washed, then plated into 6-well plates at a density of 
90,000 cells per well, in 2ml basal media (defined in Section 2.1.3.1) for 1-2 days. Basal media was 
then removed and replaced with StemPro adipogenic differentiation media for up to 21 days, with 
media changed every 2-3 days. 
 
2.2 Molecular Biology Methods 
2.2.1 RNA Extraction 
RNA extraction from cells was performed using Trizol reagent on all cell types; however the 
extraction method for each culture method was slightly different. 
 
2.2.1.1 Monolayer Cell Cultures 
The method of RNA extraction using Trizol was identical for all monolayer cell cultures: chondrocytes 
and MSCs cultured in osteogenic or adipogenic cultures. Media was removed from wells, collected 
and stored at -20oC for later use. Cells were washed in 1xPBS, and then 700µl Trizol reagent was 
added to each well and shaken for 1-2 minutes. Liquid was collected to labelled tubes, then a further 
300µl Trizol added to each well and collected to 1.5ml microcentrifuge tubes. Trizol-containing tubes 
were stored at -80oC until further processing. 
40 
 
2.2.1.2 Chondrogenic Pellet Cultures 
At the end of the culture period, media was removed and pellets stored in their tubes at -20oC until 
further processing. Pellets were pooled into time points (three per tube), and 100µl of collagenase, 
trypsin and hyalurinodase (CTH) in 300µl DMEM was added and incubated for three hours at 37oC on 
a rotor. Tubes were then centrifuged for five minutes at 5000rpm, supernatant was removed, and 
pellets resuspended in 10% RNA Later Stabilisation reagent in PBS, and stored at -80oC until further 
processing. Samples were then thawed, centrifuged for five minutes at 5000rpm and supernatant 
removed and replaced by 300µl β-mecaprethanol 1:100 in RLT buffer (supplied in kit), vortexed and 
liquid transferred to a Qiashredder column. Samples were then centrifuged for two minutes at 
12,000 rpm, filter discarded, and 350µl 70% ethanol added, mixed, and transferred to an RNEasy 
spin column, and continued as per Section 2.2.1.4 from the first RW1 wash. 
 
2.2.1.3 Articular Cartilage Explants 
Media was removed from wells, collected and stored at -20oC for later use. Cartilage explants were 
weighed, snap-frozen in 2ml tubes and stored at -80oC until further processing. 2ml tubes containing 
snap-frozen cartilage explants were retrieved from -80oC freezer and placed in liquid nitrogen. 
Approximately 30-100mg samples of tissue were homogenised using a Mikro-Dismembrator (Braun 
Biotech International, Germany), with 1ml Trizol reagent added immediately after homogenisation, 
and left to incubate at room temperature for 45 minutes (minimum 30 minutes, maximum one 
hour). A further 300µl Trizol was added to tissue to ensure the entire sample was collected. Liquid 
was then transferred to 1.5ml microcentrifuge tubes and stored at -80oC until further processing. 
 
2.2.1.4 RNA Isolation 
The following method was identical for all samples regardless of cell type or culture method. Trizol-
containing tubes were thawed at room temperature, and 300µl chloroform per ml of Trizol was 
added, vortexed vigorously for 15 seconds, and incubated at room temperature for 3-5 minutes. 
Tubes were then centrifuged at 12,000rpm (≈13,000xg) for 15 minutes in a microcentrifuge to 
separate the aqueous phase from phenol waste. The aqueous phase was transferred to a new 2ml 
tube, and an equal amount of 70% ethanol added and gently mixed. RNA isolation was performed 
using the Qiagen RNeasy Mini Kit. Samples were loaded into spin columns supplied with the kit and 
centrifuged, then washed with RW1 buffer. DNA was removed by incubating samples with Qiagen 
RNase-free DNase for one hour at 37oC. Samples were then washed once in RW1 buffer and twice in 
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RPE buffer, then RNA was eluted using 32µl RNase-free H2O and stored at -80
oC until further 
processing. 
 
2.2.2 Reverse Transcription 
In all experiments, the full set of sample data for that experiment was reverse transcribed at the 
same time, using the same master mix. All RNA samples were denatured at 70oC for five minutes in a 
heat block on removal from -80oC storage. RNA was quantified and the quality of the RNA checked 
using a Nanodrop® Spectrophotometer. An equal amount of each RNA sample (minimum 0.5µg, 
usually 1µg) was reverse transcribed using the Qiagen Omniscript RT kit, with random 
pentadecamers and Bioline RNase inhibitor included in the master mix. RNA samples with the added 
master mix were centrifuged quickly and incubated for three hours at 37oC prior to five minutes at 
93oC to stop the reaction. cDNA samples were then diluted such that there was 150µl per original µg 
of RNA, then stored at 4oC while in use, and at -20oC for long-term storage. 
 
2.2.3 Real-Time RT-PCR 
All gene expression data were obtained using a Rotor-Gene™ 3000 (Corbett life sciences Australia). A 
master mix was made up for each gene containing 1xImmomix, molecular biology grade water, 
1xSYBR® Green I and forward and reverse primers at 10µM each, which was combined in PCR tubes 
with the cDNA samples. Runs were performed either on a 72-sample ring (20µl master mix and 5µl 
cDNA sample) or a 100-sample ring (12µl master mix and 3µl sample). A standard curve was 
produced using pooled cDNA samples diluted 4x4, and this was run in duplicate, with water as a 
negative control. Each run had the following thermal profile: 95oC for 10 minutes, then 45-55 cycles 
of 95oC for 10 seconds, a primer-specific annealing temperature for 15 seconds, extension at 72oC 
for 20 seconds, and finally melt data was obtained by gradual heating to 95oC. Melt curves were 
constructed from the melt data, and standard curves were constructed using the diluted samples, 
allowing quantification of all samples relative to the standard curve. All results were expressed as 
fold change compared to internal controls. 
 
2.2.3.1 Ovine Primers 
Ovine primer sets were designed for quantitative real-time PCR using Macvector® primer design 
software. Primer pairs were obtained from Sigma Aldrich, Australia and are outlined in Table 2.1 
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below. The specificity of all the primers was confirmed by demonstrating a single product of 
appropriate size and sequencing (AGRF, Sydney, Australia). Where ovine gene sequences were 
unavailable, bovine sequences were used to develop primers, as the bovine genome has a high 
sequence affinity with the ovine genome. 
Table 2.1: Ovine primer pairs used in all studies 
Gene Species  
Accession Number 
Sequence 5’ to 3’ Temp 
ADAMTS-1 Bos taurus 
XM589626 
F – CCA ACT GGA GCC ACA AAC ATT G 
R – GGA CAG AGT GAA GTC GCC ATT C 
55 
ADAMTS-4 Bos taurus 
NM181667 
F – AAC TCG AAG CAA TGC ACT GGT 
R – TGC CCG AAG CCA TTG TCT A 
60 
ADAMTS-5 Bos taurus 
AF192771 
F – GCA TTG ACG CAT CCA AAC CC 
R – CGT GGT AGG TCC AGC AAA CAG TTA C 
55 
Aggrecan Bos taurus 
U76615 
F – TCA CCA TCC CCT GCT ACT TCA TC 
R – TCT CCT TGG AAA TGC GGC TC 
58 
Collagen 2a1 Bos taurus 
X02420 
F – TGA CCT GAC GCC CAT TCA TC 
R – TTT CCT GTC TCT GCC TTG ACC C 
55 
GAPDH Ovis aries 
U94889 
F – CCT GGA GAA ACC TGC CAA GTA TG 
R – GGT AGA AGA GTG AGT GTC GCT GTT G 
58 
MMP-1 Ovis aries 
AF267156 
F – CAT TCT ACT GAC ATT GGG GCT CTG 
R – TGA GTG GGA TTT TGG GAA GGT C 
55 
MMP-2 Ovis aries 
AF267159 
F  – TGC TAC CAC CTC CAA CTA CGA TG 
R –  GTG CCA GTA TCA ATG TCA GGG G 
60 
MMP-3 Bos taurus 
AF135232 
F – TCC CCC AGT TTC CCC TAA TG 
R –GAT TTC TCC CCT CAG TGT GCT G 
58 
MMP-9 Bos taurus 
X78324 
F – AGG TGA ATC AGG TGG ACT ATG TGG 
R – AGA AAG GAA GGT GGG AAG AGA GG 
59 
MMP-13 Ovis aries 
AY091604 
F – TGA CAG GCA GAC TTG ATG ATA AC 
R – CAT TTT GGA CCA CTT GAG AGT TC 
58 
MMP-14 Ovis aries 
AF267160 
F - ACC AGG TGA TGG ATG GAT ACC C 
R - CCC AGT GCT TGT CTC CTT TGAAG 
56 
S100A8 Bos taurus  
BC111678 
F – GGC AAC TCT ATT TTG GGG AGA CC 
R – CCT TTA TCA CCA GCA CGA GGA AC 
56 
S100A9 Bos taurus 
NM01046328 
F – TTC TCG GCT TGG TAG GAG GG 
R – CTG GTG GAA GAT GTT GAT GAT GG 
55 
TIMP-1 Ovis aries 
S67450 
F -  GGT TCA GTG CCT TGA GAG ATG C 
R -  GGG ATA GAT GAG CAG GGA AAC AC 
57 
TIMP-2 Bos taurus 
M32303 
F – ACT CTG GCA ACG ACA TCT ACG G 
R – TCT TCT TCT GGG TGG CAC TCA G 
57 
TIMP-3 Bos Taurus 
NM174473 
F – CTT CCT TTG CCC TTC TCT ACC C 
R – TCT GGT CAA CCC AAG CAT CG 
57 
TLR4 Ovis aries 
NM001135930 
F – GCT GAA TCT CTA CAA AAT CCC CG 
R – AAA GGC TCC CCA GGC TAA ACT C 
56 
2.2.3.2 Human Primers 
Human primer sets were designed for quantitative real-time PCR using Macvector® primer design 
software. Primer pairs were obtained from Sigma Aldrich, Australia and are outlined in Table 2.2 
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(cartilage genes) and Table 2.3 (differentiation genes used in Germany) below. The specificity of all 
the primers was confirmed by demonstrating a single product of appropriate size and sequencing 
(AGRF, Sydney, Australia), with the exception of those listed in Table 2.3, which were run on agarose 
gel electrophoresis to ensure specificity. 
Table 2.2: Human primer pairs used in all cartilage studies 
Gene Species  
Accession Number 
Sequence 5’ to 3’ Temp 
ADAMTS1  Homo sap. 
BC036515 
F – TGT GTC CAG TCA CCG CTA TGT G 
R – TCT TCA CCA CCA CCA GGC TAA C 
55 
ADAMTS4  Homo sap. 
AF148213 
F – AGA CAC AGG CAG GGA GAG ACA AAG 
R – GGA GAA AAC TTA GTC CTT GGG CTT G 
57 
ADAMTS5  Homo sap. 
NM_007038 
F – AAC TCC CAG GAC AGA CCT ACG ATG 
R – GCA GAT TCT CCC CTT TCC ACA AG 
59 
Aggrecan Homo sap. 
NM_001135 
F –  TCA CCA TCC CCT GCT ATT TCA TC 
R – TCT CCT TGG ACA CAC GGC TC 
56 
Collagen 2a1 Homo sap. 
NM_033150.2 
F – CAG TTC GGA CTT TTC TCC CCT C 
R – AGT TTC CTG CCT CTG CCT TGA C 
55 
GAPDH Homo sap. 
NM_002046.3 
F –  TCT CCT CTG ACT TCA ACA GCG AC 
R – TCT CTC TTC CTC TTG TGC TCT TGC 
57 
MMP-1 
 
Homo sap. 
NM_002421.2 
F – TGG ACC TGG AGG AAA TCT TGC 
R – TCA CAC GCT TTT GGG GTT TG 
55 
MMP-2  Homo sap. 
NM004530 
F  – TGA CGG AAA GAT GTG GTG TG 
R – CTC CTG AAT GCC CTT GAT GT  
57 
MMP-3  
 
Homo sap. 
AF405705 
F – GCC TTC TCC TCC ACC CTA TC 
R – TCA TCA GCC TCC ACT TCC TT 
51 
MMP-9  Homo sap. 
NM004994 
F – CAG AGA TGC GTG GAG AGT 
R – AAT AGG TGA TGT TGT GGT 
54 
MMP-13  Homo sap. 
NM_002427.2 
F – AAA ACG CCA GAC AAA TGT GAC C 
R – GCA TCA ATA CGG TTG GGA AGT TC 
55 
MMP-14 Homo sap. 
BC064803 
F – CCA GGG TCT CAA ATG GCA ACA TAA TGA AA 
R – CCA TGG AAG CCC TCG GCA AA 
60 
RAGE Homo sap. 
NM001136 
F – ACG GCT GGT GTT CCC AAT AA 
R – TGT TCC TTC ACA GAT ACT CCC TTC  
55 
S100A8 Homo sap. 
NM002964 
F – TGC TAG AGA CCG AGT GTC CTC AG 
R – CCATCTTTATCACCAGAATGAGGAAC  
55 
S100A9 Homo sap. 
NM002965 
F – TTC AAA GAC CTG GTG CGA AAA G 
R – GCA TTT GTG TCC AGG TCC TCC 
55 
TIMP- 1 Homo sapiens 
NM_003254.2 
F – GAC ACC AGA AGT CAA CCA GAC C 
R – GGT AGT GAT GTG CAA GAG TCC A 
55 
TIMP-2 Homo sap. 
BC071586 
F – GCG GTC AGT GAG AAG GAA GTG G 
R – CTT GCA CTC GCA GCC CAT CTG 
58 
TIMP-3 Homo sap. 
NM_000362.4 
F – TGC CCT TCT CCT CCA ATA CA 
R – CTT CCT TCC CTC CCT CAC TC 
55 
TLR4 Homo sap. 
NM003266 
F – CAACCTCCCCTTCTCAACCAAG 
R – GATTTGTCTCCACAGCCACCAG  
56 
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Table 2.3: Human primer pairs used for differentiation studies 
Gene Species  
Accession Number 
Sequence 5’ to 3’ Temp 
ALP Homo sap. 
NM_000478 
F – TGG AGC TTC AGA AGC TCA ACA CCA 
R – ATC TCG TTG TCT GAG TAC CAG TCC 
55 
Collagen 1 Homo sap. 
BC036531 
F – ACG TCC TGG TGA AGT TGG TC 
R – ACC AGG GAA GCC TCT CTC TC 
55 
Collagen 2a1 Homo sap. 
NM_033150 
F – GGA CTT TTC TCC CCT CTC T 
R – GAC CCG AAG GTC TTA CAG GA 
55 
Collagen X Homo sap. 
NM_000493 
F – CCC TCT TGT TAG TGC CAA CC 
R – AGA TTC CAG TCC TTG GGT CA 
55 
GAPDH Homo sap. 
NM_002046 
F – GAA GGT GAA GGT CGG AGT C 
R – GAA GAT GGT GAT GGG ATT TC 
55 
LPL Homo sap. 
NM_000237.2 
F – GAG ATT TCT CTG TAT GGC ACC 
R – CTG CAA ATG AGA CAC TTT CTC 
55 
Osteopontin Homo sap. 
NC_000004.11 
F – ACG CCG ACC AAG GAA AAC TC 
R – GTC CAT AAA CCA CAC TAT CAC CTC G 
55 
PPARγ2 Homo sap. 
NW_004078011.1 
F – GCT GTT ATG GGT GAA ACT CTG 
R – ATA AGG TGG AGA TGC AGG CTC 
55 
RUNX2 Homo sap. 
NW_004078026.1 
F – GCA GTT CCC AAG CAT TTC AT 
R – CAC TCT GGC TTT GGG AAG AG 
55 
S100A8 Homo sap. 
NM002964 
F – TGC TAG AGA CCG AGT GTC CTC AG 
R – CCATCTTTATCACCAGAATGAGGAAC  
55 
S100A9 Homo sap. 
NM002965 
F – TTC AAA GAC CTG GTG CGA AAA G 
R – GCA TTT GTG TCC AGG TCC TCC 
55 
SOX9 Homo sap. 
NW_004078092.1 
F – ACA CAC AGC TCA CTC GAC CTT G 
R – GGG AAT TCT GGT TGG TCC TCT 
55 
 
2.2.4 Western Blotting 
Cell lysates were collected from monolayer cultures by washing in 1xPBS then adding 100µl 1xRIPA 
to the first well of each treatment group (10µl 500mM EDTA and 10µl Protease Inhibitor cocktail 
added to 500µl 2xRIPA (300mM NaCl, 100mM Tris pH 7.4, 2% Deoxycholate, 0.2% SDS and 2% Triton 
X-100 in deionised water) and made up to 1ml with deionised water), scraping cells using a cell 
scraper, and transferring the contents of the first well to each of the subsequent wells (while placed 
on ice) until cell lysates collected from all wells of the same treatment group. Cell lysates were then 
stored at -80oC until ready to continue, when lysates were thawed and centrifuged at 12,000rpm for 
10 minutes at 4oC, supernatant collected and cell debris discarded, and protein was measured using 
a BCA assay, according to the manufacturer’s instructions. Equal amounts of cell lysates were mixed 
with sample buffer and loaded onto a 10% Bis-Tris gel with SDS running buffer, and electrophoresis 
was run at 4oC at 200V for approximately 90 minutes, or until the buffer/dye front reached the 
bottom of the gel, then transferred onto pre-wet membranes using 1xNUPAGE Transfer buffer at 4oC 
at 30V for one hour. Membranes were blocked for one hour in 5% BSA/TBS, and then incubated 
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overnight in primary antibody in 2% BSA/TBS at 4oC. Membranes were washed four times for five 
minutes in 0.02% Tween/TBS (TBST), then incubated in secondary antibody in 2% BSA/TBS for one 
hour at room temperature. Membranes were again washed four times for five minutes in TBST, then 
visualised using chemiluminescence technique (ECL kit) using ImageQuant LAS 4000 control software 
Version 1.0. 
 
2.3 Biochemical Assays 
2.3.1 Proteoglycan Release 
The release of proteoglycan from explant cultures was determined as sulphated glycosaminoglycan 
(GAG) in the conditioned culture media (µg of GAG per mg of wet weight cartilage). GAG as a 
measure of proteoglycan aggrecan content or release, was quantified using a modification of the 
colorimetric 1,9-dimethylmethylene blue (DMMB) binding assay [285]. A 50mg/L solution was 
prepared by dissolving 50mg of DMMB in 5mL of absolute ethanol followed by dilution to a volume 
of 1L with 0.2% (w/v) sodium formate buffer (sodium formate and concentrated formic acid, pH 3.5). 
Conditioned media or a chondroitin sulfate A standard (50-200µg/ml in DMEM) was aliquotted into 
a 96-well plate. DMMB reagent (250µL) was added to each well using an electronic multi-channel 
pipette. Absorbance at 650 nm was recorded immediately in a plate reader. 
 
2.3.2 Collagen Release 
Collagen release was determined using a simplified microtiter plate adaptation of the hydroxyproline 
assay by Stegemann and Stadler [286]. 200µL of conditioned media was vacuum dried followed by 
hydrolysis in 250µL 6N HCl for 16h at 110oC. The reactions were neutralised by the addition of 250µL 
6N NaOH. 10-50µL of the neutralised hydrolysate was added to a 96-well plate, in duplicate, 
followed by the addition of 50µL collagen assay buffer (10xStock Buffer contained 5.0g of citric acid 
monohydrate, 1.2mL of glacial acetic acid, 12.0g of sodium acetate trihydrate (or 7.24g of anhydrous 
sodium acetate) and 3.4g of sodium hydroxide in 100mL of aqueous solution (pH 5.75)) and 50µL 
chloramine T reagent (1.41g of chloramine T (hydrated form) dissolved in 20.7mL of Milli-Q water 
and mixed with 26mL of n-propanol and 53.3mL of stock buffer). After 20 minutes incubation at 
room temperature, 50µL of colour reagent (1.5g of p-dimethylaminobenzaldehyde (DMAB) 
suspended in 6.0mL of n-propanol followed by the slow addition of 2.6mL 60 % (v/v) perchloric acid) 
was added and incubated at 60oC for 15 minutes. Colour development was determined by 
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absorbance at 562nm 15 minutes after removal from 60oC. The total hydroxyproline content was 
calculated from a standard curve using a hydroxyproline standard. 
2.3.3 MMP Activity 
MMP-2 and MMP-9 protein secretion and activation in pooled culture medium from triplicate 
cultures was measured using gelatin zymography under non-reducing conditions as described 
previously [287]. MMP-13 activity in the same pooled conditioned medium was detected using the 
SensoLyte Plus™ 520 MMP - 13 Assay Kit (Anaspec, San Jose, CA, USA). 
 
2.3.3.1 Gelatin Zymography 
Gels used were Novex 10% gelatin zymogram (Invitrogen). All reagents used were from Invitrogen. 
Conditioned media samples were combined with 2xNovex sample buffer (non-reducing) and 
electrophoresis run at 4°C at 125 Volts constant for two hours. The gel was then incubated in 
1xNovex zymography renaturing buffer for one hour at room temperature with gentle agitation, 
followed by 1xNovex zymography developing buffer at 37oC for 16 hours. The gel was then stained 
with 0.2% Brilliant Blue R-250 in 50% ethanol and 10% acetic acid for 60 minutes at room 
temperature with gentle agitation, followed by destaining (10% Acetic acid, 20% Methanol, 70% H20) 
for 30 minutes or until the stacking gel was clear and clearing bands were visible in the resolving gel. 
Samples known to have MMP-2 and MMP-9 were run as standards in all gels. 
 
2.3.3.2 MMP-13 Activity Assay 
MMP-13 activity was detected in conditioned media using the SensoLyte™ 520 MMP-13 Assay Kit 
(Anaspec) according to manufacturer’s instructions. Briefly, 100µL aliquots of conditioned media 
were incubated with 4-aminophenylmercuric acetate (APMA) at a final concentration of 1mM for 15 
minutes at 37oC. The APMA activated sample was used as an indicator of “total-activatable-MMP-13 
activity” in a given sample and was compared with an equal volume of media without APMA, 
representing the “spontaneously active MMP-13”. Samples (20 µL) ± APMA were placed in individual 
wells of a 384-well plate followed by 20µL 1 x MMP-13 substrate solution per well of a 384-well 
plate). The fluorescence of the samples was then read at 490/520 nm using a plate reader every 30 
minutes up to four hours or until the reading plateaued, with the plate incubated at 37oC in the dark 
between readings. 
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2.4 Histology 
2.4.1 Toluidine Blue Staining 
Human osteochondral specimens received from total knee arthroplasty (with patient consent and 
approval of NSCCAH Human Research Ethics Committee) were fixed in 10% (v/v) neutral buffered 
formalin for 48 hours at room temperature, then decalcified in 10% formic acid in 5%(v/v) formalin 
for 5-7 days. Sections were rinsed and kept in 70% ethanol for at least 24 hours, then dehydrated in 
graded ethanol (1x75%, 1x85%, 1x95%, 2x100% for three hours, and 1x100% for six hours). Samples 
were then incubated in methyl benzoate for one day and infiltrated with celloidin in two stages: 
8.1% (w/v) celloidin in methyl benzoate for one day; then 9.4% (w/v) celloidin in methyl benzoate for 
one week followed by chloroform removal of excess celloidin. Sections were then infiltrated with 
Paraplast paraffin with multiple changes over four days under vacuum, paraffin embedded, 
sectioned every 4µm using a microtome, and mounted on slides. Mouse knees were fixed in 10% 
neutral buffered formalin for 24 hours, decalcified for three days in 10% formic acid/5% formalin, 
and paraffin embedded. Specimens were then sectioned through the joint so that six slides of four 
micron sections at 80 micron intervals were taken. This encompassed the area either side of the 
DMM injury. Extra sections were taken between levels for immunohistochemistry. Chondrogenic 
pellets were fixed in 4% formalin overnight, dehydrated through graded ethanol and xylene and 
embedded in paraffin prior to sectioning every 5µm through the pellet.  
 
The Toluidine Blue staining procedure was modified from two methods in [288]. Paraffin embedded 
samples were de-waxed by submersion in xylene (2x5 minutes), then rehydrated in graded ethanol 
(2x100%, 1x95%, 1x70%, three minutes each) then left in 70% ethanol for 15 minutes. Sections were 
then stained with 0.04% Toluidine Blue in 0.1M sodium acetate buffer, pH 4.0 for 10 minutes. 
Sections were rinsed in H2O then stained with 0.1% Fast Green for two minutes and rinsed again. 
Sections were then dehydrated in three changes of isopropyl alcohol then three changes of xylene, 
followed by mounting with a resinous mountant (Euckitt). 
 
2.4.2 Immunohistochemistry 
Mouse and human joints were prepared as per Section 2.4.1. Paraffin embedded samples were de-
waxed by submersion in xylene (2x5 minutes), then rehydrated in graded ethanol (2x100%, 1x95%, 
1x70%, three minutes each), and washed in deionised water (dH2O). Enzymatic antigen retrieval was 
performed using Proteinase K diluted 1:10 in TBST wash buffer (0.05M Tris, 0.15M NaCl, 0.05% 
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Tween 20, pH 7.6) for 30 minutes at room temperature, then rinsed in tap water. Slides were then 
quenched in 0.3% H2O2 for five minutes, rinsed in H2O and blocked for 10 minutes in Dako serum-
free blocking protein prior to an overnight incubation at 4oC in primary or control antibody in 
antibody diluent at the concentrations listed in Table 2.4. Slides were washed in TBST wash buffer 
(0.05M Tris, 0.15M NaCl, 0.05% Tween 20, pH 7.6) and incubated for 30 minutes in Envision + 
polymer (mouse or rabbit as appropriate), washed in TBST and detected using NovaRed peroxidase 
substrate, by incubating for 15 minutes then washing in H2O. Slides were then counterstained in 
Mayer’s Haematoxylin and Scott’s Blue, dehydrated and mounted. 
Table 2.4: Immunohistochemistry antibody concentrations 
Antibody Type Species Against Final Concentration 
Anti-S100A8 Primary Human 1:1000 (1.5µg/ml) 
Anti-S100A8 Primary Mouse 1:200 
Anti-S100A9 Primary Human 1:750 (1.33µg/ml) 
Anti-S100A9 Primary Mouse 1:500 
 
2.4.3 Alizarin Red-S Assay 
Alizarin Red-S Assay is used as a marker for osteogenic differentiation via the determination of 
calcium mineral content. At the end of the culture period, cells were washed in 1xPBS and fixed in 
4% formalin for one hour at room temperature. Cells were washed in 1xPBS twice, then 1ml 2% 
Alizarin Red-S (pH 4.2) was added for five minutes, after which cells were washed in dH2O until water 
ran clear, then photographed under the microscope in 1ml 1xPBS.  
 
2.4.4 Oil Red O Assay 
Oil Red O Assay is used as a marker of adipogenesis via the determination of intracellular lipid 
droplets. Cells were washed in 1xPBS and fixed in 10% formaldehyde for one hour at room 
temperature. Cells were washed twice in 1xPBS, and then enough Oil Red O working solution was 
added to cover cells for 15 minutes, after which cells were washed in dH2O until water ran clear, 
then photographed under the microscope in 1ml 1xPBS. Working solution was prepared by diluting 
stock solution 3:2 in dH2O incubating at room temperature for one hour then filtering through a 
0.2µm syringe filter (no more than three hours prior to adding to cells). Stock solution was prepared 
by adding 0.5mg Oil Red O powder in 100ml isopropanol, and incubating for at least one hour at 
room temperature.  
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2.5 Statistics 
Data was analysed using the Mann-Whitney U test. All analyses were performed using StataSE 10.0 
(StataCorp, College Station, TX, USA). The alpha level was set at 0.05. Due to the exploratory nature 
of the work presented in this thesis, no corrections were used in order to avoid losing true positives. 
 
2.6 List of Reagents 
Table 2.5: List of Reagents 
Reagent Supplier 
ABC reagent Vector Laboratories  
Acetic Acid (Glacial) Sigma Aldrich Australia 
Aggrecan G1 Mort rabbit antibody Generous gift from John Mort 
Alizarin Red-S Sigma Chemical Co. 
Antibody diluent Dako 
BAY-11-7082 Inhibitor Cayman Chemical 
BCA Assay kit (Pierce) Thermoscientific 
Biotinylated Goat Anti-Rabbit IgG (H+L) Vector Laboratories 
Bovine Serum Albumin (BSA) Sigma Aldrich Australia 
Bovine testicular hyaluronidase Sigma Aldrich Australia 
Brilliant Blue R-250 Sigma Aldrich Australia 
Celloidin NBS Biologics 
Chloramine T hydrate Sigma Aldrich Australia 
Chloroform Fronine Laboratory Supplies  
Chondroitin sulphate A  
(from bovine trachea) 
Sigma Aldrich Australia 
Citric Acid Monohydrate Sigma Aldrich Australia 
CLI-095 Inhibitor InvivoGen 
Collagen 1 mouse antibody clone I-8H5 MP Biomedicals 
Collagen 2 mouse antibody clone 11-4C11 MP Biomedicals 
Collagenase (from Clostridium histolyticum) Sigma Aldrich Australia 
Dexamethasone Sigma Aldrich Australia 
Deoxycholate Sigma Aldrich Australia 
Dimethyl sulfoxide (DMSO) Ajax chemicals 
dNTPs Amersham Biosciences, Buckinghamshire, UK 
DMAB (4-(Dimethylamino)-benzaldehyde) Sigma Aldrich Australia 
DMEM (Dulbecco’s modified Eagles medium) Sigma Aldrich Australia 
DMEM-F12 Sigma Aldrich Australia 
DMMB (1,9-dimethylmethylene blue) Sigma Aldrich Australia 
ECL Kit Amersham Pharmacia Biotech 
EDTA (Ethylenediamine tetracetic acid; 
disodium salt, dihydrate) 
Sigma Aldrich Australia 
Envision + Rabbit Dako 
Envision + Mouse Dako 
Ethanol Fronine Laboratory Supplies 
Euckitt mountant Thermofisher 
Fast Green BDH 
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FCS (Foetal calf serum) Trace Biosciences Pty. Ltd.  
Recombinant Fibroblast Growth Factor (FGF)-
2 
R&D Systems, Wiesbaden-Nordenstadt, Germany 
Formaldehyde Sigma Aldrich Australia 
Formalin Ajax Chemicals 
Formic Acid Fronine Laboratory Supplies 
Gentamycin Pharmacia Pty. Ltd., Bentley, WA, Australia 
L-Glutamine ICN Biochemicals Inc. 
Goat anti-rabbit IgG-HRP  Santa Cruz 
Goat anti-mouse IgG-HRP Santa Cruz 
Haematoxylin Fronine 
Hyaluridonase Sigma Aldrich Australia 
Hydrochloric Acid Fronine Laboratory Supplies 
Hydrogen Peroxide (H2O2) Ajax Chemicals 
L-Hydroxyproline Merck Pty. Ltd., Kilsyth, VIC, Australia 
Immomix Bioline, Alexandria, NSW, Australia 
Interleukin-1 (IL-1) PeproTech Inc., Rocky Hill, NJ, USA 
Interleukin-1β (IL-1β) PeproTech Inc., Rocky Hill, NJ, USA 
Isopropanol Sigma Aldrich Australia 
ITS+ Premix BD Biosciences 
L-ascorbate-2-phosphate Sigma Aldrich Australia 
Lipopolysaccharide (LPS) from E. coli Sigma Aldrich Australia 
β-Mercaproethanol Sigma Aldrich Australia 
Methanol  Fronine Laboratory Supplies. 
Methyl benzoate Alfa Aesar 
Monoclonal anti-β-actin antibody Sigma Aldrich Australia 
Normal Goat Serum Sigma Aldrich USA 
NovaRed peroxidase substrate Vector Laboratories 
Novex 10% Bis-Tris gel Invitrogen Australia Pty. Ltd. 
Novex 10% Zymogram (gelatin) gel Invitrogen Australia Pty. Ltd. 
Novex Sample Buffer Invitrogen Australia Pty. Ltd. 
Novex zymography Running Buffer Invitrogen Australia Pty. Ltd. 
Novex zymography Renaturing Buffer Invitrogen Australia Pty. Ltd. 
Novex zymography Developing Buffer Invitrogen Australia Pty. Ltd. 
NuPAGE Transfer buffer  Invitrogen Australia Pty. Ltd. 
Oil Red O Sigma Aldrich Australia 
Omniscript RT Kit Qiagen, Valencia, CA, USA 
Paraffin Paraplast (Leica) 
PD98059 Inhibitor Cayman Chemical 
Penicillin-streptomycin Sigma Chemical Co. 
Perchloric Acid BDH Laboratory Supplies, Poole, Dorset, UK 
Phosphate Buffered Saline (PBS) Life Technologies (Gibco) 
Primers for qRT-PCR Sigma Aldrich Australia 
Pronase from Streptomyces griseus Roche Diagnostics Australia Pty. Ltd 
Protease Inhibitor Cocktail Sigma Aldrich Australia 
Proteinase K Dako 
Protein Block, serum free Dako 
n-propanol (Propan-1-ol) Fronine Laboratory Supplies. 
Pyruvate Sigma Chemical Co. 
Qiashredder kit Qiagen 
Random pentadecamers Sigma Aldrich Australia 
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Red Cell Lysis Buffer Sigma Chemical Co. 
RNA Guard; RNase inhibitor Amersham Biosciences 
RNALater stabilisation reagent Qiagen 
RNase-free DNase set Qiagen 
RNeasy mini kit Qiagen 
RS-LPS Invivogen 
S100 Antibodies Generous donation from Johannes Roth and 
Thomas Vogl, made in-house at Institute of 
Immunology, Münster, Germany 
S100 Proteins Generous donation from Johannes Roth and 
Thomas Vogl, made in-house at Institute of 
Immunology, Münster, Germany 
SB203580 Inhibitor Cayman Chemical 
Scott’s Blue Fronine 
SDS Sigma Aldrich Australia 
See Blue Plus marker Invitrogen Australia Pty. Ltd. 
SensoLyte 520 MMP-13 Assay kit AnaSpec, San Jose, CA, USA 
Sodium acetate trihydrate Sigma Aldrich Australia 
Sodium Chloride Sigma Aldrich Australia 
Sodium Formate Fronine Laboratory Supplies 
Sodium hydroxide Fronine Laboratory Supplies 
StemPro® Adipogenesis Differentiation kit Life Technologies GmbH, Darmstadt, Germany 
StemPro® Osteogenesis Differentiation kit Life Technologies GmbH, Darmstadt, Germany 
SYBR Green I Invitrogen Australia Pty. Ltd. 
Toluidine Blue BDH 
Tri Reagent (Trizol) Invitrogen Australia Pty. Ltd. 
Tris Base Ajax Chemicals, Auburn, NSW, Australia 
Triton X-100 Bio-Rad Australia 
Trypan Blue Invitrogen Australia Pty. Ltd. 
Trypsin Sigma Aldrich Australia 
Transforming growth factor (TGF)-β3 R&D Systems, Wiesbaden-Nordenstadt, Germany 
Tween Amaresco 
U0126 Inhibitor Cayman Chemical 
Xylene BDH Laboratory Supplies 
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Chapter 3 S100A8 and S100A9 in healthy cartilage 
3.1 Introduction 
 S100A8 and S100A9 have classically been reported to be involved in inflammation and inflammatory 
diseases, most prevalently in the form of a heterodimeric molecule S100A8/S100A9, and generally 
secreted by immune cells. The involvement of S100A8 and S100A9 has been well documented in 
many inflammatory and auto-immune diseases including rheumatoid arthritis, an inflammatory 
disease of the joints, with increased levels of S100A8 and S100A9 locally in the synovial fluid, as well 
as systemically in the plasma [260-262]. The origin of this increase in S100A8 and S100A9 is thought 
to be the activated immune cells that flood the joint, residing in particular in the synovium. Until 
recently, it was thought that S100A8 and S100A9 were exclusively expressed by activated immune 
cells under inflammatory stimuli. This idea of exclusivity has now given way to an understanding that 
S100A8 and S100A9 can be induced in multiple cell types in pathological or inflammatory situations. 
One such cell is the chondrocyte, the sole cell type present in cartilage, which produces S100A8 or 
S100A9 at baseline levels and which can be up-regulated under inflammatory stimuli such as IL-1 
[187]. The ability of chondrocytes to produce S100A8 and S100A9 could be an important factor not 
only in rheumatoid arthritis, but also in osteoarthritis (OA); a joint disease not classically described 
as an inflammatory disease, but nonetheless one that involves various inflammatory cytokines, as 
discussed in Section 1.2.3.2.  
 
Cartilage is aneural and avascular, with an ECM comprised largely of aggrecan and collagen II, and 
only one cell type called chondrocytes, known to be responsible for maintaining the metabolic 
balance in normal articular cartilage. Proteoglycan and collagen degradation is fundamental to the 
pathophysiology of OA where there appears to be a shift to a more catabolic gene and protein 
profile and in which a major role is suggested for MMPs and ADAMTS [289]. In an in vitro monolayer 
culture, chondrocytes were found to respond to S100A8 and S100A9, causing a shift to a catabolic 
gene expression profile with increases in the aggrecanases ADAMTS-4 and ADAMTS-5, as well as 
collagenase MMP-13 [187, 279].  
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The specific aims of this chapter were to: 
 Confirm that S100A8 and S100A9 are produced by chondrocytes under inflammatory 
stimulus at both the gene and protein levels in healthy ovine chondrocyte monolayer 
cultures. 
 Confirm the effect of S100A8 and S100A9 on gene expression in healthy chondrocyte 
monolayer cultures. 
 Determine the effect of S100A8 and S100A9 on healthy full-thickness cartilage explants in 
vitro over a time course of 14 days on gene expression changes, activation status of 
catabolic enzymes as well as biochemical degradation of the cartilage matrix. 
 
3.2 Materials and Methods 
Materials and methods used in the chapter are outlined in Chapter 2.  
Primer sets used for real-time RT-PCR are shown in Table 2.1.  
 
3.3 Results 
3.3.1 Validation – Batch Analysis 
During the course of the following experiments, various batches of S100A8, S100A9 and S100A8/A9 
were used. All batches were from the same source, and were produced using the same method 
(described in [290]). All batches were deemed to be of sufficient activity after being tested on 
human macrophages. Identity of proteins was ascertained by amino acid sequencing and 
electrospray ionization mass spectrometry. All preparations revealed a purity of >98%. Endotoxin 
contaminations were excluded by limulus amebocyte lysate assay (BioWhittaker) by our 
collaborators (Dr Vogl, University of Munster, described in supplementary material from [291]) prior 
to sending the proteins. Batch analysis was performed to compare all S100A8, S100A9 and 
S100A8/A9 batches used in this thesis as different activities on cultured chondrocytes were noted 
with the various batches used. Articular cartilage explant cultures were treated with S100A8, S100A9 
or S100A8/S100A9 at 0.1µM for four days at 37oC. All batches are referred to by their stock 
concentration. Four batches of S100A8 (109µM, 102µM, 47µM and 79µM), three batches of S100A9 
(85.7µM, 70.7µM and 95.7µM) and two batches of S100A8/A9 (120µM and 170.83µM) were tested. 
The outcome measure was expression of various genes that are regulated by S100 proteins in vitro. 
In general, a similar trend was seen for the effect of S100A8, S100A9 and the complex on 
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chondrocytes regardless of the batch used, with differences in magnitude between batches (Figure 
3.1). Results presented in sections 3.3.3 and 3.3.4 show pooled results from multiple experiments 
that used different batches of S100A8, S100A9 and S100A8/A9, and are therefore a true indication 
of the effect of these proteins.   
Figure 3.1: Batch analysis. Gene expression analysis of A) GAPDH, B) collagen type II, C) ADAMTS-5 and D) 
MMP-3 from ovine cartilage explants treated with different batches of S100A8, S100A9 or S100A8/S100A9 at 
0.1µM for four days (referred to by their stock concentrations in the legend). 
 
3.3.2 S100A8 and S100A9 are expressed by chondrocytes under 
inflammatory stimulus 
Chondrocyte monolayer cultures were grown to confluence before they were exposed to an 
inflammatory stimulus, IL-1α at 1ng/ml for 24 hours. Gene expression of S100A8 and S100A9 was 
measured using qRT-PCR, and protein levels determined on whole cell lysates using Western Blot 
and specific monoclonal antibodies against S100A8 and S100A9. The gene expression results are 
presented as mean ± standard error of the mean (SEM), with n=4. Protein levels were confirmed in 
two separate experiments, with each lane representing pooled lysates from triplicate samples. 
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S100A9 mRNA was detected in control cultures and was significantly up-regulated (8-fold, p=0.018) 
by IL-1α (Figure 3.2). In contrast, S100A8 message was not detected in either control or IL-1-
stimulated monolayer cultures of ovine articular chondrocytes (S100A8 mRNA was detected using 
these primers in later experiments in cartilage explants; see Section 3.3.6, validating these primers in 
ovine tissue). In contrast to mRNA, a single band (MW ≈22kDa) was detected with the anti-S100A8 
antibody in the control chondrocyte lysates with no change in levels in IL-1α-treated cells. The 
molecular weight of S100A8 monomer is 10kDa, and the homodimer is 20kDa, which was the main 
band detected in the human S100A8 standard. The S100A8 band from ovine cell lysates had a 
slightly higher molecular weight; however this could be due to species differences in protein size. In 
contrast, no S100A9 protein was detected in chondrocyte lysates either at the expected weight of 
the monomer (≈14kDa), or the homodimer (≈28kDa, the band detected in the human S100A9 
standard) (Figure 3.3). 
Figure 3.2: Gene expression analysis of S100A9 from ovine articular chondrocytes treated ± IL-1α at 1ng/ml for 
24 hours, *=p<0.05 compared to control values.  
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Figure 3.3: Western Blot analysis of cell lysates obtained from monolayer ovine chondrocyte cultures treated ± 
1ng/ml IL-1α for 24 hours, with 50ng human recombinant S100A8 (left) or S100A9 (right) as standards (STD). 
Migration positions are shown on the left hand side, based on SeeBlue Plus 2 Pre-stained standard. 
Housekeeping protein β-actin expression is shown below as a loading control. NT = non-treated control.  
 
3.3.3 S100A8 and S100A9 induce catabolic gene expression changes in 
chondrocytes 
Chondrocyte monolayer cultures were grown to confluence then exposed to either S100 (S100A8, 
S100A9 or S100A8/A9 at 0.01µM) or an inflammatory stimulus (IL-1α at 1ng/ml, as a positive 
control) for 24 hours. qRT-PCR analysis showed multiple significant gene expression changes induced 
by the addition of S100A8 or S100A9 homodimers to the culture media whereas addition of the 
heterodimer S100A8/A9 had very few significant effects on gene expression. All graphs in Figure 3.4 
and Figure 3.5 represent pooled gene expression data from four different experiments, with a 
combined n≥8 for each treatment group (Control n=12, S100A8 n=9, S100A9 n=10, S100A8/S100A9 
n=8, IL-1α n=9; different sample sizes between treatment groups are due to some samples not 
having sufficient RNA, or not being of sufficient quality to reverse transcribe to cDNA). Graphs are 
presented as fold change compared to control, with mean ± SEM, and p<0.05 considered a 
significant difference. Fold change values are summarised in Table 3.1. 
 
Addition of S100A8 or S100A9 homodimers to chondrocyte monolayer cultures had no significant 
effect on the housekeeping gene GAPDH expression, whereas the addition of the heterodimer led to 
significant down-regulation (0.67 fold) of GAPDH, while the addition of IL-1α significantly up-
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regulated its expression (1.50 fold, Figure 3.4). As GAPDH was significantly regulated by one or more 
culture conditions, it was not considered a suitable house-keeping gene, and expression of all other 
genes was normalised to total RNA. IL-1α significantly down-regulated the genes encoding aggrecan 
and collagen type II, as well as MMP-2, MMP-14 and TIMP-2. IL-1α significantly up-regulated the 
catabolic enzymes ADAMTS-1, ADAMTS-4, ADAMTS-5, MMP-1, MMP-3, MMP-9, MMP-13 as well as 
the endogenous inhibitor TIMP-3, while TIMP-1 was unchanged. S100A8 and S100A9 homodimers 
generally induced a similar pattern of change (although with some differences in magnitude) in the 
gene expression profile as IL-1α: both proteins caused significant down-regulation of the genes 
encoding aggrecan, collagen type II and TIMP-2, up-regulation of ADAMTS-4, ADAMTS-5, MMP-1, 
MMP-3 and MMP-13. However, unlike IL-1α, S100A8 and S100A9 homodimers did not have a 
significant effect on ADAMTS-1, MMP-2, MMP-9, or MMP-14 gene expression levels but down-
regulated TIMP-3 expression. In contrast to the homodimers, the heterodimer S100A8/A9 
significantly down-regulated only one of the genes examined, TIMP-3. S100A8 and S100A9 were 
below the detection limit. These results confirmed that both S100A8 and S100A9 homodimers shift 
chondrocytes to a catabolic gene expression profile, similar to that caused by IL-1α albeit generally 
at a smaller magnitude, with the exception of MMP-1 and MMP-3, which had comparable levels of 
up-regulation.  
 
Table 3.1: Summary of qRT-PCR results of ovine chondrocytes cultured in monolayer and treated with S100A8, 
S100A9 or S100A8/S100A9 at 0.01µM or IL-1α at 1ng/ml for 24 hours (Control n=12, S100A8 n=9, S100A9 
n=10, S100A8/S100A9 n=8, IL-1α n=9 unless indicated otherwise). Results are expressed as fold change 
compared to non-treated control ± SEM. 
Gene S100A8 S100A9 S100A8/A9 IL-1α 
GAPDH 1.29 ± 0.15 1.24 ± 0.11 0.67 ± 0.07 1.50 ± 0.17 
Aggrecan 0.46 ± 0.06 0.52 ± 0.07 0.98 ± 0.09 0.41 ± 0.09 
Collagen II 0.40 ± 0.09 0.51 ± 0.05 0.58 ± 0.08 0.10 ± 0.02 
ADAMTS-1 1.02 ± 0.11 1.01 ± 0.19 0.81 ± 0.12 7.05 ± 0.96 
ADAMTS-4 3.32 ± 0.44 1.75 ± 0.24 0.83 ± 0.12 1211.89 ± 117.76 
ADAMTS-5 6.07 ± 1.36 3.53 ± 0.42 0.79 ± 0.13 79.27 ± 7.75 
MMP-1 19150.32 ± 9211.37 1160.70 ± 497.21 0.82 ± 0.17 4903.16 ± 1085.13 
MMP-2 0.77 ± 0.10 0.83 ± 0.08 3.48 ± 1.67 0.21 ± 0.02 
MMP-3 608.92 ± 253.55 166.62 ± 65.39 0.82 ± 0.12 636.42 ± 116.67 
MMP-9 1.65 ± 0.62 
(n=5) 
1.18 ± 0.23 
(n=6) 
0.96 ± 0.21 
(n=4) 
5.75 ± 0.99 
(n=8) 
MMP-13 170.45 ± 71.15 21.93 ± 2.13 0.76 ± 0.10 12487.73 ± 4180.36 
MMP-14 0.95 ± 0.10 1.08 ± 0.09 0.81 ± 0.08 0.66 ± 0.05 
TIMP-1 0.89 ± 0.10 0.89 ± 0.11 0.87 ± 0.09 0.75 ± 0.10 
TIMP-2 0.51 0.06 0.60 ± 0.05 0.93 ± 0.19 0.09 ± 0.01 
TIMP-3 0.69 ± 0.05 0.66 ± 0.10 0.67 ± 0.07 4.65 ± 0.43 
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Figure 3.4: Gene expression analysis from ovine chondrocyte monolayer cultures treated with S100A8, S100A9 
or S100A8/S100A9 at 0.01µM or IL-1α at 1ng/ml for 24 hours, bars show mean fold change compared to non-
treated control ± SEM *=p<0.05 compared to control values, **=p≤0.0001 compared to control values. 
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Figure 3.5: Gene expression analysis from ovine chondrocyte monolayer cultures treated with S100A8, S100A9 
or S100A8/S100A9 at 0.01µM or IL-1α at 1ng/ml for 24 hours, bars show mean fold change compared to non-
treated control ± SEM *=p<0.05 compared to control values, **=p≤0.0001 compared to control values. 
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3.3.4 S100A8 and S100A9 induce catabolic gene expression changes in 
cartilage explants  
The previous results demonstrated that recombinant human S100A8 and S100A9 were able to 
significantly regulate gene expression in ovine chondrocytes, consistent with previous reports in 
other species: murine cell line [279]; ovine primary chondrocytes [187]; and human OA chondrocytes 
[188]. However, at the time of these experiments, no similar evaluation of the effect in cartilage 
explant cultures, which more closely resemble the physiological conditions in the joint, had been 
reported.   
 
Normal (healthy) ovine articular cartilage explant cultures were treated with either S100 (S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM) or an inflammatory stimulus (IL-1α at 10ng/ml, as a positive 
control – required for maximal effect in explants compared with 1ng/ml in monolayers) for four days 
(as opposed to 24 hours in monolayer – required to achieve maximal GAG loss in explants) at 37oC. 
All graphs in Figure 3.6 and Figure 3.7 represent pooled data from five separate experiments, with 
total sample sizes of: control n=26, S100A8, S100A9 and S100A8/S100A9 n=27, IL-1α n=8. Graphs are 
presented as fold change compared to a non-treated control, as mean ± SEM with p<0.05 considered 
a significant difference. A summary of fold changes and SEM is shown in Table 3.2. 
 
The pattern of gene regulation generally agreed with that of the chondrocyte monolayer cultures 
but with some interesting differences, however greater variability between replicates was noted in 
explants. Treatment with S100A8, S100A9 or IL-1α led to the down-regulation of GAPDH (Figure 3.6), 
further demonstrating the unsuitability of this gene as a means of normalising data for our studies. 
As with chondrocyte monolayer cultures, IL-1α treatment of explants up-regulated ADAMTS-5, 
MMP-1, MMP-3, MMP-9 and MMP-13, and down-regulated aggrecan, collagen type II and TIMP-2. 
In contrast to chondrocyte monolayer cultures, addition of IL-1α to the explant cultures up-regulated 
S100A9 (which was not detected in the former culture condition), as well as TIMP-1, which was not 
regulated by IL-1α in monolayer cultures, and MMP-14, which was down-regulated by IL-1α in 
chondrocyte monolayer cultures. S100A8 and S100A9 homodimers up-regulated catabolic enzymes 
ADAMTS-5, MMP-1 and MMP-3 and down-regulated aggrecan and collagen type II, as they did in 
chondrocyte monolayer cultures. MMP-13 tended to be up-regulated by the homodimers, but did 
not reach statistical significance due to the increased variability in explant cultures. MMP-14 and 
S100A9 were additionally up-regulated by the addition of S100A8 and S100A9 homodimers; 
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ADAMTS-4 and S100A8 were below detection levels. Additionally, TIMP-2 was up-regulated by 
S100A9, being previously down-regulated by S100A9 in chondrocyte monolayer cultures. TIMP-2 and 
MMP-14 were the only genes significantly regulated by the S100A8/A9 heterodimer, both being 
increased. 
 
Data presented in this chapter demonstrated subtle but distinct differences in the response of 
chondrocytes to both S100 homodimers and IL-1α in explants compared to monolayer cultures. 
Nevertheless, these results confirmed that both 100A8 and S100A9 homodimers continue to drive 
chondrocytes in a more physiologically relevant setting (i.e. embedded in cartilage ECM), towards a 
catabolic gene expression profile, with up-regulation of aggrecanases and collagenases, a decrease 
in extracellular matrix production and no corresponding regulation of the endogenous inhibitors 
TIMPs. The subsequent experiments investigated whether these changes were due to differences in 
dose in the case of IL-1α, or the time course of stimulation (four versus one day) for S100 proteins 
and IL-1α.   
 
Table 3.2: Summary of qRT-PCR results of ovine articular cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for four days (control n=26, S100A8, S100A9 and 
S100A8/S100A9 n=27, IL-1α n=8). Results are expressed as fold change compared to non-treated control ± 
SEM. 
Gene S100A8 S100A9 S100A8/A9 IL-1α 
GAPDH 0.84 ± 0.05 0.79 ± 0.05 0.96 ± 0.07 0.41 ± 0.04 
Aggrecan 0.81 ± 0.05 0.84 ± 0.06 0.96 ± 0.08 0.24 ± 0.04 
Collagen II 0.67 ± 0.09 0.71 ± 0.08 0.87 ± 0.09 0.05 ± 0.008 
ADAMTS-1 2.38 ± 1.18 1.29 ± 0.18 1.31 ± 0.24 1.20 ± 0.41 
ADAMTS-5 12.91 ± 6.70 5.07 ± 1.21 1.54 ± 0.27 30.58 ± 8.9 
MMP-1 3942.23 ± 3495.49 202.13 ± 57.94 3.78 ± 2.19 3954.90 ± 2894.75 
MMP-2 1.33 ± 0.19 1.18 ± .017 1.37 ± 0.25 1.40 ± 0.26 
MMP-3 217.76 ± 127.80 35.04 ± 8.00 1.96 ± 0.40 1492.64 ± 840.12 
MMP-9 25.16 ± 12.43 1.30 ± 0.49 1.44 ± 0.89 28.78 ± 22.2 
MMP-13 12.00 ± 9.79 4.54 ± 2.85 3.86 ± 1.91 18.10 ± 11.50 
MMP-14 1.24 ± 0.13 1.50 ± 0.11 1.27 ± 0.07 1.42 ± 0.12 
S100A9 21.04 ± 8.19 5.12 ± 0.81 1.86 ± 0.35 24.14 ± 12.86 
TIMP-1 1.08 ± 0.14 1.36 ± 0.14 1.14 ± 0.10 1.49 ± 0.14 
TIMP-2 1.10 ± 0.10 1.33 ± 0.15 1.42 ± 0.15 0.43 ± 0.04 
TIMP-3 0.97 ± 0.08 1.08 ± 0.09 1.03 ± 0.09 0.85 ± 0.19 
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Figure 3.6:  Gene expression analysis from ovine articular cartilage explant cultures treated with S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for four days, bars show mean fold change compared 
to non-treated control ± SEM *=p<0.05, **=p≤0.0001 compared to control values.  
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Figure 3.7: Gene expression analysis from ovine articular cartilage explant cultures treated with S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for four days, bars show mean fold change compared 
to non-treated control ± SEM *=p<0.05, **=p≤0.0001 compared to control values.  
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3.3.5 Gene expression changes in cartilage explants did not translate into 
biochemical cartilage degradation 
Conditioned media was collected from the articular cartilage explant cultures from Section 3.3.4 at 
the end of the four-day culture period. Release of glycosaminoglycans (GAGs) and collagen into the 
media was measured as sulphated GAG and hydroxyproline respectively (Figure 3.8). The graphs 
present µg GAG per mg wet weight cartilage and µg Hydroxyproline (HyPro) per mg wet weight 
cartilage respectively, with GAG release representing pooled samples from five separate 
experiments, and total sample sizes of: control, S100A8, S100A9, n=52, IL-1α n=24, S100A8/S100A9 
n=54, and HyPro release representing one experiment with n=6 per treatment group. 
 
As expected, IL-1α treatment resulted in significantly more GAG release than the control cultures, 
however, despite the large increase in gene expression of ADAMTS-5 by S100A8 and S100A9, there 
was no significant increase in GAG release by S100A8, and a significant (but only marginal when 
compared to IL-1α) increase by S100A9 compared to control cultures (Figure 3.8). Despite the 
increases in gene expression of key collagenases (MMP-1, MMP-13) by IL-1α, S100A8 and S100A9 
homodimers, this did not translate into release of collagen from the extracellular matrix; in the case 
of S100A8 there was a significant decrease in collagen release (Figure 3.8). 
Figure 3.8: Release of A) sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± SEM, control, 
S100A8, S100A9, n=52, IL-1α n=24, S100A8/S100A9 n=54), and B) hydroxyproline (media HyPro as µg/mg wet 
weight, mean ± SEM, n=6) from ovine articular cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for four days, *=p<0.05, **=p≤0.0001 compared to control 
values. 
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3.3.6 S100A8 sustains gene expression changes over two week culture 
periods 
The preceding results demonstrated that S100A8 and S100A9 homodimers stimulated chondrocyte 
expression of key catabolic enzymes in explant cultures, with notable differences between 
monolayer and explant cultures. Furthermore, despite a similar pattern of aggrecanolytic enzyme 
up-regulation in response to IL-1α, no equivalent increased GAG release was observed from S100 
stimulated cultures. To determine whether these unexpected findings might be due to temporal 
differences between the catabolic stimulants, articular cartilage explant cultures were treated with 
either S100 (S100A8, S100A9 or S100A8/S100A9 at 0.1µM) or an inflammatory stimulus (IL-1α at 
10ng/ml, as a positive control) for 24 hours, 48 hours, four days, seven days or 14 days. Long-term 
cultures were refreshed every four days with media containing appropriate treatment. All graphs are 
presented as fold change compared to non-treated controls, represented as mean ± SEM, with 
p<0.05 considered a significant difference. Sample sizes are detailed in Table 3.3 below. Reduced 
sample size in some treatment groups is due to either insufficient RNA extract or quality to reverse 
transcribe. In particular in the IL-1α D14 treatment group all samples had very low RNA, suggesting 
that these cells were no longer viable. 
 
Table 3.3: Sample sizes for ovine articular cartilage explants cultured over a two-week period 
Treatment Sample size 
D1 
Sample size 
D2 
Sample size 
D4 
Sample size 
D7 
Sample size 
D14 
Control 4 6 6 6 3 
S100A8 5 4 6 5 5 
S100A9 5 6 6 6 4 
S100A8/A9 3 4 6 4 5 
IL-1α 9 7 5 3 0 
 
qRT-PCR analysis showed that IL-1α was the most consistently regulated treatment group over the 
two-week time period, however there were several temporal differences in cartilage treated with 
S100A8 and S100A9, and in some cases, the heterodimer. GAPDH expression was generally stable 
throughout the first 14 days of the culture period, however all groups treated with S100 showed 
significant down-regulation of GAPDH at 14 days, perhaps suggesting that extended in vitro cultures 
of cartilage explants (14 days) resulted in changes in normal function (Figure 3.9). Over the entire 
culture period tested, IL-1α caused up-regulation of ADAMTS-4, ADAMTS-5 (Figure 3.10), MMP-1, 
MMP-3, MMP-13 (Figure 3.11) and S100A9 (Figure 3.13), and down-regulation of collagen type II 
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gene expression (Figure 3.9). Aggrecan gene expression was down-regulated by IL-1α from 48 hours 
onwards; MMP-2 after 24 hours only; MMP-14 after 48 hours only; and TIMP-2 for the first four days 
of culture. Additionally, S100A8 was up-regulated by IL-1α over the first two days of culture, and 
then was undetectable, MMP-2 and MMP14 were up-regulated at day seven, MMP-9 at days one 
and four, TIMP-1 at days two and seven, and TIMP-3 after 48 hours only.  
 
S100A8 treatment caused up-regulation of MMP-1, MMP-3 and S100A9 throughout the 14 day 
culture period, and ADAMTS-5 gene expression levels were up-regulated only during the first week. 
ADAMTS-4 was up-regulated by S100A8 at days two, seven and 14; MMP-13 at day seven and MMP-
2 at day 14. Very few genes were down-regulated by S100A8, and all changes were transient: TIMP-2 
at 24 hours; MMP-2 at 48 hours; aggrecan at seven days; and TIMP-1 at 14 days of culture. S100A9 
treatment caused fewer gene expression changes than S100A8, and most occurred at days one and 
two. MMP-1 and MMP-3 were the only genes consistently up-regulated by S100A9 over the entire 
time course, with MMP-1 up-regulation not reaching significance at day seven. S100A9 gene 
expression was up-regulated over the first week, without reaching statistical significance at day four. 
The aggrecanases showed temporal regulation by S100A9, with ADAMTS-5 up-regulated at 24 hours, 
ADAMTS-1, ADAMTS-4 and ADAMTS-5 all up-regulated at 48 hours, then none at four days, and 
ADAMTS-4 up-regulated again at 14 days. MMP-14 and TIMP-3 were transiently up-regulated by 
S100A9 after 48 hours only, and TIMP-1 was up-regulated at days two and four, then down-
regulated at day 14. The S100A8/A9 heterodimer only caused transient up-regulation of the 
following genes: ADAMTS-1, MMP-2 and MMP-14 at 48 hours; ADAMTS-5 at seven days; and MMP-1 
and MMP-3 at 14 days of culture. 
 
67 
 
Figure 3.9: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values. 
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Figure 3.10: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values. 
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Figure 3.11: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values. 
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Figure 3.12: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values, ND = not detected. 
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Figure 3.13: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values. 
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Figure 3.14: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to 
control values, ND = not detected.  
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Table 3.4: Summary of qRT-PCR results of ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, 
four, seven or 14 days. Results are expressed as fold change compared to non-treated control ± SEM, ND = not detected. 
Gene S100A8 D1 S100A8 D2 S100A8 D4 S100A8 D7 S100A8 
D14 
S100A9 D1 S100A9 D2 S100A9 D4 S100A9 D7 S100A9 
D14 
GAPDH 0.70 ± 0.09 1.07 ± 0.32 0.90 ± 0.10 0.63 ± 0.10 0.55 ± 0.07 1.11 ± 0.26 0.99 ± 0.08 0.97 ± 0.10 1.28 ± 0.21 0.53 ± 0.03 
Aggrecan 0.33 ± 0.08 0.66 ± 0.06 0.93 ± 0.08 0.58 ± 0.15 0.84 ± 0.02 0.58 ± 0.11 0.81 ± 0.15 0.99 ± 0.09 0.89 ± 0.12 0.82 ± 0.02 
Collagen II 0.47 ± 0.12 0.61 ± 0.15 1.13 ± 0.13 0.51 ± 0.22 0.89 ± 0.10 0.49 ± 0.14 0.75 ± 0.22 1.09 ± 0.09 0.87 ± 0.08 1.18 ± 0.56 
ADAMTS-1 1.20 ± .053 1.29 ± 0.46 0.74 ± 0.19 0.77 ± 0.29 0.46 ± 0.31 4.91 ± 3.05 3.53 ± 1.47 1.05 ± 0.19 0.84 ± 0.25 0.57 ± 0.07 
ADAMTS-4 6.73 ± 2.16 3.26 ± 0.68 1.33 ± 0.39 8.89 ± 3.57 3.17 ± 0.33 52.82 ± 45.99 9.92 ± 4.51 0.75 ± 0.18 1.67 ± 0.24 1.85 ± 0.23 
ADAMTS-5 11.05 ± 
2.27 
15.75 ± 
6.09 
2.74 ± 1.64 11.21 ± 
4.17 
2.76 ± 1.64 31.39 ± 20.09 29.35 ± 
7.14 
2.17 ± 0.50 2.73 ± 0.57 1.66 ± 0.58 
MMP-1 58.53 ± 
13.29 
40.48 ± 
22.50 
35.91 ± 
19.24 
57.59 ± 
26.69 
44.42 ± 
7.88 
482.26 ± 
411.37 
47.76 ± 
10.71 
24.41 ± 
21.56 
4.55 ± 2.14 20.01 ± 
8.55 
MMP-2 0.49 ± 0.12 0.56 ± 0.15 1.66 ± 0.37 1.06 ± 0.32 1.26 ± 0.49 0.67 ± 0.14 2.21 ± 0.67 1.04 ± 0.18 0.92 ± 0.10 1.88 ± 0.09 
MMP-3 42.48 ± 
8.11 
38.79 ± 
9.81 
30.28 ± 
8.15 
211.37 ± 
76.82 
69.18 ± 
24.80 
784.02 ± 
678.31 
58.85 ± 
12.36 
6.42 ± 1.83 14.72 ± 
6.86 
29.63 ± 
3.68 
MMP-9 1.61 ± 0.83 ND 2.05 ± 0.91 ND ND 2416.33 ± 
2204.83 
ND 0.37 ± 0.06 ND ND 
MMP-13 18.98 ± 
11.44 
1.91 ± 1.46 1.87 ± 0.96 14.15 ± 
5.78 
17.68 ± 
13.18 
69.15 ± 59.28 1.15 ± 0.46 7.33 ± 6.52 2.93 ± 1.23 4.60 ± 2.70 
MMP-14 0.47 ± 0.07 1.53 ± 0.40 1.23 ± 0.09 1.97 ± 0.71 0.67 ± 0.08 0.96 ± 0.18 3.00 ± 0.48 1.46 ± 0.15 0.85 ± 0.10 0.96 ± 0.08 
S100A8 0.98 ± 0.44 2.29 ±1.07 ND ND ND 4.63 ±2.48 4.29 ± 3.15 ND ND ND 
S100A9 4.62 ± 1.82 4.09 ± 1.08 5.78 ± 4.27 15.66 ± 
4.29 
7.37 ± 2.21 10.97 ± 6.43 7.11 ± 2.95 2.01 ± 0.55 4.74 ± 1.12 2.13 ± 0.70 
TIMP-1 0.68 ± 0.10 1.38 ± 0.24 1.06 ± 0.18 2.42 ± 0.68 0.62 ± 0.08 1.42 ± 0.52 1.86 ± 0.18 1.34 ± 0.18 1.64 ± 0.36 0.70 ± 0.07 
TIMP-2 0.36 ± 0.06 1.38 ± 0.45 1.11 ± 0.16 1.18 ± 0.29 0.62 ± 0.32 0.44 ± 0.13 2.27 ± 0.53 1.03 ± 0.16 0.90 ± 0.20 0.54 ± 0.23 
TIMP-3 0.45 ± 0.16 1.05 ± 0.18 0.97 ± 0.14 1.02 ± 0.31 0.64 ± 0.06 1.27 ± 0.45 1.64 ± 0.15 1.34 ± 0.17 0.98 ± 0.19 1.16 ± 0.19 
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Table 3.5: Summary of qRT-PCR results of ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, 
four, seven or 14 days. Results are expressed as fold change compared to non-treated control ± SEM, ND = not detected. 
Gene S100A8/A9  
D1 
S100A8/A9 
D2 
S100A8/A9 
D4 
S100A8/A9 
D7 
S100A8/A9 
D14 
IL-1α D1 IL-1α D2 IL-1α D4 IL-1α D7 
GAPDH 0.80 ± 0.19 0.98 ± 0.11 0.89 ± 0.12 1.03 ± 0.19 0.67 ± 0.05 1.21 ± 0.15 0.99 ± 0.10 0.44 ± 0.05 1.22 ± 0.06 
Aggrecan 0.47 ± 0.22 1.40 ± 0.20 1.38 ± 0.20 0.88 ± 0.09 0.96 ± 0.07 0.23 ± 0.03 0.13 ± 0.02 0.27 ± 0.06 0.09 ± 0.006 
Collagen II 0.61 ± 0.12 1.20 ± 0.17 1.33 ± 0.20 0.74 ± 0.13 0.93 ± 0.08 0.08 ± 0.03 0.03 ± 0.004 0.05 ± 0.01 0.008 ± 0.003 
ADAMTS-1 0.79 ± 0.32 2.01 ± 0.32 1.67 ± 0.40 1.81 ± 0.92 0.54 ± 0.10 4.50 ± 1.15 1.46 ± 0.41 0.68 ± 0.17 4.27 ± 0.71 
ADAMTS-4 0.21 ± 0.17 5.87 ± 4.25 1.02 ± 0.22 1.10 ± 0.59 1.76 ± 0.28 431.34 ± 
80.28 
308.95 ± 
46.58 
365.17 ± 
165.62 
820.60 ± 
64.82 
ADAMTS-5 0.42 ± 0.13 1.38 ± 0.28 1.78 ± 0.58 1.93 ± 0.29 0.82 ± 0.28 86.32 ± 
20.93 
16.09 ± 2.81 38.53 ± 
12.08 
255.65 ± 
35.74 
MMP-1 0.57 ± 0.34 2.15 ± 1.27 0.78 ± 0.37 0.99 ± 0.83 17.09 ± 2.87 3052.07 ± 
541.02 
706.11 ± 
116.17 
6049.69 ± 
4530.25 
3232.06 ± 
543.37 
MMP-2 0.47 ± 0.12 1.64 ± 0.26 1.73 ± 0.43 0.98 ± 0.38 0.56 ± 0.11 0.42 ± 0.14 0.82 ± 0.28 1.26 ± 0.22 5.71 ± 2.08 
MMP-3 0.38 ± 0.17 1.29 ± 0.28 1.71 ± 0.66 1.70 ± 1.13 7.28 ± 1.15 2110.77 ± 
369.57 
1359.90 ± 
208.37 
2247.23 ± 
1263.08 
5258.42 ± 
642.18 
MMP-9 2.37 ± 1.43 ND 0.58 ± 0.16 ND ND 148.05 ± 
130.41 
ND 8.27 ± 3.71 ND 
MMP-13 5.58 ± 5.48 3.13 ± 2.32 12.71 ± 7.21 10.71 ± 
10.08 
3.00 ± 1.19 120.01 ± 
18.93 
6.24 ± 0.82 26.50 ± 
17.88 
3449.47 ± 
1528.17 
MMP-14 0.47 ± 0.12 1.53 ± 0.06 1.51 ± 0.16 0.89 ± 0.28 1.15 ± 0.21 0.64 ± 0.14 0.64 ± 0.06 1.34 ± 0.16 9.14 ± 1.96 
S100A8 0.25 ± 0.14 0.92 ± 0.31 ND ND ND 28.07 ± 
10.53 
62.80 ± 8.62 ND ND 
S100A9 1.15 ± 1.01 1.49 ± 0.79 1.00 ± 0.10 1.21 ± 0.35 0.79 ± 0.18 26.82 ± 5.55 76.37 ± 9.60 10.16 ± 2.62 221.90 ± 
56.15 
TIMP-1 0.42 ± 0.23 1.18 ± 0.33 1.35 ± 0.14 1.32 ± 0.19 1.13 ± 0.22 1.50 ± 0.18 1.83 ± 0.14 1.51 ± 0.19 2.33 ± 0.08 
TIMP-2 0.43 ± 0.14 1.11 ± 0.20 1.10 ± 0.18 1.37 ± 0.59 0.70 ± 0.18 0.17 ± 0.02 0.23 ±0.03 0.39 ± 0.06 1.04 ± 0.43 
TIMP-3 0.27 ± 0.06 1.57 ± 0.42 1.32 ± 0.15 0.96 ± 0.17 1.12 ± 0.09 0.85 ± 0.19 1.30 ± 0.09 0.77 ± 0.20 0.63 ± 0.11 
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3.3.7 S100 alone cannot lead to biochemical cartilage degradation or 
activate MMPs over two-week culture periods 
Results from four day explant cultures showed that despite a similar pattern of aggrecanolytic 
enzyme up-regulation in response to IL-1α treatment, no similarly increased GAG or collagen release 
was observed from S100-stimulated cultures. It was then shown over a time course of 14 days that 
whilst there were clear temporal differences in gene expression between S100- and IL-1α-treated 
explants, over the 14-day time course there was significantly increased expression of key 
aggrecanases ADAMTS-4 and ADAMTS-5 and collagenases MMP-1 and MMP-13 by S100A8 and 
S100A9 homodimers. To determine whether aggrecan and collagen release is a later event in S100-
treated explants than expected (based on IL-1α), rather than a treatment-specific effect, conditioned 
media was collected from the articular cartilage explant cultures from Section 3.3.6 at the end of the 
respective culture periods (one, two, four, seven or 14 days). Release of glycosaminoglycans (GAGs) 
and collagen into the media was measured as sulphated GAG and hydroxyproline respectively. The 
release is presented as cumulative (i.e. total release over the entire culture period) µg GAG per mg 
wet weight cartilage and µg Hydroxyproline (HyPro) per mg wet weight cartilage respectively, from 
one experiment with n=6 per treatment group per time point, except for IL-1α treated groups that 
had an n=9 for each time point (Figure 3.15; mean ± SEM, with p<0.05 considered statistically 
significant).  
 
As expected, cumulative GAG release from control cultures increased with time in culture. IL-1α 
significantly increased the amount of GAG released to media at all time points tested, however there 
was no significant increase in GAG release by S100, with the exception of S100A9 at day two, where 
GAG release reached significance, although the actual value was less than half that of IL-1α (4.26 
versus 9.2 µg GAG per mg wet weight cartilage). Collagen release showed a similar pattern although 
perhaps delayed compared with GAG, again with the only significant increases in collagen release 
seen with IL-1α stimulation at days two, seven and 14, with no significant increases induced by S100 
treatment at any time. 
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Figure 3.15: Release of A) sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± SEM, 
control, n=6, except IL-1α n=9), and B) hydroxyproline (media HyPro as µg/mg wet weight, mean ± SEM, n=6 
except IL-1α n=9) from ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 
0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days, *=p<0.05 compared to control values. 
 
MMP gene expression was increased over the 14-day time course, however, MMPs need to be 
secreted and activated in order to degrade proteoglycans and collagens. In order to determine 
whether MMPs were differentially activated by IL-1 versus the S100 proteins, MMP-13, MMP-2 and 
MMP-9 secretion and activity in conditioned media were evaluated. MMP-2 and MMP-9 protein 
secretion and activation in conditioned media was determined using gelatin zymography. Figure 3.16 
demonstrates that pro-MMP-2 was present in all media samples, with bands becoming more 
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pronounced over the time course of the culture period, but with very little difference in the intensity 
of the bands within the time points tested regardless of the treatment, although S100A9 appeared 
to induce slightly more pro-MMP-2 at days seven and 14 than the other treatments. Active-MMP-2 
became visible from day two until the end of the 14-day culture period, again with not much 
difference between treatment groups except for slightly higher levels produced by S100A9 
treatment at days seven and 14. In contrast to MMP-2, MMP-9 was not detected in any treatment 
groups at any time points, with the exception of a very faint band at day 14 in the S100A9-treated 
group.  
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Figure 3.16: MMP activity in conditioned media from ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for 
one, two, four, seven or 14 days. MMP-2 and MMP-9 were detected in conditioned media by gelatin zymography. Migration position of pro- and active-MMP-2 and MMP-9 
is shown on the left hand side, corresponding to around 92kDa (MMP-9) and 66kDa (MMP-2), STDs (samples from previous experiments) are shown on the left hand side of 
each panel. Samples were run on multiple gels (12 wells per gel); spaces indicate where a new gel starts. 
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MMP-13 activity was measured using a commercial fluorescent peptide assay (as described in 
section 2.3.3.1) both after adding an MMP activator, APMA, (i.e. “Pro-MMP-13” Figure 3.17 upper 
panel) and without APMA addition (“spontaneously active MMP-13” Figure 3.17 lower panel). Each 
bar represents pooled media from each treatment group, with each group normalised to wet weight 
of the cartilage. Measurements were taken every half hour over a four-hour period, with each bar 
representing the rate of increase in fluorescence per half hour. It is clear from these graphs that IL-
1α induced secretion of pro-MMP-13 protein and its activation, which increased over the culture 
period from day two until the end of the 14-day culture period. In contrast, neither S100 homodimer 
nor the heterodimer could induce secretion of pro-MMP-13 above that seen in control cultures, nor 
any spontaneous MMP-13 activity at any time point. 
 
Taken together, these results show that whilst there are significant increases in expression of key 
catabolic enzymes by S100A8 and S100A9 across the culture period of this experiment, unlike 
stimulation with IL-1, these do not translate into increased protein secretion into the media, protein 
activation or proteolysis of the extracellular matrix in this articular cartilage explant system.  
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Figure 3.17: MMP-13 activity in conditioned media from ovine articular cartilage explants cultured with 
S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for one, two, four, seven or 14 days either 
without or following incubation with the MMP-activator APMA (1mM). Bars represent pooled media samples 
(n=6 per treatment group). 
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3.4 Discussion 
The importance of S100A8 and S100A9 in rheumatoid arthritis has been well documented in the 
literature (reviewed in Section 1.3.2.5), with large increases of both S100s in synovial fluid and 
plasma [260-262]. S100A8 and S100A9 have also been observed in synovial fluid of osteoarthritic 
joints, at levels of around 5µg/ml [234]. In both cases, high levels of extracellular S100A8 and/or 
S100A9 would be present in the joint, however very few studies have investigated the effect this 
would have on joint tissues. This study aimed to determine what effect extracellular S100A8 and/or 
S100A9 would have on cartilage, using in vitro monolayer cultures and in the more physiologically 
relevant model of cartilage explants.  
 
The present study showed that 24 hour exposure of chondrocyte monolayer cultures to IL-1α 
differentially regulated S100A8 and S100A9, with S100A9 mRNA significantly increased with no 
detection of S100A8 mRNA. In contrast, S100A8 protein was present in the cell lysates with no 
detection of S100A9 protein. A previous study by Zreiqat et al. [187] showed an increase in both 
S100A8 and S100A9 mRNA in mouse femoral head cultures stimulated with 10ng/ml recombinant IL-
1α for four days using microarray methods. Whilst this is the same concentration of IL-1α, there may 
be species differences (especially considering both used human IL-1α) and also differences in 
monolayer and explant responses. Since S100A8 protein cannot be present without initial mRNA 
expression, perhaps this is an earlier but not sustained effect, and S100A9 mRNA had not yet been 
translated into protein expression. Alternatively, it may be that the anti-human S100A9 antibody 
used does not detect ovine S100A9 protein in Western Blotting. The anti-human S100A9 antibody 
has been previously used in sheep in immunohistochemistry and showed positive staining 
(unpublished observations); however to the author’s knowledge it has not been used in a Western 
Blot in any other ovine cells/tissues. Since the heterodimer is the most prominent form in the body, 
it is plausible to suggest that regulation of S100A8 and S100A9 would occur simultaneously; 
however, results presented in this chapter show differential regulation of S100A8 and S100A9 by IL-
1α. This may be an important factor in cartilage degradation, as both chondrocyte monolayer and 
cartilage explant cultures were regulated at the gene expression level by both homodimers, with 
significant changes in a number of genes, whereas the heterodimer had little or no effect.  
 
Non-treated chondrocytes in monolayer cultures maintained their chondrogenic phenotype as 
reflected in their synthesis of ECM components aggrecan and collagen II, with relatively low 
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expression of catabolic MMPs and ADAMTS. Chondrocyte monolayer cultures treated for 24 hours 
with S100A8, S100A9 or IL-1α clearly shifted towards a largely catabolic profile, with down-
regulation of key ECM proteins, and up-regulation of aggrecanases, collagenases and other MMPs, 
accompanied by a decrease in the endogenous inhibitors TIMP-2 and TIMP-3. In all regulated genes, 
the direction of regulation by S100A8 and S100A9 was the same as IL-1α, regardless of whether it 
reached statistical significance. These results agree with previously reported chondrocyte monolayer 
studies treated with S100 proteins. Zreiqat et al. [187] reported a decrease in ECM genes and an 
increase in catabolic genes in response to S100A8 or S100A9 homodimer treatment with no 
response from the heterodimer. However, and in contrast with the data presented in this chapter, 
they found increased ADAMTS-1 expression by S100A8 and S100A9, with no differences in TIMP-3. 
van Lent et al. [279] also found up-regulation by S100A8 at a concentration of 1µg/ml of catabolic 
genes MMP-2, -3, -9, -13 as well as ADAMTS-4 and -5, in a murine cell line H4 [292]; S100A9 and the 
heterodimer treatment were not tested. 
 
Chondrocyte monolayer cultures provide a simple in vitro system in which to measure direct effects 
of stimuli, however they do not accurately mimic the in vivo situation due to the lack of ECM and 
other joint tissues/cell types. While articular cartilage explant cultures still do not incorporate other 
tissue types; they nonetheless provide a more physiologically relevant model of cartilage than 
monolayer cultures, as the ECM and pericellular matrix are intact. Chondrocyte studies were 
performed using 0.01µM S100 protein (based on [187] in which 0.01µM S100A8 and S100A9 were 
found to be sufficient to induce significant gene expression changes), however it was thought that 
cartilage explants would likely require a higher concentration (based on observations using other 
cytokines/proteins in cartilage explant cultures, unpublished data). Our initial studies demonstrated 
that 0.1µM, a similar concentration as that used by van Lent et al. [279], was sufficient to induce 
significant changes, this concentration was therefore used throughout. The 0.1µM concentration 
used is equivalent to ≈1µg/ml, a concentration well within the physiological levels seen in OA 
synovial fluid [234]. The reason for the higher concentration required in explants compared to 
chondrocyte monolayer cultures is probably due to the protein needing to diffuse through the 
matrix to reach the cells. For this reason the culture period was also extended to four days; a time 
point previously found to cause sufficient IL-1α-induced gene expression changes and maximal 
aggrecan release to media. In general, gene expression data matched that of the chondrocyte 
monolayer cultures, however, the standard error was greater in explants, suggesting one or more of 
the following: diffusion through the matrix differed somewhat between samples; topographical 
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variation in response of chondrocytes to catabolic stimuli [293]; presence of multiple phenotypes of 
chondrocytes from different layers of the cartilage, which would not be evident in pooled/uniform 
monolayer culture; or perhaps the matrix components themselves interacted with the S100 
proteins. It has been shown that S100 proteins bind to heparan sulphate in the context of 
endothelial cells [223], and whilst there are an abundance of heparan sulphate proteoglycans in the 
cartilage ECM, particularly in the pericellular matrix and on the cell surface [294], it is unknown 
whether or not they bind and regulate the function of S100 proteins in this tissue.  
 
There were some notable differences in gene expression profile between explants and chondrocyte 
monolayer cultures. Whilst the ECM components aggrecan and collagen II were decreased by the 
two homodimers, the changes were much smaller than that seen for the isolated chondrocytes, and 
were also much less compared to the decreases induced by IL-1α. ADAMTS-4 was not detected in 
explant cultures in the initial experiment, unlike chondrocyte monolayers in which ADAMTS-4 was 
significantly up-regulated. This is likely because of the temporal regulation of ADAMTS-4, which was 
later seen in the time course experiment. In addition, whilst there was a trend for the up-regulation 
of MMP-13 by S100A8 and S100A9, this did not reach statistical significance because of the large 
variation between replicates, even in non-treated controls. Up-regulation of TIMP-2 in explants by 
S100A8 and S100A9 was opposite to the response of chondrocytes to S100A8 and S100A9, where 
TIMP-2 was down-regulated. A major interesting difference was the fact that whilst S100A9 was not 
detected in chondrocyte monolater cultures, it was up-regulated not only by IL-1α in cartilage 
explants, but was also self-regulated, with S100A8 and S100A9 homodimers both causing up-
regulation of S100A9. This positive feedback loop would further increase levels of S100A9 in the 
cartilage and potentially drive further catabolic activity. It is interesting that S100A8 gene expression 
was not regulated by the homodimers, and could again suggest a role for S100A8 and S100A9 in 
cartilage due to the uncoupling of the expression of these two proteins that could favour 
homodimer formation over the more common and largely catabolically inactive heterodimer.  
 
Since there were major increases in MMP and ADAMTS gene expression, and down-regulation of 
aggrecan and collagen II by the S100 homodimers, we sought to determine if this led to degradation 
of the cartilage ECM, by determining the amount of aggrecan and collagen released from the 
cartilage into the media. Surprisingly, there was no difference between non-treated and S100-
treated groups, in contrast with IL-1α treated groups where there was a significant increase in 
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aggrecan but not collagen release in short term (four day) cultures. To explore this further, the 
experiment was repeated over a time course of two weeks to determine: if the up-regulation of 
catabolic genes by the S100 homodimers led to a later breakdown of cartilage, and if the differences 
in gene regulation between S100 proteins and IL-1 initially observed were temporal rather than 
stimulant-related. Collectively, the findings can be summarised as follows: S100A9 tended to up-
regulate catabolic genes at early time points (24 and 48 hours) then its effect diminished over the 
remaining 12 days; the effect of S100A8 tended to be less than that of S1009 after 24 hours, 
however this effect increased after 48 hours and was sustained for the remaining 12 days; the 
heterodimer S100A8/A9 did not appear to induce any sustained regulation of gene expression, with 
significant changes detected only at single time points.  
 
An interesting finding was the fact that S100A8 mRNA was only detected at 24 and 48 hours, and 
was only up-regulated significantly by IL-1α, and not by any of the S100-treated groups. This was in 
contrast to S100A9 mRNA expression, which was detected throughout the two-week culture period, 
not only significantly up-regulated by IL-1α but also by the S100A8 and S100A9 homodimers. Whilst 
there was an increase over time of both aggrecan and collagen release into the media, at no time 
point was there a difference between non-treated and S100-treated groups. This lack of any 
biochemical breakdown of the cartilage ECM would suggest that some form of post-transcriptional 
regulation of aggrecanases and collagenases was occurring. Post-transcriptional regulation can occur 
at various points in the conversion of mRNA transcript to active protein: translation from mRNA to 
protein; secretion of protein; activation of pro-forms; and degradation/inhibition once 
secreted/activated. The aggrecanases ADAMTS-4 and ADAMTS-5 are translated in an inactive form, 
and are activated by furin and furin-like enzymes via removal of the pro-domain in the trans-golgi 
network prior to secretion [99]. Post-transcriptional regulation could therefore be occurring in S100-
treated explants due to a few reasons: lack of appropriate/sufficient activating enzymes in the 
chondrocyte; lack of secretion of activated ADAMTS; sequestration of activated ADAMTS in the 
cartilage ECM; or inhibition of ADAMTS. TIMP-3 is a unique endogenous inhibitor of ADAMTS-4 and 
ADAMTS-5, and could theoretically be contributing to the lack of aggrecan cleavage. In the studies 
presented in this chapter in cartilage explant cultures there was no increase in TIMP-3 mRNA, 
suggesting this mechanism is not relevant to this study; however, it should be noted that TIMP-3 
mRNA levels are not significantly altered in OA, rather it is post-translational degradation of TIMP-3 
that shifts the balance between MMPs and their inhibitors [108-111].  
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MMPs are secreted in their pro- form and require cleavage to be activated. Pro- and active-MMP-13, 
MMP-2 and MMP-9 levels were measured in conditioned media to determine if lack of protein 
expression and/or activation could explain the lack of translation from gene up-regulation into 
biochemical cartilage breakdown. We confirmed that whilst there were marked increases in pro- and 
active-MMP-13 in conditioned media from IL-1α-treated cartilage explants at all time points, there 
was no corresponding increase in either pro- or active-MMP-13 by any S100-treated group 
compared to non-treated controls of the same time point. As was the case for ADAMTS-4 and 
ADAMTS-5, this suggests some post-transcriptional regulation of MMP-13. MMP-13 can be activated 
by other MMPs (MMP-2, MMP-3 and MMP-14), and can itself take part in the activation of MMP-2 
and MMP-9 [295]. Elevated levels of MMP-3 mRNA were induced by S100A8 and S100A9 treatment 
in cartilage explants, however there was no induction of MMP-14 in the studies presented in this 
chapter. Alternatively, TIMPs could be inhibiting MMP-13, although this was not reflected in gene 
expression levels, or again, there could be sequestration in the matrix which would stop the MMP-
13 protein from being released into the media. No evidence could be found in literature of any 
inhibition of translation of MMP-13 mRNA or secretion, so it is unlikely these are the reasons for the 
lack of activity. Similarly, gelatin zymography revealed that all conditioned media contained similar 
levels of pro-MMP-2 when compared with non-treated controls of the same treatment group (in 
agreement with gene expression data). Moreover, pro-MMP-2 levels increased over time, with no 
increase in S100-treated groups compared to non-treated controls, with the exception of S100A9 at 
days seven and 14, which appeared to be a brighter band than other treatment groups from the 
same time points. Later time points also showed the presence of active-MMP-2; however, again, 
there was no real difference between treatment groups. Pro- or active-MMP-9 bands were not 
detected in any treatment group at any time point. As stated before, MMP-13 can activate both pro-
MMP-2 and -MMP-9, and the lack of MMP-13 protein in conditioned media from S100-treated 
cartilage could explain the lack of activation. A study in murine embryonic fibroblast by English et al. 
[296] showed that pro-MMP-2 can also be activated at the cell surface by the formation of a trimeric 
molecule involving MMP-14, TIMP-2 and pro-MMP-2, giving TIMP-2 multiple roles both as an 
activator at low concentrations, and as an inhibitor at high concentrations. Again, levels of TIMP-2 
and MMP-14 mRNA were not differentially regulated by S100A8, S100A9 or IL-1α, so it is unlikely 
this is the reason for the lack of activation of MMP-2. 
 
These experiments confirm that chondrocytes treated with S100A8 or S100A9, but not the 
heterodimer, shift to a more catabolic gene expression profile. This has been shown for the first time 
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to be true in a more physiologically relevant in vitro model of articular cartilage explants, and that 
despite this shift, there is no corresponding breakdown of the cartilage matrix. This suggests that 
S100A8 and S100A9 do not have the capacity to stimulate the necessary systems to activate 
ADAMTS and MMPs and therefore cannot induce cartilage breakdown on their own. They may play a 
role in priming the cartilage towards degradation; however, it may be that a second stimulus is 
required for actual degradation to occur. Interestingly, a positive feedback loop was also identified 
for S100A9 gene expression, which may contribute to further priming of the cartilage towards a 
degradative state (results summarised in Figure 3.18). 
 
This chapter therefore raises the following questions that will form the basis for Chapters 4 and 5: 
 What are the mechanisms involved in the regulation of gene expression induced by S100A8 
and S100A9 homodimer treatment in cartilage: what signalling pathways are activated by 
S100A8 and S100A9? 
 Is there a second stimulus that can act in concert with S100A8 and S100A9 (as primers) to 
achieve biochemical breakdown of the cartilage ECM via activation of MMPs and ADAMTS? 
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Figure 3.18: Summary of results presented in this chapter – S100A8 and S100A9 homodimers act as primers of 
cartilage degeneration in cartilage explants by causing a shift to a catabolic gene expression profile; however, 
this does not translate into MMP activation or the consequent biochemical degradation of the cartilage matrix, 
which is in contrast with IL-1α which causes gene expression changes, MMP activation and subsequent 
biochemical degradation of the cartilage. 
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Chapter 4 Signalling Pathways Activated by S100A8 and S100A9 in 
Cartilage 
4.1 Introduction 
Chapter 3 identified that S100A8 and S100A9 homodimers (but not the heterodimer) acted to prime 
chondrocytes for entering a degradative state, not only in monolayer cultures, but also in the more 
physiologically-relevant in vitro model of full thickness articular cartilage explants.  This “priming” 
process was characterised by up-regulation of the key catabolic enzymes, ADAMTS and MMPs, 
whilst ECM components aggrecan and type 2 collagen were down-regulated, suggesting that S100A8 
and S100A9 homodimers are driving the cartilage remodelling process balance towards a more 
catabolic gene expression profile. 
 
The receptors for S100A8 and S100A9 in cartilage chondrocytes are yet to be determined, although a 
few candidates have been proposed: documented receptors for S100A8/A9 include CD36 [243], 
NADPH oxidase [244], carboxylated glycan receptors such as RAGE [197, 239, 279, 297] (although 
this is controversially reported), and TLR4 [211]. S100A8/A9 activation of signalling pathways seems 
to be different in various cells/tissue types [197, 234, 241, 242, 244, 252], possibly accounting for 
some of the controversial reporting of S100A8/A9 binding to RAGE. On endothelial cells, S100A8/A9 
has also been found to bind to carboxylated N-glycans [222] and heparan sulphate proteoglycans 
[211] (via binding to S100A9), confirmed by competition assays with heparin, heparan sulphate and 
chondroitin sulphate B [223]. The stimulation of endothelial cells by S100A8/A9 binding has been 
shown to signal through the MAPK pathways; p38, ERK1/2, and NF-κB [233]. In monolayer 
chondrocyte cultures, blocking TLR4 with a synthetic inhibitor (TAK-242) decreased S100-induced 
gene expression changes by up to 80%, whereas blocking of RAGE or carboxylated glycans had no 
effect [188]. Blocking TLR4 has been shown to partially reverse the stimulatory action of S100A8 in 
both mice (in neutrophils) [220] and humans (monocytes) [291], but does not completely block it, 
pointing to the possible involvement of other pathways being activated by S100A8. To the author’s 
knowledge, no studies have been performed in cartilage looking at MAPK pathways activated by 
S100A8 and/or S100A9 in chondrocytes, and no signalling studies have been performed in cartilage 
explants. The aim of this chapter was to identify the signalling pathway(s) potentially involved in the 
up-regulation of the cartilage catabolic genes by S100A8 and S100A9. 
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The specific aims of this chapter were to: 
 Determine if stimulation of chondrocyte monolayer cultures with extracellular S100A8 
and/or S100A9 leads to the activation of MAPK, NF-κB or TLR4 signalling pathways, and 
whether inhibiting these pathways can inhibit gene expression changes documented in 
Chapter 3. 
 Optimise an in vitro system of inhibiting MAPK, NF-κB or TLR4 signalling in articular cartilage 
explants. 
 Determine if addition of extracellular S100A8 and/or S100A9 activates MAPK, NF-κB or TLR4 
signalling pathways in articular cartilage explant cultures, and whether inhibiting these 
pathways can inhibit gene expression changes documented in Chapter 3. 
 
4.2 Materials and Methods 
Materials and methods used in this chapter are outlined in Chapter 2.  
Primer sets used for real-time qRT-PCR are shown in Table 2.1.  
Variations from the general methods were: 
 Addition of inhibitors to culture media required an extra pre-incubation step both in 
chondrocyte monolayer cultures and articular cartilage explants. 
 
Additional methods used in this chapter were as follows: 
4.2.1 Pre-incubation with Inhibitors 
Chondrocytes were cultured to confluence and then incubated in serum-free media for four hours as 
described in Section 2.1.2. The appropriate inhibitor was added to the culture media for one hour 
prior to adding S100 proteins or IL-1α (PD98059 at 30µM, SB203580 and U0126 at 20µM, CLI-095 
and RS-LPS at 1µg/ml). Cartilage explants were cultured as described in Section 2.1.1 with an 
additional 24-hour pre-incubation step added between the washing step with the serum-free media 
and treatment of the cartilage with S100A8, S100A9, S100A8/A9 or IL-1α. The appropriate inhibitor 
was added to the culture media during this pre-incubation step at the following concentrations: 
PD98059 at 100µM, SB203580 at 300µM, and U0126 at 20µM.    
 
90 
 
4.3 Results 
4.3.1 Signalling Pathways in Chondrocyte Monolayer Cultures 
4.3.1.1 MAPK Pathways 
Addition of S100A8 and S100A9 to chondrocyte cultures led to significant increases in catabolic gene 
expression (MMP-1, MMP-13 and ADAMTS-5) as expected (Chapter 3), and change in expression of 
these genes was used as the primary outcome to evaluate the effect of the inhibitors. Chondrocyte 
monolayer cultures are simple systems in which to explore mechanisms of action, and were 
therefore chosen as the initial means of determining signalling pathways activated by S100A8 and 
S100A9 in cartilage. MAPK pathways have been implicated in osteoarthritis [66, 80, 86, 157, 159], 
and are documented in other cell types to be phosphorylated after binding of S100A8/A9 to RAGE 
[242], or TLR4 [247]; MAPK pathways were therefore targeted in this study. The inhibitors chosen for 
this study were all commercially available small molecule inhibitors, and incubation times and 
concentrations were based on the information available in the literature. Table 4.1 below shows a 
summary of the literature for MAPK inhibitors used in in vitro cartilage studies. Since the majority of 
studies listed used IL-1 as a stimulant, and since it is known to activate MAPK signalling pathways, IL-
1α was used as a positive control in this study. Figure 4.1 shows the MAPK signalling cascade, with 
arrows indicating the pathways that the chosen inhibitors act on. PD98059 is a general MAPK 
inhibitor that acts on MAPKK (MEK) [298], SB203580 specifically blocks the p38 MAPK pathway 
[299], and U0126 is a selective inhibitor of MEK1 and MEK2, and acts by inhibiting the kinase activity 
of MEK1/2, preventing the activation of MAP kinases p42 and p44 which are encoded by the erk2 
and erk1 genes respectively [300]. All inhibitors were reconstituted in dimethyl sulfoxide (DMSO) to 
the maximum possible concentration in order to reduce the amount of DMSO in culture media as 
DMSO is toxic at high concentrations. All DMSO- and inhibitor-treatments were made up to 0.1% 
DMSO, which corresponded to the inhibitor with the highest concentration of DMSO. 
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Table 4.1: Summary of literature on MAPK inhibitors tested on chondrocytes in vitro 
Ref Pathway Species Stimulant Inhibitor, Company, Doses 
Tested, Pre-incubation 
Time 
Effect on Gene 
Expression 
[301] MEK Human IL-1β/IL-1α PD98059, Calbiochem, 15, 
30µM, 30 mins 
Partial inhibition of 
MMP-3 and MMP-13 
[302] MEK Bovine IL-17 
(20ng/ml) 
PD98059, Calbiochem, 5-
30µM, 30 mins 
Inhibition of MMP-3, 
MMP-13, ADAMTS-4 
[303] p38 Human IL-1β SB203580, Sigma, 5, 
10µM, 30 mins 
None of interest 
tested 
[301] p38 (low) 
JNK (high) 
Human IL-1β/IL-1α SB203580, Calbiochem, 
10, 20µM, 30 mins 
Partial inhibition of 
MMP-3 and MMP-13 
[302] p38 (low) 
JNK (high) 
Bovine IL-17 
(20ng/ml) 
SB203580, Calbiochem, 
10-20µM, 30 mins 
Inhibition of MMP-3, 
MMP-13, ADAMTS-4 
[303] JNK Human IL-1β SP600125, Sigma, 10, 
20µM, 30 mins 
None of interest 
tested 
[302] JNK Bovine IL-17 
(20ng/ml) 
SP600125, Anthra, 1-
30µM, 30 mins 
Inhibition of MMP-3, 
MMP-13, ADAMTS-4 
[301] MEK-1/2 Human IL-1β/IL-1α U0126, Promega, 25, 
50µM, 30 mins 
Partial inhibition of 
MMP-3 and MMP-13 
[303] MEK-1/2 Human IL-1β U0126, Sigma, 1, 10µM, 30 
mins 
None of interest 
tested 
[304] MEK1/2 Human OSM U0126, Calbiochem, 5, 
10µM, 30 mins 
Partial inhibition of 
MMP-13 and 
ADAMTS-4 
[302] MEK1/2 Bovine IL-17 
(20ng/ml) 
U0126, Promega, 5-25µM, 
30 mins 
Inhibition of MMP-3, 
MMP-13, ADAMTS-4 
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Figure 4.1: MAPK signalling pathways (adapted from [305]) 
 
S100A8 and IL-1α induced significant up-regulation of GAPDH compared to a non-treated control, 
although neither DMSO nor any of the inhibitors on their own changed GAPDH gene expression 
(Figure 4.2). That GAPDH was regulated by one or more of the treatment conditions meant that it 
could not be used to normalise expression of the genes of interest, rather equal amounts of total 
RNA were reverse transcribed and expression is relative to that in control cultures (media alone). 
The genes of interest examined in this study were chosen based on the large responses to S100A8 
seen in Chapter 3 in chondrocyte monolayer culture. Results demonstrated that 0.1% DMSO alone 
did not regulate any of the genes tested (Figure 4.2); PD98059 alone significantly down-regulated 
ADAMTS-5, MMP-1 and MMP-3; SB203580 alone significantly down-regulated aggrecan, ADAMTS-5, 
MMP-3 and MMP-13; and U0126 alone significantly down-regulated collagen II, ADAMTS-5 and 
MMP-3. Addition of DMSO did not impact upon S100A8- or IL-1α-induced gene expression changes.  
 
S100A8 induced down-regulation of aggrecan and collagen II gene expression and up-regulation of 
ADAMTS-5, MMP-1, MMP-3 and MMP-13. S100A8-induced gene expression changes in ADAMTS-5, 
MMP-3 and MMP-13 were blocked by all three inhibitors; aggrecan was inhibited by U0126; collagen 
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II by SB203580 and U0126; and MMP-1 by PD98059 and U0126. As expected, IL-1α treatment 
significantly down-regulated aggrecan and collagen II gene expression whilst up-regulating ADAMTS-
5, MMP-1, MMP-3 and MMP-13. Similarly to S100A8-treated cultures, all three MAPK inhibitors 
(PD98059, SB203580 and U0126) significantly inhibited the IL-1α-induced gene expression changes 
seen in ADAMTS-5, MMP-3 and MMP-13, and IL-1α-induced down-regulation of aggrecan was only 
inhibited by U0126. In contrast to S100A8-treated cultures, IL-1α-induced collagen type II and MMP-
1 regulation was also blocked by all three MAPK inhibitors. Interestingly, whilst gene expression 
changes by IL-1α were blocked in order of magnitude changes by U0126>SB203580>PD98059, 
PD98059 inhibited gene expression to a higher degree than SB203580 in S100A8-treated cartilage. 
Table 4.2 shows the average percentage inhibition by the three MAPK inhibitors of the S100A8 or IL-
1α induced gene expression. Results from the JNK pathway inhibitor SP600125 are not shown here 
as a suitable concentration could not be determined during preliminary optimisation experiments.  
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Figure 4.2: Gene expression analysis from ovine chondrocyte monolayer cultures treated with S100A8 at 
0.01µM or IL-1α at 1ng/ml ± 0.1% DMSO, PD98059 at 30µM, SB203580 at 20µM or U0126 at 20µM for 24 
hours, *=p<0.05 compared to control values, ^=p<0.05 compared to appropriate 0.1% DMSO group. 
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Table 4.2: Summary of average inhibition of S100A8- and IL-1α-induced gene expression changes by the three 
MAPK inhibitors (PD98059, SB203580 and U0126); expressed as percentage change compared to appropriate 
0.1% DMSO treatment group. NI = no inhibition. 
Gene Treatment PD98059 SB203580 U0126 
Aggrecan S100A8 15.74% NI 26.14% 
IL-1α 10.41% 12.58% 45.90% 
Collagen II S100A8 29.41% 17.23% 38.65% 
IL-1α 29.90% 41.34% 105.38% 
ADAMTS-5 S100A8 83.48% 34.79% 93.76% 
IL-1α 38.76% 76.76% 92.83% 
MMP-1 S100A8 89.45% 7.73% 99.68% 
IL-1α 72.31% 93.32% 99.77% 
MMP-3 S100A8 87.36% 30.43% 97.37% 
IL-1α 77.25% 88.71% 96.14% 
MMP-13 S100A8 96.54% 95.57% 99.61% 
IL-1α 77.36% 99.69% 99.73% 
 
4.3.1.2 NF-κB Pathway 
The NF-κB signalling pathway that has been implicated in OA [86], is downstream of the TLR4 
signalling pathway (a documented binding partner of S100A8/A9) [211] and is therefore a viable 
potential candidate for activation after S100A8 treatment of chondrocyte monolayer cultures. Table 
4.3 shows the results of a literature search for NF-κB studies performed in chondrocytes in vitro. 
BAY-11-7082 synthetic inhibitor was chosen as it is commercially available. In other cell types BAY-
11-7082 has been shown to act through irreversible inhibition of IκB-α phosphorylation resulting in 
the inactivation of NF-κB [306]. In validation studies to determine appropriate inhibitor 
concentrations and using IL-1α as a positive control, no inhibition of control or cytokine-induced 
gene expression was observed with doses ranging from 1-10µM (data not shown). No further 
evaluation of this NF-κB signalling pathway inhibitor with S100 proteins was performed. 
Table 4.3: Summary of NF-κB inhibitors in cartilage in vitro 
Ref Species Stimulant Inhibitor, Company, Doses 
Tested, Pre-incubation time 
Effect on Gene Expression 
[302] Bovine IL-17 
(20ng/ml) 
BAY-11-7085, Calbiochem, 0.5-
2.5µM, 30 mins 
Inhibition of MMP-3, MMP-
13, ADAMTS-4 
[301] Human IL-1β/IL-1α PDTC, 100, 200µM (dissolved in 
H2O 100mM stock), 30 mins 
Partial inhibition of MMP-3 
and MMP-13 
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4.3.1.3 TLR4 Pathway 
S100A8 and S100A9 binding to TLR4 is well documented in immune cells [211], and has been 
reported as the dominant signalling pathway in the context of in vitro chondrocyte experiments and 
experimental murine models [188]. LPS, as a classical activator of TLR4, can activate both MAPK and 
NF-κB and was selected as the “positive control” stimulant to test inhibition of TLR4 binding [247]. 
Table 4.4 shows a summary of the literature found on TLR4 inhibitors used in chondrocytes in vitro. 
CLI-095 acts by blocking the signalling mediated by the intracellular domain of TLR4 [307, 308]. 
Rhodobacter sphaeroides (RS)-LPS is a TLR4 antagonist that reportedly competes with LPS to bind to 
TLR4 and inhibits hexa-acylated endotoxin:MD-2 complex function at TLR4 [309-313]. Both inhibitors 
were used at 1µg/ml, according to data sheets and literature. 
 
Table 4.4: Summary of TLR4 inhibitors in cartilage in vitro 
Ref Pathway Species Stimulant Inhibitor, Company, Doses 
Tested, Pre-incubation 
Time 
Effect on Gene 
Expression 
[314],[315] TLR4  
(MyD88 
dependent 
and 
independent) 
Human LPS 
(1µg/ml) 
TAK242, Pfizer (not 
commercially available), 
0.01, 1µM   
Commercially available 
version: CLI-095, Invivogen 
Inhibition of 
MMP-13, 
ADAMTS-4 
 
GAPDH expression was up-regulated by S100A8 and LPS, but not DMSO or either of the inhibitors 
alone (Figure 4.3). DMSO alone did not significantly regulate any gene, and the addition of DMSO to 
S100A8 or LPS did not significantly differ from that of S100A8 or LPS alone respectively. Inclusion of 
RS-LPS in chondrocyte monolayer cultures resulted in changes in gene expression levels similar to 
those seen for LPS, with both agents significantly down-regulating aggrecan and collagen type II 
gene expression and up-regulating ADAMTS-5, MMP-1, MMP-3 and MMP-13 gene expression. RS-
LPS did partially inhibit LPS-induced up-regulation of MMP-1 and MMP-3. CLI-095 significantly 
inhibited LPS-induced up-regulation of ADAMTS-5 (77%), MMP-1 (95%), MMP-3 (84%) and MMP-13 
(84%), as expected, but the amelioration of LPS-induced inhibition of aggrecan and collagen II 
expression was not significant (14.94% and 20.98% respectively). S100A8-induced up-regulation of 
ADAMTS-5 (90%, 33%), MMP-1 (98%, 42%) and MMP-13 (88%, 35%) was inhibited by both CLI-095 
and RS-LPS respectively, and MMP-3 (88%) by CLI-095 only. In all cases, inhibition by CLI-095 was 
more pronounced than by RS-LPS.  
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Figure 4.3: Gene expression analysis from ovine chondrocyte monolayer cultures treated with S100A8 at 
0.01µM or LPS at 1µg/ml ± 0.1% DMSO, CLI-095 at 1µg/ml or RS-LPS at 1µg/ml for 24 hours, *=p<0.05 
compared to control values, ^=p<0.05 compared to appropriate 0.1% DMSO-treated group. 
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4.3.2 Optimisation of an In Vitro Articular Cartilage Explant Culture System 
using Inhibitors 
The preceding data in chondrocyte monolayer culture demonstrated that S100A8 signals at least in 
part through binding to TLR4 and activating a number of MAPK pathways. Articular cartilage explant 
cultures provide a more physiologically-relevant in vitro system in which to study potential signalling 
mechanism in cartilage than the monolayer cartilage cultures, however they also add complexity, as 
the presence of the ECM makes diffusion of molecules to the cells more difficult. The inhibitors 
chosen in this set of experiments were all small synthetic molecules, in order to ease the diffusion of 
these molecules through the dense ECM to the cells. To the author’s knowledge this is the first study 
in which inhibitors were utilised in a cartilage explant system. Only those inhibitors that were able to 
be optimised in chondrocyte monolayer cultures, and which showed significant inhibition of S100A8 
or S100A9-induced gene regulation were used for this study. Due to a shortage of S100 protein, 
those inhibitors which could not be optimised in cartilage explants using IL-1α (as a positive control) 
were not tested with S100 in explants. Similarly, due to this shortage of S100 protein, this study 
focused on MAPK inhibitors, as these have not previously been studied in chondrocytes with S100A8 
and S100A9.  
 
Previous studies conducted by our group (unpublished data) have shown that cartilage explants 
require a significant increase in the concentration of additives such as cytokines and proteins 
(usually around 10 times), and longer culture periods to allow for better diffusion through the 
cartilage, compared to that of monolayer cultures. This section will summarise the experimental 
results of the optimisation of concentration and pre-incubation time for each inhibitor.  
 
4.3.2.1 DMSO Toxicity 
DMSO was used as the solvent for each inhibitor, and as it was expected that high concentrations of 
inhibitors would be required for explant cultures and several inhibitors required high DMSO 
concentrations for solubility, preliminary experiments were performed to determine the maximum 
DMSO concentration that could be used without detrimental effect to the chondrocytes. Explants 
were treated with IL-1α at 10ng/ml (detailed protocol can be found in Section 2.1.1), with 0%, 2.5%, 
5%, 7.5% or 10% DMSO added, n=3. At the end of the culture period (four days), conditioned media 
was collected, and RNA extracted from explants as per detailed protocol in Section 2.2.1. As 
expected, IL-1α increased the amount of GAG released to media by ≈3 times compared to control 
99 
 
levels; addition of 2.5% DMSO did not alter this while 5% DMSO brought GAG release down to 
control levels, and at higher concentrations (7.5% and 10%) GAG release was well below the control 
levels (Figure 4.4).  
 
Little RNA was able to be extracted from the cells treated with 7.5% or 10% DMSO, further 
confirming the results seen in GAG release and suggesting that high concentrations of DMSO could 
be killing the cells. RNA from these high percentage DMSO treatment groups was therefore not 
reverse transcribed. All DMSO-treated groups up-regulated GAPDH expression (Figure 4.4). 
ADAMTS-5 and MMP-1 were up-regulated by IL-1α as expected, and the addition of 2.5% DMSO did 
not alter the gene expression profile. Addition of 5% DMSO to IL-1α-treated cultures resulted in 
down-regulation in the expression of ADAMTS-5 (≈4 times) and MMP-1 (≈190 times) compared to IL-
1α alone.  Based on this data it was considered that DMSO doses >2.5% had a detrimental effect on 
chondrocytes in explant culture, and concentrations of <2.5% were therefore used throughout the 
studies carried out in this chapter. 
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Figure 4.4: Gene expression analysis from ovine articular cartilage explants treated with IL-1α at 10ng/ml for 
four days (except for control), with addition of 1%, 2.5%, 5%, 7.5% or 10% DMSO (mean ± SEM, n=3 per 
treatment group); and Release of sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± 
SEM, n=3 per treatment group) from ovine articular cartilage explants treated with IL-1α at 10ng/ml for four 
days (except for control), with addition of 1%, 2.5%, 5%, 7.5% or 10% DMSO. 
 
4.3.2.2 MAPK Inhibitor Optimisation in Explant Culture Systems 
Based on chondrocyte monolayer data obtained in Section 4.3.1.1, MAPK inhibitors PD98059, 
SB203580 and U0126 were tested in the cartilage explant system stimulated with 10ng/ml IL-1 to 
determine the optimal conditions. All literature (see above tables) and the preceding monolayer 
culture experiments used pre-incubation times of 30 minutes, however, since cartilage explants have 
an ECM that the inhibitors need to diffuse through, different pre-incubation times of zero, two, four, 
24 and 48 hours were tested using various concentrations, starting with the same inhibitor 
concentrations as used in monolayer cultures, and increasing concentrations. The outcome measure 
was inhibition of IL-1α-induced GAG release, with gene expression of MMP-1 and MMP-3 measured 
to confirm inhibitory effects, as these genes are highly regulated by IL-1α. Neither PD98059 nor 
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SB203580 were able to reduce GAG release at the monolayer concentrations (PD98059 30µM, 
SB203580 100µM) at any of the pre-incubation time points (Figure 4.5). PD98059 only partially 
inhibited IL-1α-induced GAG release at a concentration of 100µM and a pre-incubation time of 24 
hours. SB203580 could inhibit IL-1α-induced gene expression after four hours of pre-incubation at 
very high concentrations (500µM, 1mM), and showed full inhibition after 24 or 48 hours pre-
incubation at concentrations of 300µM, 500µM and 1mM. U0126 was similarly tested at 
concentrations of 50µM and 100µM with a 24 hour pre-incubation time, as this was deemed to be 
the most appropriate based on PD98059 and SB203580 results. GAG release was inhibited by both 
concentrations, with 100µM causing a return to control levels. The concentration was reduced to 
20µM for the gene expression studies, as it was thought this would be sufficient based on the GAG 
release results.  All inhibitors were confirmed using a secondary outcome measure of inhibition of IL-
1α-induced gene expression changes in MMP-1 and MMP-3, and all three inhibitors were deemed to 
sufficiently inhibit these genes (Table 4.5). 
 
Table 4.5: Summary of qRT-PCR results of ovine articular cartilage explants treated with IL-1α at 10ng/ml for 
four days, pre-incubated for 24 hours in PD98059, SB203580 or U0126 at the indicated concentrations (n=3 
per treatment group). Results are expressed as fold change compared to IL-1α-treated cultures. 
Gene Inhibitor Concentration Mean SEM Percentage Change 
MMP-1 PD98059 100µM 0.29 0.26 70.56% 
 SB203580 200µM 0.34 0.15 65.81% 
  300µM 0.022 0.0047 97.85% 
 U0126 20µM 0.0049 0.0013 99.51% 
  50µM 0.00086 N/A (n=1) 99.91% 
  100µM 0.00085 N/A (n=1) 99.92% 
MMP-3 PD98059 100µM 0.23 0.16 77.20% 
 SB203580 200µM 0.035 0.019 96.51% 
  300µM 0.015 0.0035 98.51% 
 U0126 20µM 0.011 0.0027 98.94% 
  50µM 0.016 N/A (n=1) 98.36% 
  100µM 0.0021 N/A (n=1) 99.79% 
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Figure 4.5: Release of sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± SEM, n=3 per 
treatment group) from ovine articular cartilage explants treated with IL-1α at 10ng/ml for four days (except for 
control), with addition of PD98059, SB203580 or U0126 at the concentrations and pre-incubation times as 
indicated (explants were pre-incubated with U0126 for 24 hours at all concentrations tested).  
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4.3.3 Signalling Pathways Activated by S100A8 in Articular Cartilage 
Explant Cultures 
In Section 4.3.1.1, we determined that S100A8-induced up-regulation of catabolic genes (MMP-1, 
MMP-13 and ADAMTS-5) could be inhibited in chondrocyte monolayer cultures by adding MAPK 
inhibitors PD98059, SB203580 or U0126, which block MEK, p38 and MEK1/2 respectively. These 
three MAPK inhibitors (PD98059, SB203580 and U0126) were tested in cartilage explant culture 
systems to determine if any of them could block S100-induced gene expression changes in this more 
physiologically-relevant system. Based on the optimisation experiments outlined in Section 4.3.2, 
inhibitors were added for 24 hours to the culture media prior to the addition of S100 or IL-1α for 
four days, and inhibitors were used at the following concentrations: PD98059 100µM, SB203580 
300µM and U0126 20µM. Compared to results from monolayer cultures, gene expression levels in 
explant cultures were more variable, limiting the power to detect statistically significant effects of 
the inhibitors. In the following sections therefore, inhibitor effects that failed to reach statistical 
significance but were of a magnitude >50% and consistent with those observed in monolayer are 
also highlighted. 
 
No significant changes were observed in the gene expression levels when the MEK inhibitor PD98059 
or 0.13% DMSO alone were added by themselves to cartilage explant cultures (Figure 4.6). IL-1α 
significantly down-regulated aggrecan and collagen II gene expression and up-regulated ADAMTS-5, 
MMP-1, MMP-3 and MMP-13. Significant inhibition of IL-1-induced MMP-1 and MMP-3 expression, 
and >50% inhibition of MMP-13 was achieved by PD98059. S100A8 and S100A9 down-regulated 
aggrecan and up-regulated MMP-3, with S100A8 also up-regulating ADAMTS-5 and MMP-1. The 
addition of PD98059 failed to significantly inhibit any of the S100A8 or S100A9 induced gene 
changes.   
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Figure 4.6: Gene expression analysis from cartilage explant cultures treated with S100A8, S100A9 at 0.1µM or 
IL-1α at 10ng/ml ± 0.13% DMSO, or PD98059 at 100µM for four days, *=p<0.05 compared to control values, 
^=p<0.05 compared to appropriate 0.13% DMSO group. 
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The p38 inhibitor SB203580 was used at a concentration of 300µM so the DMSO content was much 
higher (at 2%) than that of the PD98059 experiment. This higher level of DMSO when added alone 
significantly up-regulated GAPDH, MMP-1, MMP-3 and MMP-13 compared to a non-treated controls 
(Figure 4.7). Treating the cartilage explants with 300µM SB203580 alone led to a significant down-
regulation of GAPDH, aggrecan and collagen type II, and up-regulation of ADAMTS-5, MMP-1, MMP-
3 and MMP-13. There was significant inhibition of IL-1α-induced ADAMTS-5 and MMP-13, and whilst 
failing to reach statistical significance, MMP-3 was decreased compared to IL-1α-treated levels by 
84%. While these results suggested a role for p38 in IL-1-induced gene expression changes, the 
unexpected magnitude of expression change with 300µM SB203580 alone confounded the 
interpretation of the effects of the inhibitor on S100A8 and S100A9 induced expression changes. 
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Figure 4.7: Gene expression analysis of cartilage explant cultures treated with S100A8, S100A9 at 0.1µM or IL-
1α at 10ng/ml ± 2% DMSO, or SB203580 at 300µM for four days, *=p<0.05 compared to control values, 
^=p<0.05 compared to appropriate 2% DMSO group. 
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The solubility of U0126 allowed for DMSO to be kept at 0.3%, at which level it did not significantly 
alter gene expression of any of the genes tested. U0126 alone significantly down-regulated aggrecan 
and collagen II, suggesting a role for MEK1/2 in cartilage homeostasis (Figure 4.8). IL-1α significantly 
down-regulated aggrecan and collagen II and up-regulated ADAMTS-5, MMP-1 and MMP-3. IL-1α-
induced up-regulation of ADAMTS-5, MMP-1 and MMP-3, and whilst not being statistically 
significantly inhibited by U0216, showed marked decreases of 68.4%, 98.9% and 88.1% respectively 
when U0126 was added, consistent with the effects seen in monolayer culture. S100A9 significantly 
up-regulated ADAMTS-5, MMP-1 and MMP-3, with ADAMTS-5 and MMP-1 being significantly 
inhibited by addition of U0126, and MMP-3 expression reduced by 76.3%. In these cultures S100A8-
induced up-regulation of ADAMTS-5, MMP-1 or MMP-3 were not significant, however addition of 
the inhibitor decreased these by 54.9%, 83.4% and 85.9% respectively. 
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Figure 4.8: Gene expression analysis of cartilage explant cultures treated with S100A8, S100A9 at 0.1µM or IL-
1α at 10ng/ml ± 0.3% DMSO, or U0126 at 20µM for four days, *=p<0.05 compared to control values, #p<0.05 
compared to appropriate 0.3% DMSO group. 
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4.4 Discussion 
Only one other study has attempted to elucidate the signalling pathways activated by S100A8 or 
S100A9 in chondrocytes. In this study by Schelbergen [188], blocking TLR4 with CLI-095 in human 
osteoarthritic chondrocytes in monolayer culture led to the inhibition of S100A9-induced collagen II 
down-regulation and MMP-3 up-regulation, and to a lesser extent, MMP-1 and MMP-13 up-
regulation. In contrast, the addition of specific antibodies for RAGE and carboxylated n-glycans did 
not attenuate these gene expression changes. Our results agree with that of Schelbergen et al., with 
the exception of the attenuation of collagen II down-regulation; however, this could be due to 
differences in the extent of change in collagen II gene expression, diseased versus healthy cells, or 
species-dependant signalling. The aim of this study was to determine how S100A8 and S100A9 were 
causing changes in gene expression in chondrocytes and cartilage explant cultures by examining 
various signalling pathways (MAPK pathways p38 and MEK1/2 (ERK), NF-κB and TLR4 pathways) 
implicated in cartilage degradation. MAPK signalling pathways are activated by IL-1 and have been 
implicated in osteoarthritis [66, 158]. Small molecule synthetic inhibitors for MEK, p38 MAPK, 
MEK1/2 (ERK) MAPK, NF-κB and TLR4 were added to culture media in either chondrocyte monolayer 
cultures or cartilage explant cultures prior to treatment with S100A8 or S100A9. The two most 
documented binding partners for S100A8 and S100A9 are RAGE and TLR4. No synthetic inhibitor 
exists for RAGE inhibition, rather neutralising monoclonal antibodies are used, and as such agents 
are unlikely to diffuse through the cartilage ECM in explant cultures, they were not investigated in 
the present studies.   
 
The results obtained from chondrocyte monolayer cultures suggested that S100A8 binds to TLR4, 
activating the TLR4 signalling pathway, and the addition of either a specific synthetic inhibitor, CLI-
095, or to a lesser extent a TLR4 antagonist (RS-LPS) diminished the up-regulation of key cartilage 
degrading metalloproteinases ADAMTS-5, MMP-1, MMP-3 and MMP-13 seen as a result of S100A8 
treatment. The percentage change in inhibition seen in this experiment by S100A8 with addition of 
CLI-095 was greater than the percentage change in LPS-treated cultures, which strongly suggests 
that TLR4 is the major binding partner for S100A8 in chondrocyte cultures. This may not, however, 
be the only signalling pathway activated, as reduction in S100-induced enzyme expression was also 
seen with addition of PD98059, the general MEK inhibitor, SB203580, the p38 pathway inhibitor and 
U0126, the MEK1/2 inhibitor. The effect of the MAPK inhibitors on S100A8-treated chondrocytes 
differed slightly from IL-1α-treated chondrocytes. PD98059 and U0126 showed greater inhibition in 
S100A8-treated cultures than in IL-1α-treated cultures (in terms of percentage inhibition), whereas 
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SB203580 had a greater effect in IL-1α-treated cultures. This could suggest that the p38 signalling 
pathway is not as important in S100A8-induced signalling as the ERK pathway (downstream of 
MEK1/2). In both IL-1α-treated and S100A8-treated cultures, the MEK1/2 inhibitor showed the 
greatest inhibition of the three inhibitors, and may therefore be the most appropriate pathway to 
consider as a treatment for OA, as it would potentially block the effects of IL-1α and S100A8. It 
would be important to further investigate activation downstream of MEK1/2, and to find signalling 
molecules along this pathway not involved in normal chondrocyte metabolism.  
 
Interestingly, not all genes were affected by all inhibitors: SB203580 did not affect MMP-1 
expression, RS-LPS did not affect MMP-3 expression, and PD98059, CLI-095 and RS-LPS all had no 
effect on aggrecan or collagen II expression. The lack of inhibition of the S100A8-induced down-
regulation of aggrecan and collagen II could suggest that these genes are not regulated via TLR4, but 
through some other mechanism. It is possible that anabolism (aggrecan and collagen biosynthesis) 
and catabolism are regulated via different mechanisms under the same stimulus, which could 
explain the differing inhibition between MMPs/ADAMTS and aggrecan/collagen type II. 
 
Chondrocyte monolayer cultures provide a reasonably simple system in which to study signalling 
pathways, due to the homogenous nature of the cells in these culture conditions. The limitation of 
monolayer cultures, on the other hand, is that they do not mimic the environment in which 
chondrocytes are usually in. Cartilage explant cultures provide a more physiologically relevant in 
vitro model, as they retain the extracellular matrix. Studies in Chapter 3 demonstrated that S100A8 
and S100A9 exert similar effects on cartilage explants as they do in monolayer cultures, so the 
explant system was utilised to study signalling pathways. Despite numerous optimisation 
experiments in order to move from chondrocytes to explants, determining the signalling pathways 
activated by S100A8 in cartilage explants proved to be difficult. In part this was because of the 
inherently greater variability in gene expression in chondrocytes in explants compared with a 
uniform monolayer, likely reflecting differences due to joint location [316] and cartilage depth [26]. 
The diffusion of the inhibitors through the matrix in the explant culture may also not be 
homogenous, and matrix components may interfere in the action of these inhibitors. S100 and IL-1α 
concentrations required to elicit effects in explants are higher than for isolated chondrocytes again, 
potentially limiting inhibitor efficacy. Additionally, the concentration of inhibitors and DMSO 
required for explants also had some undesirable effects that interfered with interpretation of 
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results. In order to inhibit IL-1-induced GAG release and MMP expression in explants, SB203580 was 
used at very high concentrations, which may change its action by inhibiting different or multiple 
pathways. Börsch-Haubald et al. [317] found that SB203580 can directly inhibit arachidonic acid 
metabolism through the cyclooxygenase pathway, and suggest that caution must be used when 
interpreting data from SB203580 studies. DMSO is known to be toxic at high concentrations, but 
studies are finding that much lower concentrations of DMSO than previously thought can be 
cytotoxic to some cells, and are capable of significantly affecting gene expression at 0.75% and in 
some cases as low as 0.1%  [318]. In a range of inflammatory cell types, levels of DMSO at 1% (v/v) or 
greater decreased the amount of reactive oxygen species and IL-6 production, with some cells 
showing differential regulation of IL-6 at 0.25% and 0.5% [319].  
 
Despite the above limitations, two of the inhibitors, PD98059 and U0126, gave fairly reproducible 
results in cartilage explants with the expected inhibition of IL-1- induced gene expression changes 
reflecting those seen in monolayers. However, PD98059 did not show similar inhibition of expression 
changes induced by S100A8 as seen in monolayers, nor S100A9. In contrast, U0126 showed marked 
inhibition of metalloproteinase expression stimulated by both S100A8 and S100A9 in explants.  This 
is consistent with this inhibitor being the most effective in monolayers (for S100A8), and may 
suggest that the MEK/ERK pathway is of particular importance in both S100A8 and S100A9 signalling 
in chondrocytes.  
 
Overall the results outlined in this chapter (summarised in Figure 4.9), confirm that at least in part 
the effect of S100A8 on chondrocytes occurs though binding to TLR4, which leads to the up-
regulation of catabolic genes encoding MMPs and ADAMTS. This binding (S100A8-TLR4) was found 
to lead to the activation of MAPK pathways p38 and ERK, both of which have also been shown to be 
activated downstream of LPS stimulation via TLR4 [320]. However, down-regulation of ECM 
component genes by S100A8 may be caused by signalling through MAPK pathways without binding 
to TLR4, as inhibition of TLR4 did not attenuate these gene expression changes. This may suggest 
binding through more than one chondrocyte cell surface receptor. More work needs to be done to 
optimise the use of synthetic inhibitors in cartilage explant culture systems to confirm that effects 
seen in monolayer are reflective of those when chondrocytes are embedded in their dense ECM, and 
thus more closely mimicking the in vivo situation. Future studies could address the issues raised by 
using DMSO by finding an alternate solvent for the inhibitors to reduce the toxic effects seen in this 
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chapter. Studies could also be performed to better understand the kinetics of the diffusion of the 
inhibitors through the matrix (which may be altered by using a different solvent) in order to 
decrease variability and increase repeatability. 
 
 
Figure 4.9: Summary of results presented in this chapter – S100A8 and S100A9 homodimers bind to TLR4 and 
activate this signalling pathway, as well as MAPK pathways. Blocking these pathways with synthetic inhibitors 
leads to attenuation of S100A8- and S100A9-induced gene regulation of catabolic enzymes. 
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Chapter 5 Searching for a Second Messenger 
5.1 Introduction 
Work performed in Chapter 3 investigated the effect of S100A8 and S100A9 proteins on in vitro 
cartilage degradation. While addition of both proteins resulted in a shift to a catabolic gene 
expression profile they did not modulate protein levels or activation, which is a critical step in the 
cleavage of ECM components, and as a result did not lead to cartilage degradation. These findings 
suggest that S100A8 and S100A9 are “priming” the cartilage towards a degradative state (see Figure 
3.18 for a graphical summary of Chapter 3 findings). We hypothesised that a second signal or 
messenger may be required for the cartilage degradative state to be realised. An example of a 
system that requires two distinct signals is the inflammasome; an integral part of the innate immune 
system [321]. In this system, production of pro-IL-1β is initiated by pro-inflammatory stimuli via 
receptors such as IL-1R and TLR4 (priming the system), however, cleavage and subsequent activation 
of IL-1β requires a second message. Certain danger signals such as pathogen associated molecular 
patterns (PAMPs) and damage associated molecular patterns (DAMPs) are recognised by pattern-
recognition receptors (PRRs) and initiate the formation of the inflammasome, which leads to the 
activation of caspase-1, which in turn cleaves pro-IL-1β, leading to its activation.  
 
Notable connections exist between the work presented in this thesis and the inflammasome system. 
S100A8 and S100A9 have been described as DAMPs in the context of their role in the immune 
system [211, 212] with TLR4 as a major signalling molecule. Despite these connections, it is unlikely 
that the inflammasome system is associated with the role played by S100A8 and S100A9 in cartilage 
(since there is no evidence of the inflammasome in cartilage), despite the close resemblance with 
our findings where S100A8 and S100A9 induced their effects on gene expression levels with no 
activation of protein production as a “priming” step. It does, however, give credence to the 
hypothesis of a second signal or messenger being required to further activate the system. 
 
The synovium is a structure in the joint that is known to produce local factors such as cytokines and 
release them into the synovial fluid, therefore making them accessible to the cartilage. Could there 
be a specific cytokine or range of cytokines that act in coordination with S100 to cause cartilage 
degradation? And what effect would S100A8 and/or S100A9 have on cartilage that has already 
undergone osteoarthritic changes? Do factors that have already been released by the diseased 
tissue in the joint or the increased baseline levels of enzymes  modulate the effect of S100A8 and/or 
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S100A9 on the cartilage, and possibly contribute to the transition from being “primers” of cartilage 
degradation to key players in a multi-stage path to cartilage degradation? 
 
Work presented in this chapter will investigate whether S100A8 and/or S100A9 exert their effect by 
synergistically and/or additively working with a second signal to induce production and activation of 
enzymes, and therefore degradation of the cartilage ECM. 
 
The specific aim of this chapter was to: 
 Search for a “second messenger” that works in a synergistic and/or additive way with 
S100A8 and/or S100A9 to induce cartilage degradation via activation of catabolic enzymes 
and loss of ECM components aggrecan and collagen II. This was done by examining gene 
expression of catabolic genes, enzyme activation and physical/biochemical cartilage 
degradation in the form of GAG and collagen release from cartilage explants in the following 
culture conditions: 
1. Co-treatment of healthy ovine cartilage explants with S100A8, S100A9 or S100A8/A9 
± IL-1α 
2. Co-culture system of healthy ovine cartilage explants and synovium explants treated 
with S100A8, S100A9  or S100A8/A9 
3. Human osteoarthritic cartilage explants treated with S100A8, S100A9 or S100A8/A9 
 
5.2 Materials and Methods 
Materials and methods used in the chapter are outlined in Chapter 2.  
Primer sets used for real-time qRT-PCR are shown in Table 2.1 (ovine) and Table 2.2 (human).  
Variations from the general methods were: 
 Co-treatment of cartilage explants with S100 and IL-1α 
 Co-culturing of cartilage with synovium  
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Additional methods used in this chapter were as follows: 
5.2.1 Co-treatment of Cartilage with IL-1α and S100 
Cartilage explants were dissected and cultured as described in Section 2.1.1. IL-1α was added to 
standard culture media with S100A8, S100A9 or S100A8/A9 in one of three ways:  
 IL-1α and S100 (S100A8, S100A9 and S100A8/A9) at maximal concentrations (IL-1α at 
10ng/ml, S100A8, S100A9 and S100A8/A9 at 0.1µM) added simultaneously for four days 
(gene expression), or one, two, four, seven or 14 days for aggrecan and collagen release;  
 IL-1α at low concentrations (0.01ng/ml, 0.1ng/ml or 1ng/ml) added either at the same time 
as S100A8, S100A9 or S100A8/A9, or 48 hours after S100A8, S100A9 or S100A8/A9 
treatment (in both cases, S100A8, S100A9 and S100A8/A9 were kept at 0.1µM). 
All other parameters of cartilage explant culture were kept the same as detailed in Chapter 2. 
 
5.2.2 Co-culturing Cartilage Explants and Synovium 
Co-culturing of cartilage explants with synovium involved dissecting the joint capsule and synovial 
lining (referred to as synovium) from the ovine knee joints prior to dissection of the cartilage 
explants. Synovium was collected in PBS containing 50µg/ml gentamycin, and cut into smaller, 
approximately equally sized pieces of around 100mg wet weight. The synovium was then left to 
stabilise separately from the cartilage explants at 37oC for 48 hours in Dulbecco’s modified Eagle 
medium (DMEM) buffered with 3.7g/L sodium carbonate, containing 10% Fetal Calf Serum (FCS), 
2mM Glutamine and 50µg/ml gentamycin. Cultured synovial tissue was then washed three times for 
at least 10 minutes in serum-free media to remove FCS, then one piece placed in appropriate wells 
with cartilage (dissected and prepared as described in Section 2.1.1), treated and cultured for four 
days as described in Chapter 2 at usual concentrations of 0.1µM (S100A8, S100A9 and S100A8/A9) 
or 10ng/ml (IL-1α). At the end of the culture period, cartilage and synovium were weighed and snap 
frozen separately, and stored at -80oC. 
 
5.3 Results 
5.3.1  Interleukin-1α as a Second Messenger 
The aim of this chapter was to find a molecule that can work in a synergistic manner with S100A8 
and/or S100A9 to enhance the “priming” of the cartilage done by S100A8 and S100A9 by activating 
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MMPs and causing biochemical cartilage degradation. Cytokines such as IL-1 and TNFα are abundant 
in the joint in OA [48]. IL-1α was shown in Chapter 3 to be capable of inducing ADAMTS and MMP 
activation and aggrecan and collagen degradation in cartilage explants, and therefore was chosen as 
a plausible candidate as a “second messenger”. In initial studies IL-1α was applied at the normal 
concentration used in cartilage explant cultures of 10ng/ml. 
 
5.3.1.1 Maximal Concentrations 
Ovine articular cartilage explant cultures were treated with S100A8, S100A9 or S100A8/S100A9 at 
0.1µM ± IL-1α at 10ng/ml for four days at 37oC. The use of maximal concentrations for IL-1α and 
S100A8, S100A9 or S100A8/A9 was based on previous studies in our lab using co-treatment of 
cartilage explants (IL-1α + APC) [322]. The following graphs (Figure 5.1 and 5.2) all show fold changes 
compared to the control (mean ± SEM), with the following number of biological replicates: Control, 
S100A8, S100A9 and S100A8/A9 treatment groups, n=6; IL-1α and IL-1α + S100A8 groups, n=5; IL-1α 
+ S100A9 group, n=4; and IL-1α + S100A8/A9 group, n=2. Fold changes and SEM are tabulated in 
Table 5.1. 
 
GAPDH expression was not regulated by S100, however all groups treated with IL-1α significantly 
down-regulated this housekeeping gene (Figure 5.1). In general, S100A8, S100A9, S100A8/A9 and IL-
1α all behaved as they had previously (see Chapter 3, Section 3.3.4, Figs 3.6 and 3.7), with S100A8 
and S100A9 homodimers causing up-regulation of catabolic genes ADAMTS-5, MMP-1, MMP-3 and 
self-regulating S100A9 (the heterodimer did not regulate any gene), and IL-1α additionally causing 
down-regulation of aggrecan and collagen type II (Figure 5.1 and 5.2). Co-treatment of S100 and IL-
1α had a similar effect to that seen for IL-1α alone in all genes measured, with no significant 
differences between IL-1α-treated groups. Results obtained demonstrated that S100 and IL-1α did 
not inhibit each other’s actions, and neither did they act additively, perhaps due to the maximal 
concentrations used of each.  
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Table 5.1: Summary of qRT-PCR results of ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for four days. 
Results are expressed as fold change compared to non-treated control ± SEM. 
 - IL-1α + IL-1α 
Gene Control S100A8 S100A9 S100A8/A9 Control S100A8 S100A9 S100A8/A9 
GAPDH 1.00 ± 0.10 0.90 ± 0.10 0.97 ± 0.10 0.89 ± 0.12 0.44 ± 0.05 0.42 ± 0.05 0.38 ± 0.08 0.45 ± 0.02 
Aggrecan 1.00 ± 0.06 0.93 ± 0.08 0.99 ± 0.09 1.38 ± 0.20 0.27 ± 0.06 0.20 ± 0.06 0.23 ± 0.09 0.44 ± 0.03 
Collagen II 1.00 ± 0.15 1.13 ± 0.13 1.09 ± 0.09 1.33 ± 0.20 0.05 ± 0.01 0.03 ± 0.01 0.05 ± 0.01 0.08 ± 0.001 
ADAMTS-1 1.00 ± 0.42  0.74 ± 0.19 1.05 ± 0.19 1.67 ± 0.40 0.68 ± 0.17 1.36 ± 0.61 0.71 ± 0.21 0.75 ± 0.28 
ADAMTS-4 1.00 ± 0.17 1.33 ± 0.39 0.75 ± 0.18 1.02 ± 0.22 365.17 ± 
165.62 
549.45 ± 
150.91 
300.66 ± 97.03 235.28 ± 44.33 
ADAMTS-5 1.00 ± 0.18 2.74 ± 1.05 2.17 ± 0.50 1.80 ± 0.58 38.53 ± 12.08 56.37 ± 22.76 27.83 ± 6.23 45.08 ± 26.25 
MMP-1 1.00 ± 0.71 35.92 ± 19.24 24.41 ± 21.56  0.78 ± 0.37 6049.69 ± 
4530.25 
5878.70 ± 
4131.94 
1222.54 ± 
546.94 
1038.09 ± 
24.56 
MMP-2 1.00 ± 0.32 1.66 ± 0.37 1.04 ± 0.18 1.73 ± 0.43 1.26 ± 0.22 2.70 ± 0.79 1.27 ± 0.35 1.62 ± 0.29 
MMP-3 1.00 ± 0.27 30.28 ± 8.15 6.42 ± 1.83 1.71 ± 0.66 2247.23 ± 
1263.08 
2299.63 ± 
1209.43 
1044.28 ± 
429.39 
921.82 ± 17.13 
MMP-9 1.00 ± 0.70 2.05 ± 0.91 0.37 ± 0.06 0.58 ± 0.16 8.27 ± 3.71 5.46 ± 3.20 9.60 ± 6.75 4.61 ± 4.28 
MMP-13 1.00 ± 0.48 1.87 ± 0.96 7.33 ± 6.52 12.71 ± 7.21 26.50 ± 17.88 52.65 ± 35.54 118.28 ± 
108.02 
25.63 ± 24.16 
MMP-14 1.00 ± 0.08 1.23 ± 0.09 1.46 ± 0.15 1.51 ± 0.16 1.34 ± 0.16 2.62 ± 0.56 1.23 ± 0.10 1.78 ± 0.12 
S100A9 1.00 ± 0.32 5.78 ± 4.27 2.00 ± 0.55 1.00 ± 0.10 10.16 ± 2.62 18.19 ± 4.02 8.41 ± 1.56 15.31 ± 0.98 
TIMP-1 1.00 ± 0.15 1.06 ± 0.18 1.34 ± 0.18 1.35 ± 0.14 1.51 ± 0.19 1.01 ± 0.21 1.20 ± 0.23 1.43 ± 0.10 
TIMP-2 1.00 ± 0.32 1.11 ± 0.16 1.03 ± 0.16 1.10 ± 0.18 0.39 ± 0.06 0.59 ± 0.16 0.46 ± 0.20 0.71 ± 0.35 
TIMP-3 1.00 ± 0.13 0.97 ± 0.14 1.34 ± 0.17 1.32 ± 0.15 0.77 ± 0.20 0.53 ± 0.15 0.68 ± 0.31  1.57 ± 0.16 
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Figure 5.1: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for four days, *=p<0.05 compared to control values. 
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Figure 5.2: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for four days, *=p<0.05 compared to control values. 
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No aggrecan or collagen release was induced by the treatment of cartilage explants with any of the 
S100 proteins alone compared to the control group, whereas treatment with IL-1α led to a 
significant increase in the release of GAG (at all time points) and collagen (day two and day 14) in all 
treatment groups (IL-1α, IL-1α + S100A8, IL-1α + S100A9 and IL-1α + S100A8/A9, Figure 5.3). Co-
treatment of explants with any S100 and IL-1α did not alter the GAG release compared to IL-1α 
treatment alone. Overall there was similarly little effect of S100s on IL-1α induced collagen release. 
S100A8 did not significantly increase collagen release compared to IL-1α treatment alone at any 
time. S100A9 increased collagen release compared to IL-1α alone at day one and showed a similar 
trend although not significant at days two and four.  
 
Expression and activation of MMP-13 protein showed a similar profile to that of aggrecan and 
collagen release, with very little pro- or active-MMP-13 detected in the untreated or any S100-only-
treated cultures. Treatment of explants with IL-1α resulted in a marked increase in both pro- and 
active-MMP-13, and this was not affected by the co-treatment of any of the S100 proteins (Figure 
5.4). Gelatin zymography assay demonstrated that only faint pro-MMP-2 bands were present at days 
one and two, which intensified from day four onwards, when active-MMP-2 signal became evident 
(Figure 5.5). There were not, however, any visible differences between any treatment groups within 
the same time point, including those groups treated with IL-1α.   
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Figure 5.3: Release of (top) sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± SEM, 
control and S100-treated groups n=6, IL-1α-treated groups n=9), and (bottom) hydroxyproline (media HyPro as 
µg/mg wet weight, control and S100-treated groups n=6, IL-1α-treated groups n=9) from ovine articular 
cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for four days, 
*=p<0.05 compared to control values, #=p<0.05 compared to IL-1α. 
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Figure 5.4: MMP-13 activity in conditioned media from ovine articular cartilage explants cultured with S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for one, two, four, seven or 14 days either without or 
following incubation with the MMP-activator APMA (1mM). Bars represent pooled media samples (pooled 
from control and S100-treated groups n=6, IL-1α-treated groups n=9). 
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Figure 5.5: MMP activity in conditioned media from ovine articular cartilage explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM ± IL-1α at 10ng/ml for one, 
two, four, seven or 14 days. MMP-2 and MMP-9 were detected in conditioned media by gelatin zymography. Migration position of pro- and active-MMP-2 and pro-MMP-9 
are shown on the left hand side, corresponding to around 92kDa (MMP-9) and 66kDa (MMP-2). Each lane represents pooled media from control and S100-treated groups 
n=6, IL-1α-treated groups n=9. STDs are shown in lane one for each gel. 
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5.3.1.2 Low concentration IL-1α 
Experiments performed in Section 5.3.1.1 demonstrated that co-treatment of S100 and IL-1α led to 
increased up-regulation of catabolic genes; increased down-regulation of ECM genes; increased 
expression and activation of MMP-13 protein; and increased aggrecan and collagen loss compared 
to S100 alone. However, limited differences between IL-1α alone and IL-1α plus any of the S100 
proteins were noted. It was therefore difficult to determine if the high concentration of IL-1α was 
solely responsible for these results, or whether there was an additive effect being masked by the use 
of maximal concentrations of both IL-1α and S100 proteins. In this section, a series of experiments 
were designed in which IL-1α was added at a sub-optimal dose, in order to determine if any additive 
effect could be seen with co-treatment with S100. IL-1α was either added simultaneously with S100, 
or 48 hours after S100 treatment. In both cases, explants were cultured for a further four days after 
addition of IL-1α. Two different low concentrations of IL-1α were tested: 0.01ng/ml and 0.1ng/ml. 
Addition of IL-1α at a concentration of 0.01ng/ml had no effect on GAG release, whereas 0.1ng/ml 
induced a significant increase to approximately 5µg GAG per mg cartilage (Figure 5.6 left). Co-
treatment of 0.01ng/ml or 0.1ng/ml IL-1α with S100A8 or S100A9 did not increase GAG release 
compared with IL-1α alone. 
 
In the second experiment, 0.1ng/ml IL-1α was chosen, as results obtained demonstrated that GAG 
release was not induced by 0.01ng/ml compared to control (Figure 5.6 right). S100A8, S100A9 or 
S100A8/A9 was added to cartilage explants for 48 hours, and media was refreshed with either S100 
alone or co-treated with IL-1α. Co-treatment with S100 and IL-1α led to an increase in GAG release 
above levels seen for S100 alone, but either equivalent (S100A8) or lower (S100A9 and S100A8/A9) 
levels of GAG release compared to IL-1α alone, suggesting a possible inhibitory rather than 
stimulatory effect by S100 when added in this order and time frame. Based on results presented in 
this chapter, it is plausible to suggest that the increase in GAG release seen when cartilage was co-
treated with S100 and IL-1α was solely due to the action of IL-1α rather than any additive effects of 
S100 and IL-1α together.  
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Figure 5.6: Release of sulphated glycosaminoglycan (left – media GAG as µg/mg wet weight, mean ± SEM, n=3) 
from ovine articular cartilage explants treated with S100A8 or S100A9 at 0.1µM ± IL-1α at 0.01ng/ml or 
0.1ng/ml for four days, (right – mean ± SEM, n=3) from ovine articular cartilage explants treated with S100A8, 
S100A9 or S100A8/A9 at 0.1µM for 48 hours, then ± IL-1α at 0.1ng/ml for four days. 
 
5.3.2 Synovium Tissue as a Second Messenger 
The synovial joint is a multi-tissue organ involving cross-talk between tissues. Whilst in vitro cartilage 
explants provide a more physiologically relevant model than isolated chondrocyte monolayer 
cultures, they are still just one tissue type. It was hypothesised that the “second messenger” 
required to enhance the function of S100A8 and S100A9 in cartilage by activating ADAMTS and 
MMPs and thereby allowing for biochemical cartilage degradation may be expressed by other joint 
tissues. In this section, synovial tissue was therefore added to cartilage explant cultures in order to 
determine if it can secrete a factor or factors that can work synergistically with S100A8 and/or 
S100A9. 
 
Ovine articular cartilage explant cultures were treated with S100A8, S100A9 or S100A8/S100A9 at 
0.1µM or IL-1α at 10ng/ml for four days with or without a piece of synovial tissue at 37oC. Results 
are presented as fold changes compared to the control (mean ± SEM), and n=6 except for IL-1α 
(cartilage only) n=5 and IL-1α (cartilage + synovium) n=1. No significant changes in gene expression 
were induced by S100A8 alone, and only TIMP-1 was regulated by S100A9 (Figure 5.11), in contrast 
to previous experiments, probably due to differences in batch activity (see Section 3.3.1 for details). 
Interestingly, S100A8/A9 caused significant down-regulation of TIMP-1 and TIMP-2, which had not 
been seen in previous experiments. IL-1α treatment induced the usual regulation of genes, with 
significant up-regulation of ADAMTS-1, ADAMTS-4, ADAMTS-5 (Figure 5.8), MMP-1, MMP-2, MMP-3 
(Figure 5.9), MMP-9, MMP-13 (Figure 5.10), S100A8 and S100A9 (Figure 5.12), and significant down-
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regulation of GAPDH, aggrecan, collagen type II (Figure 5.7), TIMP-1, TIMP-2 and TIMP-3 (Figure 
5.11). Results obtained demonstrated that the addition of synovium alone to the cartilage cultures 
led to regulation of gene expression in a very similar manner as that of IL-1α on cartilage alone, 
except for MMP2, TIMP-1, TIMP-2 and TIMP-3 which were not regulated by synovium.  
 
Only two genes showed a statistically significant effect of S100 addition compared with 
cartilage/synovium co-culture alone, MMP-2 (up-regulated) and TIMP-3 (down-regulated) by S100A9 
(Figure 5.9 and 5.11, respectively). While not statistically significant, this pattern of additive 
regulation by S100A9 compared with synovium alone was seen in a number of other genes. 
Aggrecan and collagen II expression were both significantly down-regulated by the addition of 
synovium, and the addition of S100A9 to co-cultures induced an additional 42% and 59% down-
regulation in aggrecan and collagen II respectively, compared to the non-treated cartilage + 
synovium group. The addition of synovium to cartilage resulted in significant up-regulation of 
ADAMTS-1, ADAMTS-4, ADAMTS-5, MMP-1, MMP-3, MMP-9, MMP-13, MMP-14, S100A8 and 
S100A9, with all except MMP-9, MMP-13 and MMP-14 additionally being significantly different to 
their corresponding cartilage only group. Again although not statistically significant, the addition of 
S100A9 to the synovium and cartilage co-cultures resulted in an increase in ADAMTS-4, MMP-1, 
MMP-3 and S100A9 (by at least 75%) and S100A8 (4 fold), compared to that found for the non-
treated cartilage/synovium co-cultures. ADAMTS-1, MMP-9 and S100A8 also showed additive effects 
when treated with S100A8 and synovium, with these genes increased by at least 75% compared with 
cartilage/synovium co-cultures alone. Taken together these results suggest that factors released 
from synovium act in concert with S100, particularly S100A9, to increase the pro-catabolic 
expression pattern in cartilage over either factor alone.   
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Table 5.2: Summary of qRT-PCR results of ovine articular cartilage explants cultured in the presence or absence of synovial tissue, and treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml for four days. Results are expressed as fold change compared to non-treated control ± SEM, except for IL-1α-treated cartilage 
+ synovium, which is mean only (n=1).  
 Cartilage Cartilage + Synovium 
Gene Control S100A8 S100A9 S100A8/A9 IL-1α Control S100A8 S100A9 S100A8/A9 IL-1α 
GAPDH 1.00 ± 0.04 0.69 ± 0.12 0.85 ± 0.08 0.92 ± 0.12 0.27 ± 0.11 0.69 ± 0.19 0.48 ± 0.07 0.45 ± 0.05 0.54 ± 0.09 0.41 
Aggrecan 1.00 ± 0.13 0.98 ± 0.18 1.30 ± 0.09 1.24 ± 0.12 0.06 ± 0.02 0.35 ± 0.07 0.32 ± 0.02 0.21 ± 0.05 0.37 ± 0.04 0.14 
Collagen II 1.00 ± 0.28 0.49 ± 0.08 0.65 ± 0.17 1.13 ± 0.18 0.01 ± 
0.005 
0.07 ± 0.02 0.05 ± 
0.007 
0.03 ± 
0.006 
0.05 ± 
0.008 
0.05 
ADAMTS-1 1.00 ± 0.23 0.65 ± 0.19 0.70 ± 0.12 0.55 ± 0.14 3.12 ± 3.53 3.27 ± 0.39 5.74 ± 2.71 3.45 ± 1.24 4.11 ± 1.29 1.13 
ADAMTS-4 1.00 ± 0.25 1.38 ± 0.40 0.96 ± 0.22 0.76 ± 0.36 303.56 ± 
137.96 
25.52 ± 
8.77 
22.53 ± 
7.06 
45.68 ± 
23.84 
9.12 ± 2.45 393.02 
ADAMTS-5 1.00 ± 0.43 0.97 ± 0.18 0.97 ± 0.19 0.86 ± 0.09 15.99 ± 
17.34 
10.79 ± 
2.75 
15.16 ± 
7.90 
12.86 ± 
4.09 
8.52 ± 2.19  8.00 
MMP-1 1.00 ± 0.55 2.75 ± 2.29 1.49 ± 0.44 0.31 ± 0.13 1900.97 ± 
2765.04 
51.81 ± 
16.74 
47.75 ± 
18.72 
94.92 ± 
18.29 
35.99 ± 
19.92 
855.06 
MMP-2 1.00 ± 0.08 1.16 ± 0.28 1.62 ± 0.31 1.19 ± 0.22 4.54 ± 3.11  0.93 ± 0.12 0.97 ± 0.26 2.07 ± 0.39 1.27 ± 0.20 1.74 
MMP-3 1.00 ± 0.47 1.79 ± 0.88 1.23 ± 0.36 0.22 ± 0.14 605.36 ± 
647.88 
33.45 ± 
10.02 
45.06 ± 
15.23 
60.45 ± 
31.76 
14.08 ± 
4.28 
228.09 
MMP-9 1.00 ± 0.60 1.48 ± 0.68 0.90 ± 0.38 3.35 ± 2.29 150.06 ± 
297.51 
10.30 ± 
3.72 
18.14 ± 
13.82 
18.68 ± 
7.87 
14.31 ± 
8.38 
48.86 
MMP-13 1.00 ± 0.42 15.56 ± 
15.27 
1.79 ± 0.86 4.75 ± 3.05 124.00 ± 
132.64 
317.95 ± 
271.61 
27.83 ± 
21.88 
47.57 ± 
18.06 
39.98 ± 
28.42 
605.39 
MMP-14 1.00 ± 0.10 0.92 ± 0.13 0.99 ± 0.05 0.94 ± 0.04 1.50 ± 0.56 1.38 ± 0.23 1.47 ± 0.56 1.66 ± 0.24 1.63 ± 0.49 1.07 
S100A8 1.00  0.42 2.47  0.87 0.76  0.46 0.68  0.20 337.91  
327.18 
35.16  
19.67 
76.38  
25.77 
153.92  
57.02 
19.47  
14.450 
286.34 
S100A9 1.00 ± 0.21 1.39 ± 0.37 5.36 ± 4.32 0.66 ± 0.13 11.07 ± 
3.60 
6.80 ± 0.81 8.03 ± 1.30 15.45 ± 
3.62 
4.34 ± 0.78 12.96 
TIMP-1 1.00 ± 0.23 0.63 ± 0.16 0.38 ± 0.05 0.36 ± 0.03 0.35 ± 0.16 1.61 ± 0.23 1.16 ± 0.16 1.21 ± 0.26 0.92 ± 0.13 0.86 
TIMP-2 1.00 ± 0.21 0.89 ± 0.16 0.57 ± 0.09 0.51 ± 0.08 0.16 ± 0.10 0.94 ± 0.13  0.77 ± 0.18 0.56 ± 0.18 0.83 ± 0.24 0.17 
TIMP-3 1.00 ± 0.22 0.79 ± 0.12 0.78 ± 0.08 0.73 ± 0.10 0.14 ± 0.03 0.73 ± 0.09 0.74 ± 0.04 0.38 ± 0.08 0.68 ± 0.11 0.28 
 
128 
 
 
Figure 5.7: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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Figure 5.8: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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Figure 5.9: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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Figure 5.10: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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Figure 5.11: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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Figure 5.12: Gene expression analysis from ovine cartilage explants treated with S100A8, S100A9 or 
S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± synovium for four days, *=p<0.05 compared 
to control values, ^=p<0.05 compared to corresponding cartilage only group, #=p<0.05 compared to non-
treated cartilage and synovium group. 
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As seen earlier in Chapter 3, cartilage treated with S100 showed no change in GAG or collagen 
release into the media compared to the control cartilage, while treatment with IL-1α increased GAG 
release to almost 20µg GAG per mg cartilage, but had no effect on collagen release (Figure 5.13 top). 
Co-culture of cartilage with synovium significantly increased GAG release in both the treated and the 
control cultures. Significant increases in GAG release were found for the co-cultures treated with 
S100A8, S100A9 or S100A8/A9 compared to their corresponding cartilage only culture groups, but 
not compared to non-treated co-cultures; with the exception of S100A9-treated co-cultures, which 
showed a statistically significant additive effect. This was in agreement with gene expression results 
where S100A9-treated co-cultures resulted in additive effects, including the aggrecanase ADAMTS-4, 
which would be one of the key enzymes involved in GAG release. In contrast, only S100A9-treated 
co-cultures showed a significant increase in collagen release compared to non-treated cartilage; 
S100A8, S100A9 and S100A8/A9 co-cultures had significantly higher collagen release than their 
respective cartilage-only counterparts; however there were no additive effects observed between 
synovium and S100/IL-1α.  
 
Levels of pro-MMP-13 protein were unchanged in S100-treated cartilage compared to non-treated 
cartilage, whereas IL-1α-treated cartilage and all co-cultures had increased levels (Figure 5.13 
bottom). In contrast, while all cartilage cultures had low levels of spontaneously active-MMP-13 
(only a marginal increase in IL-1α-treated cartilage), small increases were seen in non-treated and 
S100A8 or S100A8/A9 co-cultures, a larger increase in IL-1α-treated co-culture, and a much larger 
increase in S100A9-treated co-culture. Using gelatin zymography, pro-MMP-2 was detected in 
control cartilage, as well as cartilage treated with S100A8, S100A9, S100A8/A9 or IL-1α (Figure 5.14). 
Addition of synovium to non-treated cartilage increased the levels of pro-MMP-2, led to activation of 
MMP-2, and caused production of pro-MMP-9. Addition of S100A8, S100A8/A9 or IL-1α to 
cartilage/synovium co-cultures did not have any further effect compared to non-treated co-cultures. 
In contrast, while there was no difference observed when S100A9 was added to cartilage alone, 
addition of S100A9 to cartilage/synovium co-cultures led to the additional activation of MMP-9, 
which was not observed in any other treatment group.  
 
Taken together, the results presented in this section demonstrated that S100A9 and synovium 
worked in an additive way to increase catabolic gene expression levels, activation of MMP-9 and 
MMP-13, and GAG release in cartilage explants. This suggests that synovium produces the necessary 
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factor(s) to act as a second messenger to turn “priming” of cartilage by S100A9 into biochemical 
cartilage degradation.   
 
Figure 5.13: Release of sulphated glycosaminoglycan (top left, media GAG as µg/mg wet weight, mean ± SEM, 
n=6) and hydroxyproline (top right, media HYPRO as µg/mg wet weight, mean ± SEM, n=6) from ovine cartilage 
explants treated with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml, and co-cultured ± 
synovium for four days, *=p<0.05 compared to control values, ^=p<0.05 compared to corresponding cartilage 
only group, #=p<0.05 compared to non-treated cartilage and synovium group; MMP-13 activity in conditioned 
media from ovine articular cartilage explants cultured with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-
1α at 10ng/ml and co-cultured ± synovium for four days either without (bottom left) or following incubation 
with the MMP-activator APMA (1mM, bottom right). Bars represent pooled media samples (n=6 per treatment 
group). 
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Figure 5.14: MMP activity in conditioned media from ovine articular cartilage explants treated with S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM or IL-1α at 10ng/ml co-cultured ± synovium for four days. MMP-2 and 
MMP-9 were detected in conditioned media by gelatin zymography. Migration position of pro- and active-
MMP-2 and MMP-9 is shown on the left hand side, corresponding to around 92kDa (MMP-9) and 66kDa 
(MMP-2), STD is shown in lane one. Each lane represents pooled media, n=6 per treatment group. 
 
5.3.3 Second Messengers in Human Osteoarthritic Cartilage 
In healthy ovine cartilage explants, S100A8 and S100A9 were not capable on their own of inducing 
activation of ADAMTS and MMPs or degradation of the ECM. In human OA cartilage, biochemical 
degradation of the cartilage has already begun; cytokines and activated enzymes are present at high 
levels in the joint. We therefore studied human OA cartilage to determine if the presence of already 
activated enzymes and cytokines would enhance the “priming” of cartilage by S100A8 and S100A9 
and therefore lead to further enzyme activity and biochemical degradation. Human osteoarthritic 
cartilage was collected from five patients undergoing unilateral or bilateral total knee arthroplasty, 
and, depending on the yield, cultured in cartilage explant culture systems in S100A8, S100A9 or 
S100A8/A9 at 0.1µM, or IL-1β at 10ng/ml for four days. Due to the limited cartilage yield and limited 
amounts of active protein, only one patient’s cartilage was treated with S100A9. The gene 
expression graphs in Figure 5.15 and 5.16 all show pooled fold change values from all patients (mean 
± SEM): control n=31 in total from all five patients, S100A8 n=30 in total from all five patients, 
S100A9 n=7 from one patient, S100A8/A9 n=22 in total from three patients, and IL-1β n=10 in total 
from two patients (fold changes and SEM are tabulated in Table 5.3). Since all experiments were 
performed separately, and therefore transcribed and quantified separately, baseline expression 
levels cannot be compared, only fold change to the control for each experiment.  
 
The gene expression profile closely matched that of healthy ovine cartilage stimulated with S100; 
however the fold changes obtained were markedly smaller. IL-1β significantly down-regulated 
aggrecan and collagen type II, ADAMTS-4, MMP-2, MMP-14, TIMP-1, TIMP-2 and TIMP-3, and up-
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regulated MMP-3 and MMP-13. S100A8 and S100A9 treatment caused a significant up-regulation of 
ADAMTS-1, ADAMTS-5 and MMP-3, with S100A8 also up-regulating MMP-1, and S100A9 additionally 
self-regulating S100A9 gene expression (Figure 5.15 and 5.16).  
 
Table 5.3: Summary of qRT-PCR results of human articular cartilage explants from OA patients treated with 
S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1β at 10ng/ml for four days. Results are expressed as fold 
change compared to non-treated control ± SEM. ND = not detected. 
Gene S100A8 S100A9 S100A8/A9 IL-1β 
GAPDH 1.04 ± 0.07 0.75 ± 0.18 1.01 ± 0.10 1.02 ± 0.17 
Aggrecan 0.73 ± 0.10 0.87 ± 0.36 0.85 ± 0.19 0.04 ± 0.01 
Collagen II 0.82 ± 0.17 1.36 ± 0.63 0.81 ± 0.21 0.24 ± 0.08 
ADAMTS-1 1.85 ± 0.26 1.97 ± 0.40 0.98 ± 0.13 1.27 ± 0.51 
ADAMTS-4 0.82 ± 0.12 ND 0.61 ± 0.16 0.14 ± 0.07 
ADAMTS-5 1.55 ± 0.17 1.84 ± 0.38 1.19 ± 0.20 0.87 ± 0.21 
MMP-1 1.71 ± 0.21 1.49 ± 0.31 0.82 ± 0.14 1.53 ± 0.57 
MMP-2 0.81 ± 0.16 1.33 ± 0.44 1.13 ± 0.26 0.22 ± 0.10 
MMP-3 4.41 ± 0.91 8.62 ± 1.89 1.21 ± 0.30 14.59 ± 4.69 
MMP-13 1.32 ± 0.22 0.91 ± 0.18 1.08 ± 0.29 4.36 ± 1.55 
MMP-14 0.85 ± 0.10 0.92 ± 0.21 0.96 ± 0.14 0.39 ± 0.08 
S100A9 1.70 ± 0.34 1.94 ± 0.45 1.67 ± 0.49 2.60 ± 0.91 
TIMP-1 0.74 ± 0.08 0.57 ± 0.16 0.85 ± 0.14 0.06 ± 0.01 
TIMP-2 1.04 ± 0.12 0.76 ± 0.16 0.99 ± 0.12  0.21 ± 0.03 
TIMP-3 1.00 ± 0.15 0.81 ± 0.19 1.29 ± 0.20 0.37 ± 0.09 
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Figure 5.15: Gene expression analysis of S100A9 from human osteoarthritic cartilage explants treated with 
S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1β at 10ng/ml for four days, *=p<0.05 compared to control 
values. 
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Figure 5.16: Gene expression analysis of S100A9 from human osteoarthritic cartilage explants treated with 
S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1β at 10ng/ml for four days, *=p<0.05 compared to control 
values. 
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Levels of GAG released to the media from the osteoarthritic cartilage were very low compared to 
that seen in the healthy ovine cartilage, with no significant difference between groups treated with 
S100, and a statistically significant increase induced by IL-1β (Figure 5.17). Levels of collagen 
released were consistent with healthy ovine cartilage, except for S100A9 inducing a significant 
increase and S100A8/A9 inducing a significant decrease compared to control levels. Consistent with 
the gene expression results, IL-1β caused increased levels of pro-MMP-13, although there was no 
increase in spontaneous activation. While not analysed statistically as only a single sample was 
available, both pro- and active-MMP-13 were slightly increased by S100A9. Gelatin zymography 
showed that media from all patients and all treatment groups contained both pro- and active-MMP-
2, however there were no obvious differences between treatment groups (Figure 5.18). Pro-MMP-9 
was detected in S100A8 and IL-1β treated cartilage from patient #4, and from IL-1β treated cartilage 
from patient #5.  
 
Taken together the results obtained suggest that as in ovine cartilage/synovium co-cultures there 
may be factors present in human osteoarthritic cartilage that acted with S100A9 to promote 
cartilage degradation that are not present in normal healthy cartilage. 
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Figure 5.17: Release of (top left) sulphated glycosaminoglycan (media GAG as µg/mg wet weight, mean ± 
SEM); (top right) hydroxyproline (media HyPro as µg/mg wet weight, mean ± SEM), bars represent pooled data 
from all patients (control – five patients, total n=34, S100A8 – five patients, total n=34, S100A9 – one patient, 
total n=8, S100A8/A9 – three patients, total n=22, IL-1β – five patients, total n=34); and (bottom) MMP-13 
activity in conditioned media from human osteoarthritic articular cartilage explants cultured with S100A8, 
S100A9 or S100A8/S100A9 at 0.1µM or IL-1β at 10ng/ml for four days either without (right) or following (left) 
incubation with the MMP-activator APMA (1mM). Data from all patients was pooled, and bars represent 
average values from pooled media samples (control – n=5 patients, representing n=34, S100A8 – n=5 patients, 
representing n=34, S100A9 – n=1 patient, representing n=8, S100A8/A9 – n=3 patients, representing n=22, IL-
1β – n=5 patients, representing n=34), *=p<0.05 compared to control values. 
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Figure 5.18: MMP activity in conditioned media from human osteoarthritic articular cartilage explants treated 
with S100A8, S100A9 or S100A8/S100A9 at 0.1µM or IL-1β at 10ng/ml for four days. MMP-2 and MMP-9 were 
detected in conditioned media by gelatin zymography. Migration position of pro- and active-MMP-2 and MMP-
9 is shown on the left hand side, corresponding to around 92kDa (MMP-9) and 66kDa (MMP-2), STDs are 
shown in lane one. Each lane represents pooled media, patients #1 and #5 n=8, patients #2, #3 and #4 n=6 per 
treatment group. 
 
5.4 Discussion 
The aim of this chapter was to test the hypothesis that a second messenger or additional factors 
exist that would synergistically work with S100A8 and/or S100A9 to complete cartilage degradation 
by promoting activation of key catabolic enzymes leading to the cleavage and loss of aggrecan and 
collagen type II from the ECM. We tested various approaches in order to shed light on this 
hypothesis, the first being to evaluate IL-1 as a co-factor. The ultimate endpoint of increased MMP 
activation, aggrecan and collagen release was achieved with maximal concentrations of both S100 
and IL-1α; however it was unclear whether this was due to synergistic action or dominance of IL-1α. 
Co-treatment of cartilage with sub-optimal concentrations of IL-1α suggested that the increases 
seen were unlikely due to an additive effect of both S100 and IL-1, as S100A8 and S100A9 were 
unable to cause any proteoglycan release regardless of IL-1α treatment. Based on the data obtained, 
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it is unlikely that IL-1α alone acts as a second messenger or co-factor for S100 proteins in cartilage 
explants in vitro. OA involves an array of cytokines, and it is becoming more evident that these differ 
with disease stage and severity [120]. Other cytokines such as TNFα could prove to have a synergistic 
effect with S100A8 and/or S100A9; however it is highly likely, based on the complexity of OA that 
multiple signals need to act in concert as a second messenger in a specific dose- and time-dependant 
manner. Another molecule of interest as an MMP activator is activated protein C (APC). A study by 
Jackson et al. [322] showed that the role of APC in cartilage explant cultures was as an activator of 
MMPs, enhancing the aggrecan and collagen release when combined with IL-1α, but not initiating 
any aggrecan or collagen release on its own. The same group demonstrated that this was not due to 
modulation of MMP gene expression, but rather to the activation of MMP-2, MMP-9 and MMP-13 in 
IL-1/APC co-cultures. Interestingly in a similar scenario to the S100 proteins, APC was unable to 
activate recombinant purified MMPs, and it required an unidentified co-factor secreted from IL-1-
activated cartilage to initiate cartilage degradation.  
 
The second approach taken in this chapter was an attempt to more closely mimic the in vitro 
cartilage explant system by co-culturing with a second joint tissue, synovium. In this experiment, 
non-treated co-cultures of cartilage and synovium caused gene expression changes, increased 
aggrecan release, increased production of pro-MMPs and activation of MMPs. Conflicting data exists 
in literature on GAG release in non-stimulated cartilage/synovium co-cultures, with some studies 
reporting no change in GAG release [323, 324], and others reporting an increase in GAG release due 
to the presence of synovium [325]. Two groups found that the addition of synovial tissue caused a 
decrease in proteoglycan synthesis and an increase in MMP activity compared to cartilage cultures 
[323, 326], as seen in the present data. Conversely a study by Gregg et al. [324] showed a protective 
effect of synovium in co-cultures stimulated with IL-1β on aggrecan loss at the mRNA level, using 
biochemistry (DMMB assay) and histochemistry (Toluidine Blue staining), an effect that was not 
observed in the current study. The discrepancy may be explained by species differences (the above 
studies were performed in bovine [325, 326], human OA [323] or equine [324] cartilage and 
synovium), differences in culture conditions (the use of transwell/insert culture systems [323, 324]) 
or differences in tissue amount or composition (Gregg et al. used synoviocyte monolayer cultures 
[324], Patwari et al. [326] used joint capsule tissue whereas Vankemmelbeke et al. [325] used 
synovial explants and/or joint capsule). It is clear from this experiment that there was an additive 
effect of addition of S100A9 to co-cultures, with statistically significant gene expression changes in 
molecules involved in regulating cartilage degradation, MMP-2 and TIMP-3, compared to non-
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treated co-cultures, as well as enhanced aggrecan release, and MMP-13 and MMP-9 activation. The 
dominance of S100A9 in this co-culture system is in contrast to studies performed in Chapter 3, in 
which S100A8 is the more dominant mediator of catabolic gene expression changes. It is not 
possible based solely on this data to determine whether the synovium was acting directly via 
secreting factors that worked in concert with S100A9 on cartilage, or indirectly in that S100A9 acted 
on the synovium to increase its secretion of catabolic enzymes and their activators. Alternative 
approaches to study this further would be to co-culture cartilage with a different tissue type present 
in the joint, such as subchondral bone, or an immune cell type such as macrophages, or to use 
conditioned media from these cell/tissue types rather than a physical co-culture system. The latter 
approach has been used by Hoff et al. [327], by adding synovial fluid obtained from OA patients onto 
human OA chondrocyte monolayer cultures, and measuring cytokine production. IL-6 and IL-8 were 
both increased in chondrocytes treated with OA synovial fluid compared to non-treated media, and 
cell viability was also decreased. This system could present an alternative to cartilage-synovium co-
cultures. 
 
The third approach in the search for a second messenger was to look at human osteoarthritic 
cartilage, where there would presumably be factors not present in healthy ovine cartilage. Likely this 
cartilage would have higher baseline levels of catabolic enzymes such as MMPs and ADAMTS, as well 
as cytokines and growth factors. Whilst they cannot be directly compared, as the studies in Chapter 
3 were performed separately to those described here, in general, the changes in gene expression 
profile induced by S100A8 and S100A9 in human OA cartilage was similar to that in healthy ovine 
cartilage, but to a lesser magnitude, suggesting that baseline levels of catabolic gene expression 
were indeed higher. This was in contrast to a study by Schelbergen et al. [188], in which they found a 
greater response to S100A9 in chondrocytes obtained from OA patients than in chondrocytes 
obtained from healthy human cartilage from non-OA patients with femoral neck fractures. There are 
a number of reasons why a discrepancy exists between these two studies. Firstly, the studies 
performed in healthy cartilage in this thesis all used ovine cartilage from the knee joint, whereas the 
cartilage in Schelbergen’s study was obtained from the hip joint of human patients. In this particular 
comparison experiment, they used chondrocyte monolayer cultures, compared to the cartilage 
explants used in our culture system. In terms of the aim of this chapter of finding a second 
messenger to act with S100 in a synergistic manner, it is still unclear whether this signal is present in 
isolated human OA cartilage. No increase in aggrecan release, MMP-2 or MMP-9 protein expression 
or activation was seen in the presence of S100A8, S100A9 or the S100A8/A9 heterodimer; however a 
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significant increase was seen in collagen release by S100A9 compared to non-treated control, as well 
as an increase in pro- and active-MMP-13. Due to limited tissue yield, S100A9 was however only 
tested in one patient, so more data would need to be obtained to see if the results obtained were 
patient specific. This data could indicate that S100A9 functions differently either in diseased tissue 
compared to healthy tissue or in human versus ovine tissue (or both); or that S100A9 was working in 
a synergistic manner with one of the factors already present in human OA cartilage.  
 
The aim of this study was to find a second messenger that worked synergistically and/or additively 
with S100 to complete activation of cartilage degradation started by S100A8 and S100A9 in terms of 
shifting the gene expression profile to a catabolic one. Whilst it was determined to be unlikely that 
IL-1α was acting in a synergistic way with S100A8 or S100A9, additive effects were seen when 
synovium was added to S100A9-treated cartilage explant cultures, and when human OA cartilage 
was treated with S100A9 (the results from this chapter are summarised in Figure 5.19). In summary, 
whilst we have not determined a single signal that acts in a synergistic manner with S100A8 and/or 
S100A9, data obtained from co-cultures of cartilage and synovium, and from human OA cartilage 
demonstrated that S100A9 is interacting with one or more second messenger(s) to complete the 
cartilage degradation initiated by S100 in its role as a primer of cartilage degradation.  
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Figure 5.19: Graphical summary of results obtained in this chapter – while addition of S100A8 or S100A9 to 
cartilage explant cultures was not sufficient to cause activation of MMPs and biochemical breakdown of the 
cartilage, the addition of synovium to the culture system, or the use of human osteoarthritic cartilage (rather 
than healthy sheep cartilage) had an additive effect with S100A9 to activate MMPs and cause biochemical 
breakdown of the cartilage.  
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Chapter 6 S100A8 and S100A9 In Vivo 
6.1 Introduction 
Chapters 3, 4 and 5 demonstrated a potential function for S100A8 and S100A9 in in vitro cartilage 
degradation, suggesting that these proteins may play an important role in OA. To date, few studies 
have explored the in vivo role of S100A8 and S100A9 in OA (see Table 6.1 for references), and most 
focus on inflammatory models of arthritis such as collagenase-induced arthritis, which involve a 
significant inflammatory component and may not accurately reflect human OA disease progression. 
While the association of S100A8 and S100A9 in arthritis with a strong inflammatory component is 
well established [279, 281-283, 328], summarised in Table 6.1; their role in less inflammatory forms 
of OA remains unclear. In the surgically-induced DMM model in mice, S100A8 and S100A9 mRNA 
was up-regulated at early time points (one and two weeks post-operative) and decreased at later 
stages (six weeks post-operative), but cellular protein staining was decreased compared to non-
operated and sham controls at weeks two, eight and 16, perhaps suggesting secretion of S100A8 and 
S100A9 from the cells [187]. Studies so far have not, however, determined the expression profile of 
these proteins at earlier or later time points after DMM surgery. Furthermore, studies using S100A9-
/- mice show that they are not protected from cartilage destruction and disease severity in DMM 
[328], whereas they are in inflammatory models (see Table 6.1 for details).  
 
Various animal genotypes are susceptible to spontaneous onset of OA due to age-related changes, 
similar to that of human OA. One example of a spontaneous OA model is the Col11a1+/-, or 
chondrodysplasia (cho) model, in which disorganisation of the collagen network leads to cartilage 
matrix instability and progressive OA starting at three months of age [122]. Specifically, reported 
changes in cho mice with age include increased collagen fibril diameter, increased number of 
chondrocyte clusters in the superficial cartilage layer at three months of age, and loss of 
proteoglycan staining from six months of age in the superficial zone which progresses into the 
deeper zones at nine months of age [122]. The phenotype of cho mice is induced by deletion of one 
nucleotide in the collagen XI gene, resulting in premature termination of the α1 chain of type XI 
collagen [329]. Similar natural mutations of collagen genes are seen in humans, responsible for 
early-onset OA and chondrodysplasia [330-334]. To date no studies have investigated whether 
changes in S100 proteins are associated with the OA resulting from mutations in type XI collagen.  
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Table 6.1: Summary of S100A8 and S100A9 in murine models of inflammatory arthritis. 
OA Model Findings Reference 
Antigen induced arthritis 
(AIA) 
Increased cellular staining of S100A8 and S100A9 
protein in and around chondrocytes 
[187, 279] 
 Decreased bone erosion in S100A9-/- mice, enhanced 
osteoclast formation and activity when S100A8 
injected 
[282] 
 Decreased joint swelling, proteoglycan depletion and 
MMP-mediated cartilage destruction in S100A9-/- mice 
[281] 
Collagenase induced 
arthritis (CIA) 
S100A8 and S100A9 protein expressed in synovium up 
to 21 days. Decreased synovial activation and cartilage 
destruction in S100A9-/- mice 
[328] 
 No protective effect found in S100A9-/- mice [284] 
LPS-CIA S100A8 and S100A9 protein expressed in joint tissues. 
Injection of anti-S100A9 antibody leads to decreased 
disease severity, bone and cartilage destruction 
[283] 
K/BxN (acute inflammatory 
arthritis) 
No protective effect in S100A9-/- mice [284] 
IL-1Ra knockout mice 
(spontaneous 
inflammatory arthritis) 
S100A8 and S100A9 protein expression in and around 
chondrocytes 
[279] 
 
The specific aims of this chapter were to: 
 Characterise the expression of S100A8 and S100A9 in two murine models of OA and in 
human disease: 
o A surgically-induced mouse model (DMM) from very early stage disease (1 day post-
operative) through to late-stage disease (12 weeks post-operative) 
o A spontaneous genetic model of OA (col11a1+/-) at different stages of OA 
development (three months and nine months of age) 
o Human OA joints from total knee arthroplasty (TKA), representing end-stage disease 
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6.2 Materials and Methods 
Materials and methods used in this chapter are outlined in Chapter 2.  
Variations from the general methods were: 
 Immunohistochemistry on sections of joints from spontaneous (genetic) and surgically-
induced OA mouse models and their wild-type/sham counterparts 
 
Additional methods used in this chapter were as follows: 
6.2.1  Immunohistochemistry on Genetic and Surgically-Induced 
Osteoarthritis Mouse Models 
Paraffin embedded sections were de-waxed (2x10 minutes in Xylene) and rehydrated in graded 
ethanol (2x100% for 10 minutes each, 1x95% and 1x70% for five minutes each) before being washed 
in phosphate buffered saline (PBS). Antigen retrieval was performed using 0.1% Trypsin/0.02% EDTA 
solution for 90 minutes at room temperature. Sections were washed in PBS then quenched in 1% 
H2O2/PBS for 15 minutes at room temperature. Sections were then blocked in 1.5% normal goat 
serum (NGS)/PBS for one hour at room temperature, before adding primary antibody or species- and 
concentration-matched IgG control in 1.5% NGS/PBS at 4oC overnight (antibody final concentrations 
all 4µg/ml: anti-mS100A8 0.8mg/ml at 1:200 dilution, anti-mS100A9 1.9mg/ml at 1:500 dilution, 
anti-rabbit IgG 5mg/ml at 1:1250 dilution). Sections were rinsed in PBS, and secondary antibody 
added (Biotinylated Anti-Rabbit IgG (H+L) for 30 minutes at a concentration of 1:200 in 1.5% 
NGS/PBS. Sections were stained for 30 minutes using VectaStain Elite ABC kit according to the 
manufacturer’s instructions, washed in PBS, and peroxidase substrate (NovaRed) added for the same 
amount of time to each slide, until colour appeared. Sections were then rinsed in H2O, 
counterstained with haematoxylin for 20 seconds and dipped in Scott’s Blue before being mounted. 
 
6.3 Results 
6.3.1  Surgically-Induced Osteoarthritis 
To explore the role of S100A8 and S100A9 in different sub-types of OA, a surgically-induced model of 
OA (DMM) was used to represent post-traumatic OA. Specimens used were archival paraffin-
embedded sections that had been processed as per Section 2.4.2 from male C57Bl6 mouse knee 
joints from animals who had undergone no surgery (non-operated controls, NOC), sham surgery or 
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destabilisation of the medial meniscus (DMM, performed as described in [124]) at time points post-
surgery of one, three, seven, 14 days, four or 12 weeks, as well as archival sections of joints from 
mice who had undergone AIA as a positive control (three days post-induction, described in [115, 
335]). Sections were examined for S100A8 and S100A9 staining using immunohistochemistry, as 
described in Section 6.2.1, as well as proteoglycan loss using Toluidine Blue staining, described in 
Section 2.2.1. Loss of proteoglycan was observed as early as three days post-surgery and became 
progressively worse over time, and was accompanied by progressive cartilage erosion four and 12 
weeks post-surgery. AIA sections showed severe loss of proteoglycans throughout the non-calcified 
cartilage. As expected S100A8 and S100A9 were both strongly immunopositive in the bone marrow 
cells of all joints from all surgery groups and all time points (Figures 6.1 to 6.6). S100A8 and S100A9 
stained positive in chondrocytes only one day post-surgery, and were not seen in chondrocytes of 
NOC or sham joints at the same time point (Figure 6.1). No other S100A8 or S100A9 staining was 
observed in chondrocytes at any time point. In contrast, most chondrocytes in the non-calcified 
cartilage of AIA joints stained positively for S100A8 and S100A9. These results suggest that there 
may be early involvement of S100A8 and S100A9 directly following surgery; however this 
involvement is not sustained in the DMM post-surgical model of OA.  
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Figure 6.1: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone either sham or DMM surgery, one day post-surgery. AIA 
joints are included as a positive control. Red arrows indicate areas of positive staining in cartilage, purple 
arrows indicate positive staining in bone marrow. 
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Figure 6.2: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone sham or DMM surgery, three days post-surgery. AIA joints 
are included as a positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows 
indicate positive staining in bone marrow. 
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Figure 6.3: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone sham or DMM surgery, seven days post-surgery. AIA joints 
are included as a positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows 
indicate positive staining in bone marrow. 
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Figure 6.4: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone sham or DMM surgery, 14 days post-surgery. AIA joints are 
included as a positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows indicate 
positive staining in bone marrow. 
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Figure 6.5: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone sham or DMM surgery, four weeks post-surgery. AIA joints 
are included as a positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows 
indicate positive staining in bone marrow. 
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Figure 6.6: Immunohistochemistry staining of S100A8, S100A9 or IgG control and Toluidine Blue staining in 
mouse knee joints from mice that had undergone sham or DMM surgery, 12 weeks post-surgery. AIA joints are 
included as a positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows indicate 
positive staining in bone marrow. 
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6.3.2  Spontaneous Osteoarthritis 
To explore the involvement of S100A8 and S100A9 in spontaneous OA due to genetic factors, 
archival sections of Coll11a1+/- mouse knee joints at three and nine months of age (mixed male and 
female, as gender has been previously found to have no effect on this genetic mutation, Li et al., 
unpublished data) and their wild-type, age-matched counterparts were examined for S100A8 and 
S100A9 using immunohistochemistry as described in Section 6.2.1. Macroscopic cartilage damage 
was not observed in any of the Coll11a1+/- or wild-type joints at either three or nine months of age 
(Figure 6.7), and the OA-like changes described by Xu et al. [122] in the Coll11a1+/- mice (increased 
chondrocyte clustering, loss of proteoglycan) could not be detected using these staining procedures. 
S100A9 protein was not detected in the cartilage of three or nine-month-old mice of either genotype 
although strong positive staining was observed in bone marrow of all mice, as well as cartilage from 
AIA animals (Figure 6.7). In addition to marrow and AIA cartilage samples, S100A8 protein was 
weakly detected in some chondrocytes/pericellular matrix in non-calcified cartilage in one of the 
three WT and Coll11a1+/- mice at three months of age. In contrast S100A8 was localised to 
chondrocytes/pericellular matrix of non-calcified cartilage and meniscal cells in all nine-month-old 
animals, with no difference observed between genotypes (Figure 6.7). All species-matched IgG 
controls were negative for S100A8 and S100A9. These results suggest that whilst chondrocyte 
S100A8 may be associated with ageing in this strain of mouse, it is not involved in the OA-like 
changes observed in Coll11a1+/- mice. 
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Figure 6.7: Immunohistochemistry staining of S100A8, S100A9 or IgG control in mouse knee joints from 
Coll11a1
+/-
 and wild-type littermates at ages three months and nine months. AIA joints are included as a 
positive control. Red arrows indicate areas of positive staining in cartilage; purple arrows indicate positive 
staining in bone marrow. 
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6.3.3  Human Osteoarthritis 
No animal model can accurately and completely capture all aspects of human disease, so archival 
sections of tibial plateaus from 18 human OA knee joints obtained from total knee arthroplasty (with 
patient consent and approval of NSCCAH Human Research Ethics Committee) were processed as 
described in Section 2.4.1 and examined for S100A8 and S100A9 using immunohistochemistry, as 
described in Section 2.4.2. Severe cartilage fibrillation, and in some cases, complete loss of cartilage 
was observed in all joints, with osteophyte formation or pannus invasion being common features. 
S100A8 stained positive in all sections in the bone marrow, bone lining cells (Figure 6.8) and 
chondrocytes (Figure 6.9) whereas S100A9 only stained positive in bone marrow in 12 out of 18 
joints, and in lining cells in two out of 18 joints, with no positive chondrocyte staining observed in 
any joint. Osteophytes were present in nine out of 18 joints, with all of these showing cells positive 
for S100A8, and two out of nine showing sporadic S100A9-positive cells. Cells at the joint margins 
stained positively for S100A8 in 13 out of 18 joints, and for S100A9 in four out of 18 joints. Whilst 
most cells stained positive for S100A8 in these regions, only few discreet cells stained positive for 
S100A9 (Figure 6.10).  
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Figure 6.8: Immunohistochemistry staining of S100A8 and S100A9 with IgG control in bone marrow cells and bone-lining cells from human OA joints. Red arrows indicate 
areas of positive staining. 
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Figure 6.9: Immunohistochemistry staining of S100A8 and S100A9 and Toluidine Blue staining in chondrocytes from human OA joints. Red arrows indicate areas of positive 
staining. 
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Figure 6.10: Immunohistochemistry staining of S100A8 and S100A9 and IgG control, and Toluidine Blue staining in cells at joint margins, in osteophytes and invading 
pannus cells from human OA joints. Red arrows indicate areas of positive staining. 
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6.4 Discussion 
The aim of this study was to further characterise the expression of S100A8 and S100A9 in surgical 
and spontaneous models of OA, as well as in human disease. It was clear from samples taken from 
18 patients undergoing TKA for OA that S100A8 may well play a role in cartilage in OA, as it was 
expressed by almost all chondrocytes in all 18 patients, while no chondrocytes stained positive for 
S100A9. This contrasts with mRNA expression levels of S100A8 and S100A9 demonstrated in human 
OA cartilage explants in Chapter 5, Section 5.3.3, in which S100A8 gene expression was below 
detection levels, whereas S100A9 was expressed by all treatment groups (control, S100A8, S100A9, 
S100A8/A9 and IL-1α), and significantly up-regulated by S100A9. The reason for this discrepancy 
could be that inconsistencies are always possible when comparing mRNA and protein levels (e.g. 
temporal, protein processing, secretion etc.), or due to culturing of the cartilage explants and the 
associated changes in mechanical loading and/or nutrition and growth factor stimulation affecting 
gene expression of S100A8, or could be due to patient variability. No ex-vivo human OA cartilage 
explants were taken in this experiment, however future studies could include un-cultured ex-vivo 
explants that may shed light on the effect of culturing the explants, and could explain the difference 
seen here between protein and mRNA expression.  
 
The localisation of S100A8 in chondrocytes in the OA human samples suggests an 
autocrine/paracrine effect where a similar gene expression profile, as seen in Section 5.3.3, is 
expected with up-regulation of ADAMTS-1, ADAMTS-5, MMP-1 and MMP-13 gene expression by the 
chondrocytes, further aggravating the OA environment. As expected, bone marrow cells stained 
positive for S100A8, and to a lesser extent, S100A9, as these two proteins are well known to be 
expressed by neutrophils, activated monocytes and macrophages [193, 210]. The immunostaining 
pattern seen in the cartilage sections further confirmed the uncoupling of S100A8 and S100A9 (as 
evidenced by the positive staining of S100A8 but negative staining of S100A9 in chondrocytes), 
which seems to be the driving factor behind catabolic gene expression changes seen in Chapter 3. 
Experiments performed in Chapter 3 demonstrated that the heterodimer had no effect on gene 
expression, which could possibly be an important factor in human OA chondrocytes. Interestingly, 
cells at the joint margins and in areas of pannus invasion consistently stained positive for S100A8, 
compared to the few cells that stained positive for S100A9. The invading pannus cells could include a 
population of activated immune cells, which would stain positive for S100A8 and S100A9, or could 
be activated synoviocytes, which have also been reported to produce S100A8 and S100A9 in 
inflammatory murine models of OA [279]. In areas of osteophyte formation, most cells stained 
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positive for S100A8, compared to the few that stained positive for S100A9, suggesting that S100A8 
and S100A9 may play a role in osteogenesis or chondrogenesis; a possibility that will be explored in 
Chapter 7. 
 
Animal models are used as an invaluable tool to assess the role of different factors in OA, particularly 
mice, which are relatively easily genetically manipulated in order to elucidate the specific 
contributions of single or multiple factors. As mentioned in the introduction to this chapter, multiple 
studies have been performed in inflammatory mouse models of OA in relation to S100A8 and 
S100A9 [279, 281-283, 328], with few performed on surgically induced models [187, 328], and none 
in spontaneous models of OA. The results obtained in this chapter suggest that S100A8 and S100A9 
were only involved in very early stage disease (one day post-surgery) in mice that had undergone 
DMM, suggesting that chondrocyte S100A8 and S100A9, in this model, is only associated with 
inflammation immediately after surgery, and not in the progression of disease. These results 
contrast dramatically with previous findings from Zreiqat et al. [187] in which wild-type mice 
expressed S100A8 protein in chondrocytes, which was lost from two weeks after surgery onwards. 
The explanation for this discrepancy could be that different antibodies were used in these two 
studies; different antibodies can have different specificities. However, results in both studies suggest 
that in the post-traumatic mouse DMM model, S100A8 and S100A9 are not involved in the 
progression of disease after the initial stages.  
 
The involvement of S100A8 and S100A9 in a spontaneous (genetic) model of OA was examined using 
the Col11a1+/- mouse. Whilst chondrocytes stained weakly for S100A8 in both the genetically-
modified and wild-type counterparts at nine months of age, there was no difference between the 
two, nor was any positive staining seen in chondrocytes at three months of age. These results 
suggest that, while S100A8 could be involved in the ageing process of this particular strain of mice, it 
is not involved in the gradual progressive disease seen in the Col11a1+/- mice, in agreement with the 
previous finding [187] and with that seen in the results for the DMM model reported in this chapter. 
 
The results obtained in this chapter highlight the need for caution when using animal models to 
study OA pathology. While S100A8 was clearly expressed by chondrocytes in patients with end-stage 
OA, this was not replicated in either the post-surgical model at 12 weeks or the Col11a1+/- mouse at 
nine months of age, both of which represent late-stage disease in the mouse. While these mouse 
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models provide insight into mechanisms of pathology, certainly more accurately than in vitro culture 
systems, there is much discussion about how well they replicate human disease (for a review see 
[336]). As discussed by Little and Zaki in [337], it is important to look at multiple mouse models of 
OA, and that OA is not one disease, rather a range of sub-types of disease that likely have different 
mechanisms of action and therefore require different therapeutics. Bearing this in mind, the results 
in this chapter suggest that, in mice at least, S100A8 and S100A9 are only involved in sub-categories 
or stages of disease that involve inflammation, and do not contribute to non-inflammatory types or 
stages of OA. This may not translate to the case in human disease, as seen in this chapter. Cartilage 
obtained from all patients undergoing TKR in this study showed positive S100A8 staining in 
chondrocytes, directly contrasting with the murine OA models studied. The results obtained in this 
chapter (summarised in Figure 6.11) therefore demonstrate that while S100A8 may not be involved 
in non- or less-inflammatory models of OA in mice, S100A8 plays a role in the cartilage in human OA. 
 
The positive staining of S100A8 at joint margins and in osteophytes (and positive S100A9 in some 
cells in these regions) raises the question of whether S100A8 and/or S100A9 are involved in the 
formation of osteophytes through a role in chondrogenic differentiation. This question will be 
addressed in Chapter 7 by examining the role(s) of S100A8 and S100A9 in mesenchymal stem cells 
during differentiation.  
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Figure 6.11: Summary of results obtained in this chapter. Positive S100A8 staining was seen at early time points after DMM 
surgery in mice, and in human OA cartilage and osteophytes, whereas positive S100A9 staining was not observed. Positive 
staining was not observed in Coll11a1
+/-
 cartilage for S100A8 or S100A9.  
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Chapter 7 S100A8 and S100A9 in Differentiation of Mesenchymal 
Stem Cells 
7.1 Introduction 
In Chapter 6, the expression of S100A8 and S100A9 protein was explored in human OA joints from 
patients undergoing TKA. In these joints, not only did chondrocytes stain positive for S100A8, but 
also, cells in osteophytes and at the joint margins stained abundantly positive for S100A8, and at 
times, S100A9. The presence of osteophytes in the joint us strongly associated with late-stage 
osteoarthritis [64]. They form via endochondral ossification, with the periosteum and synovial lining 
thought to be the source of mesenchymal stem cells for osteophyte development. The process 
involves proliferation of these cells, chondrogenesis and matrix deposition, followed by chondrocyte 
hypertrophy and finally bone deposition and marrow formation [338]. The mature osteophyte is 
integrated with subchondral bone, with a fibrous outer layer and a top covering of cartilage. To the 
author’s knowledge the role of S100A8 and/or S100A9 in osteophyte formation or chondrogenic 
differentiation have only been reported in a recent abstract from OARSI Congress proceedings, 2013, 
which suggests that S100A9 may play a role in the formation of osteophytes in mouse models only 
where synovial activation is present [339]. This study showed that in S100A9-/- mice, osteophyte size 
decreased significantly compared to wild-type mice in a collagenase-induced inflammatory OA 
model. In contrast, in the DMM model, no difference in osteophyte size was reported between wild-
type and S100A9-/- mice, possibly due to the differing pathogenesis of these two subsets of OA.  
 
Since S100A8 and S100A9 are expressed in osteophytes and joint margins of OA patients, and due to 
the decreased size of osteophytes in S100A9-/- mice, we hypothesised that these proteins may be 
contributing to osteophyte development via chondrogenic differentiation of MSCs. The process of 
chondrogenesis (a key step in osteophyte formation) can be recapitulated in vitro with adult MSCs, 
as originally described by Johnstone et al. in 1998 [19]. This has become the standard procedure in 
vitro using a pellet culture system, where cells are in close proximity at a high density, and the 
appropriate chemical culture conditions are utilised to provide the necessary chemical cues for 
chondrogenesis including TGF-β, ascorbic acid and dexamethasone. It is generally accepted that 
successful chondrogenesis has been achieved when MSCs express aggrecan, sox9, and type II 
collagen, without expression of collagen type I [25]. The same OARSI abstract by Schelbergen et al. 
[339] demonstrated that in vitro human fetal MSCs treated with S100A8 had a greater proteoglycan 
content after five days in standard pellet culture than untreated pellet cultures. There is very little 
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literature on the expression of S100A8 and S100A9 in mesenchymal stem cells or during their 
differentiation processes. The aim of this chapter was to investigate whether these two proteins are 
involved in chondrogenic and osteogenic differentiation. 
The specific aims of this chapter were to: 
 Confirm the multipotency of hBMMSCs from OA patients 
 Determine the expression of S100A8 and S100A9 during chondrogenic, osteogenic and 
adipogenic differentiation of hBMMSCs 
 Determine the effect of exogenous S100A8 and S100A9 on chondrogenic differentiation of 
hBMMSCs 
 
7.2 Materials and Methods 
The experiments described in this chapter were performed as part of a Boerhinger Ingleheim Fonds 
Travel Grant for a three-month collaborative project at Saarland University, Germany to undertake 
research training at Prof Henning Madry’s Laboratory. All isolation and culture of MSCs was 
performed during these three months, after which unanalysed samples were shipped back to 
Australia for further analysis.  
Materials and methods used in the chapter are outlined in Chapter 2.  
Primer sets used for real-time RT-PCR are shown in Table 2.3.  
Variations from the general methods were: 
 Pre-treatment of chondrogenic pellets for immunohistochemistry 
 
Additional methods used in this chapter were as follows: 
7.2.1 Pre-treatment of chondrogenic pellets for immunohistochemistry 
Chondrogenic pellets stained for aggrecan and collagen type II were prepared and processed as per 
Section 2.4.2, with the exception of the pre-treatment step. Rather than an enzymatic antigen 
retrieval using Proteinase K, sections were incubated in 1000 units/ml bovine testicular 
hyaluronidase in a phosphate buffer (pH 5.0) at 37oC for one hour (for collagen types I and II) or two 
hours (for aggrecan). All other parameters were as described in Section 2.4.1.  
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7.3 Results 
7.3.1 Multipotency of human BMMSCs from OA patients 
The current standard definition of a mesenchymal stem cell is one that is plastic adherent, has 
specific surface antigen expression, and is able to differentiate into multiple lineages in vitro, namely 
chondrogenic, osteogenic and adipogenic [340]. The cells used in this study were plastic adherent, 
and multipotency into the three lineages mentioned above was achieved. The source of the MSCs 
used in the present study was bone marrow aspirates taken from patients during orthopaedic 
procedures (most commonly TKA). All patients provided informed consent prior to inclusion in the 
study which was approved by the Ethics Committee of the Saarland Physicians Council, and all 
procedures were in accordance with the Helsinky Declaration. Bone marrow was processed and 
stem cells isolated and cultured as per Section 2.1.3.1. Cells from individual patients were cultured 
to confluence and passaged as required (maximum three passages), then cultured at specific cell 
density in defined differentiation media in either pellet (chondrogenic) or monolayer (osteogenic, 
adipogenic) culture for seven, 14 and 21 days as described in Sections 2.1.3.2, 2.1.3.3 and 2.1.3.4 
respectively. mRNA was collected from three replicates at each time point, with chondrogenic mRNA 
pooled for sufficient RNA quantity (osteogenic and adipogenic mean ± SEM, n=3, chondrogenic 
single values only).  
 
7.3.1.1 Chondrogenic Differentiation 
qRT-PCR analysis showed that cells from pellet culture up-regulated chondrogenic marker collagen 
type II and collagen type X (marker of hypertrophy), in a time-dependent manner with no change in 
the expression of the early chondrogenic marker Sox9 at the time points tested (Figure 7.1). Pellets 
from seven, 14 and 21 day cultures were fixed and stained with Toluidine Blue (proteoglycan 
content) as described in Section 2.4.1, or processed for immunohistochemistry to detect aggrecan, 
collagen type I and collagen type II as described in Section 2.4.2, n=3 per time point. Proteoglycan 
content increased over the culture period and by day 21 was detected throughout the structure 
(Figure 7.2). Positive staining for aggrecan and collagen type II was detected at day 21, with a 
progressive increase over time of collagen type I from day seven to day 21 (compared to IgG 
controls), suggesting that matrix deposition was initiated by the cells, and that these MSCs were 
capable of chondrogenic differentiation albeit that the matrix was fibro-cartilaginous rather than 
hyaline.  
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7.3.1.2 Osteogenic Differentiation 
Cells grown in osteogenic media expressed decreasing levels of alkaline phosphatase and collagen 
type I (an early marker of osteogenesis) over the three-week time period (Figure 7.1, n=3 per time 
point). There was no trend in early osteogenic marker runt-related transcription factor (Runx2), 
which showed an increase at day 14 compared to days seven and 21, and osteogenic marker 
osteopontin increased at day 21 compared to days seven and 14. Despite the lack of convincing 
mRNA data, cells were stained with Alizarin Red S for mineral deposition, with ≈50% of the culture 
plate staining positive (Figure 7.3). Taken together, these results suggest that there was induction of 
osteogenesis.  
 
7.3.1.3 Adipogenic Differentiation 
Cells cultured in adipogenic conditions showed a time-dependent increase in adipogenic genes 
lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor γ2 (PPARγ2) from seven to 21 
days of culture (Figure 7.1, n=3). Oil Red O staining also showed positive staining for fat droplets, 
strongly suggesting that adipogenesis had been achieved (Figure 7.3). 
 
Collectively, the results show that bone-marrow MSCs derived from patients undergoing TKA 
retained their multipotency and were capable of tri-lineage differentiation. 
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Figure 7.1: Gene expression analysis of chondrogenic markers (Sox9, collagen type II (Coll II), collagen type X (Coll X)), osteogenic markers (alkaline phosphatase (ALP), 
Runx2, osteopontin (OP), collagen type I (Coll I)), and adipogenic markers (LPL and PPARγ2) from human bone marrow-derived MSCs cultured in chondrogenic, osteogenic 
or adipogenic conditions, respectively. Bars represent mean ± SEM (chondrogenic markers single value from pooled samples only), and show δCt values normalised to 
GAPDH. 
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Figure 7.2: Toluidine Blue (proteoglycan) staining and Immunohistochemistry results (aggrecan, collagen type I 
and collagen type II and concentration- and species-matched IgG controls) from human bone marrow-derived 
MSCs cultured in pellets cultures in chondrogenic media for seven, 14 or 21 days. All samples were processed 
simultaneously, so IgG controls are representative. Red arrows indicate areas of positive staining. 
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Figure 7.3: Alizarin Red S staining (left) shows calcium deposits; and Oil Red O staining (right) shows lipid 
droplets in human bone marrow-derived MSCs cultured in osteogenic or adipogenic media respectively. 
 
7.3.2 Expression of S100A8 and S100A9 during differentiation 
Results of the previous section (7.3.1) provided evidence that the bone marrow-derived MSCs from 
OA patients undergoing TKA were capable of tri-lineage differentiation. Experiments performed in 
the following sections of this chapter set out to investigate whether S100A8 and S100A9 played any 
role in this tri-lineage differentiation of MSCs to chondrogenic, osteogenic or adipogenic lineages. 
qRT-PCR was employed to determine S100A8 and S100A9 gene expression levels from the RNA 
extracts on the cultures from the previous experiment. S100A9 expression was down-regulated in 
chondrogenic, osteogenic and adipogenic cultures to varying degrees (Figure 7.4) at days seven, 14 
and 21 compared to the control (day zero, representing undifferentiated MSCs). In contrast, there 
was little change in the expression of S100A8 in osteogenic and adipogenic cultures at days seven 
and 14 with a ≈4 fold increase at day 21. Chondrogenic cultures, on the other hand, had non-
detectable S100A8 at day seven, but an increase of ≈80 fold at days 14 and 21. These results suggest 
that S100A8 may be involved in chondrogenic differentiation of MSCs. 
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Figure 7.4: Gene expression analysis of S100A8 and S100A9 in human bone marrow-derived MSCs cultured in 
chondrogenic, osteogenic or adipogenic conditions. Bars represent mean ± SEM (chondrogenic markers mean 
only), and show δCt values normalised to GAPDH. 
 
7.3.3 Effect of S100A8, S100A9 and S100A8/A9 on Chondrogenic 
Differentiation 
Chondrogenic differentiation of MSCs is one of the key stages of osteophyte formation in OA, and in 
the previous section 7.3.2, S100A8 mRNA was found to be up-regulated during this process in vitro. 
Therefore for the remaining studies we focused on chondrogenic differentiation. To determine the 
effect of S100A8, S100A9 and S100A8/A9 on chondrogenic differentiation, exogenous S100A8, 
S100A9 or S100A8/A9 was added during chondrogenic differentiation culture. MSCs were obtained 
from bone marrow aspirates from three different patients undergoing TKA, cultured to confluence 
and placed in pellet culture under chondrogenic conditions (outlined in Section 2.1.3.3) ± S100A8, 
S100A9 or S100A8/A9 at 0.01µM for the entire 21-day culture period. Due to limited cell numbers, 
not all treatments were able to be tested on each patient’s cells: MSC#1 were treated with S100A8, 
S100A9 or S100A8/A9; MSC#2 and MSC#3 were treated with S100A8 only as data from 7.3.2 
demonstrated this was the more highly regulated of the two S100s during chondrogenesis. Gene 
expression analysis was performed on MSC#1 and MSC#2 only, due to irreparable damage to MSC#3 
RNA samples during transit from Germany. Similarly, some paraffin embedded blocks were damaged 
in transit, so immunohistochemistry samples were not available for MSC#1 treated with S100A8 or 
S100A9.  
175 
 
qRT-PCR analysis showed that in patient-derived cells MSC#2, addition of S100A8 to pellet cultures 
caused down-regulation of chondrogenic marker collagen type II (fold change =0.17) as well as the 
terminal differentiation markers collagen type X (fold change =0.03) and MMP-13 (fold change 
=0.12), with no change in Sox9 (fold change =0.73) compared to non-treated pellet cultures (Figure 
7.5), whereas S100A9 only marginally affected gene expression (fold changes: Sox9 =0.69, collagen 
type II =0.74, collagen type X =0.58 and MMP-13 =1.4). Similarly, addition of S100A9 to MSC#1 pellet 
cultures caused down-regulation of Sox9 (fold change =0.13), collagen type II (fold change =0.10), 
collagen type X (fold change =0.45) and MMP-13 (fold change =0.18), whereas addition of 
S100A8/A9 had a mixed effect; Sox9 was down-regulated (fold change =0.29); collagen type II (fold 
change =16158) and MMP-13 (fold change =2.75) were up-regulated, and collagen type X was 
unchanged compared to non-treated control pellet cultures.  
 
Immunohistochemistry was used to localise aggrecan, collagen type I, and collagen type II proteins in 
the pellet cultures, and histochemistry was employed to detect proteoglycan content using toluidine 
blue stain. Very little positive staining for proteoglycans, aggrecan, collagen type I or collagen type II 
was detected in pellets from MSC#1, either in control pellets or pellets treated with S100A8/A9, the 
latter of which did not form a smooth outer surface on the pellet (Figure 7.6). Control pellet cultures 
derived from MSC#2, in contrast, had more compact structures with a smooth edge, high 
proteoglycan content, strong positive staining for collagen type I and some positive aggrecan and 
collagen type II staining (Figure 7.7). Addition of S100A8 to the pellet cultures resulted in smaller 
pellets and decreased positive staining for proteoglycans, aggrecan, collagen type I and collagen type 
II compared to control pellets, agreeing with gene expression data. Control pellets from MSC#3, 
despite showing a rounded compact structure and smooth edge, had decreased positive staining for 
proteoglycans, aggrecan, collagen type I and collagen type II compared to pellets derived from 
MSC#2 (Figure 7.8). In contrast to MSC#2, addition of S100A8 led to an increase in the pellet’s size 
with comparable positive staining for proteoglycans, aggrecan, collagen type I and collagen type II to 
control pellets. These results suggest not only that the chondrogenic potential of MSCs differs 
between patients, but also that there is variation in the effect of S100A8, S100A9 and S100A8/A9 on 
chondrogenic differentiation between patients. 
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Figure 7.5: Gene expression of chondrogenic markers (Sox9, collagen type II (Coll II), collagen type X (Coll X) 
and MMP-13) from human bone marrow-derived MSCs cultured in chondrogenic conditions ± 0.01µM S100A8, 
S100A9 or S100A8/A9 for 21 days. MSC#1 and MSC#2 are cells derived from two different patients.  
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Figure 7.6: Toluidine Blue (proteoglycans) and immunohistochemistry results (aggrecan, collagen type I and 
type II, with concentration- and species-matched IgG) from bone marrow-derived MSCs (MSC#1) cultured in 
chondrogenic conditions ± 0.01µM S100A8/A9 for 21 days. Original magnification 10x. All samples were 
processed simultaneously, so IgG controls are representative. 
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Figure 7.7: Toluidine Blue (proteoglycans) and immunohistochemistry results (aggrecan, collagen type I and 
type II, with concentration- and species-matched IgG) from bone marrow-derived MSCs (MSC#2) cultured in 
chondrogenic conditions ± 0.01µM S100A8 for 21 days (triplicate S100A8-treated pellets are shown here). 
Original magnification 10x. All samples were processed simultaneously, so IgG controls are representative. Red 
arrows indicate areas of positive staining. 
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Figure 7.8: Toluidine Blue (proteoglycans) and immunohistochemistry results (aggrecan, collagen type I and 
type II, with concentration- and species-matched IgG) from bone marrow-derived MSCs (MSC#3) cultured in 
chondrogenic conditions ± 0.01µM S100A8 for 21 days (duplicate control and S100A8-treated pellets are 
shown here). Original magnification 10x. All samples were processed simultaneously, so IgG controls are 
representative. Red arrows indicate areas of positive staining. 
 
7.4 Discussion 
Chapter 6 demonstrated the expression of S100A8 and S100A9 in osteophytes and at joint margins 
in human OA joints. Osteophyte formation is a process involving differentiation of MSCs, hence the 
aim of this chapter was to evaluate the role (if any) played by S100A8, S100A9 and S100A8/A9 in 
MSC differentiation. The most widely accepted definition of MSCs is those cells that are plastic 
adherent, have tri-lineage differentiation potential and express certain defined surface markers 
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[340]. The bone marrow-derived cells used in these experiments were plastic adherent and capable 
of tri-lineage differentiation, and while cells used in the present study were not analysed for surface 
markers, cells from previous patients that had been isolated using the same protocol were analysed 
using flow cytometry and found to express appropriate markers [341, 342].  
 
The regenerative potential of most cells is known to decrease with age, including MSCs, where their 
multi-lineage differentiation, homing, immune modulation and wound healing properties have been 
found to decline with age [343]. Other studies have shown that chondrogenic potential in particular 
is diminished with age, whereas osteogenic and adipogenic potential are not affected [344, 345]. 
Cells derived from bone marrow aspirates from OA patients have a similar primary cell yield, but 
decreased proliferation and chondrogenic potential compared to non-OA and cells from older 
individuals [346]. The cells used in this study were obtained from older individuals with end stage OA 
undergoing TKA, and therefore would be expected to have decreased proliferative and chondrogenic 
ability compared to cells obtained from healthy individuals. These age-related changes could explain 
why the pellets formed a predominantly fibrocartilaginous matrix (rich in collagen type I) with 
evidence of hypertrophy (collagen type X) rather than a collagen type II-rich hyaline cartilage.  
 
S100A9 and S100A8 (albeit at low levels) mRNA was detected in non-differentiated MSCs, and whilst 
S100A9 was decreased during chondrogenic, osteogenic and adipogenic differentiation, S100A8 was 
increased at 14 and 21 days after initiation of chondrogenic differentiation. This is in agreement with 
the immunostaining described in Chapter 6 in Section 6.3.3, where abundant expression of S100A8 
protein was observed in osteophytes and in cells at the joint margins. The sporadic expression of 
S100A9 in cells at these regions suggests that these cells may be non-differentiated MSCs, whilst the 
majority may have differentiated into cartilage/bone cells of varying degrees of maturity. It is 
unknown whether MSCs from non-OA patients express S100A8 and/or S100A9, and therefore 
whether the decrease in S100A9 and increase in S100A8 gene expression during chondrogenic 
differentiation would be replicated in bone marrow aspirates from healthy individuals. 
 
Since S100A8 increased during chondrogenesis, it was expected that the addition of exogenous 
S100A8 to pellet cultures would enhance the chondrogenic differentiation process. This has been 
shown by Schelbergen et al. [339], where human fetal mesenchymal stem cells treated with S100A8 
and cultured for five days in chondrogenic media accumulated more proteoglycans (as measured by 
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safrannin O staining) compared to untreated cells. In contrast to these findings, our results showed 
decreased chondrogenic and terminal differentiation markers in cells from two patients treated with 
S100A8; and one out of the three patient’s cells assessed using immunohistochemistry showed clear 
differences between non-treated and S100A8-treated pellets in terms of chondrogenic matrix 
deposition. The difference in results between the current study presented in this chapter and those 
by Schelbergen et al. could be due to a number of factors: the age and disease status of cells – fetal 
MSCs would have a much greater regenerative potential than cells derived from older, diseased 
patients; the culture period – 21-day cultures (our study) compared to early five-day cultures; and 
the concentration of S100A8 used – a much lower concentration ≈0.1µg/ml in our studies, compared 
to 1 or 5µg/ml). Our results suggest two things: firstly, there was no evidence that the addition of 
S100A8 enhanced chondrogenesis; and secondly that biological variation between patients affects 
the response of MSCs to S100A8 treatment. Significant variation in chondrogenic potential of bone 
marrow-derived MSCs has been shown in healthy bovine samples [347], and it is expected that 
variation would be even greater in the human population. 
 
Bone marrow is not the only source of MSCs in the articular joint; MSC-like populations have been 
found in the infrapatellar fat pad [348], surface zone of cartilage [349], ligaments such as the 
anterior cruciate ligament [350, 351], meniscus, muscle [351], periosteum [344] and in the synovium 
[351, 352]. MSC-like cells are also found in OA synovial fluid, whereas they are barely detectable in 
synovial fluid from healthy joints, suggesting that they are released from damaged/disrupted joint 
structures [347, 353, 354]. The inherent differentiation potential may differ between cells from 
different origins, and minor phenotypic differences would be present [355]. During osteophyte 
formation, MSCs likely originate from periosteum and synovial membrane [338], rather than from 
bone marrow, and these cells may differ in their chondrogenic potential or mechanisms of action to 
that of bone marrow-derived MSCs, and could also have different expression and response to 
S100A8 and S100A9 in vivo. The samples immunostained in Chapter 6 for S100A8 and S100A9 
represented end-stage disease from patients undergoing TKA, and many had mature osteophytes on 
the joint margins. Based on the abundant positive staining for S100A8 in these regions, this may 
suggest that S100A8 plays a role in late development of osteophytes rather than early 
chondrogenesis stages. Interestingly, the S100A8/A9 heterodimer had very little effect on pellet 
formation, in fact increasing collagen type II mRNA expression, which is in agreement with the data 
obtained throughout the experiments in this thesis. This further supports the hypothesis that it is 
only when S100A8 and S100A9 form homodimers rather than the heterodimer, which may be more 
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likely when expression of the two proteins is uncoupled, that the non-inflammation-related effects 
are seen in joint tissues. 
 
Taken together, data obtained in this chapter demonstrated that human bone-marrow derived MSCs 
from OA patients had tri-lineage capability, and expressed S100A8 and S100A9. During 
differentiation (chondrogenic, osteogenic and adipogenic), S100A9 mRNA was decreased, whereas 
S100A8 mRNA increased only during chondrogenic differentiation. Unexpectedly, the addition of 
exogenous S100A8 to chondrogenic pellet cultures either had no effect or decreased chondrogenic 
potential, and the response of MSCs to S100A8 varied across different patients (results summarised 
in Figure 7.9). A limitation of this study was that no healthy control samples were able to be 
obtained to determine if the results were specific to MSCs derived from OA patients. It would be of 
interest to determine the effect of S100A8 and S100A9 on MSCs derived from other joint tissues 
such as periosteum and synovium, as these cells are the ones that stained positive for S100A8 in OA 
joint margins and are known to participate in osteophyte formation. Due to biological variation 
causing inconsistent effects of S100A8 on chondrogenesis, it would also be beneficial to increase the 
sample size in order to fully determine the effect of S100A8 on chondrogenesis of bone-marrow 
derived MSCs.  
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Figure 7.9: Bone marrow-derived MSCs expressed increased S100A8 gene expression and decreased S100A9 
gene expression during chondrogenic differentiation. When chondrogenic pellets were cultured in S100A8, 
there was either a decrease or no change in chondrogenic potential.  
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Chapter 8 Conclusions and Future Directions 
The research presented in this thesis investigated the potential role of S100A8, S100A9 and 
S100A8/A9 in cartilage degradation similar to that seen in OA, the potential mechanisms of action of 
these proteins, and how S100A8 and S100A9 interact with other factors to enhance cartilage 
degradation. 
 
8.1 Summary 
In summary, the unique findings of this research were: 
1. S100A8 and S100A9 homodimers, but not the S100A8/A9 heterodimer, caused a shift to a 
catabolic gene expression profile in cartilage explant cultures, by up-regulating MMPs and 
ADAMTS, with no regulation of their inhibitors, TIMPs; and down-regulation of matrix 
molecules aggrecan and collagen type II. 
2. Gene regulation of MMPs and ADAMTS was initiated early (day one) in culture periods by 
S100A9, and decreased over time, whereas S100A8 treatment caused sustained changes in 
gene expression over two week culture periods. 
3. S100A8 and S100A9 up-regulated gene expression of S100A9 in cartilage explant cultures, 
forming a positive feedback loop. 
4. S100A8 gene expression was only up-regulated by IL-1α at early time points (one and two 
days) in cartilage explant cultures, and could not be induced by S100A8 or S100A9 
treatment. 
5. S100A8 and S100A9 alone were not able to cause activation of ADAMTS-4, ADAMTS-5, pro-
MMP-2, -MMP-9, or -MMP-13 in cartilage explant cultures at any time over two week 
culture periods. 
6. S100A8 and S100A9 alone could not cause biochemical aggrecan or collagen degradation in 
cartilage explant cultures at any time over the two week culture periods. 
7. S100A8- and S100A9-induced gene regulation was blocked by MAPK pathway inhibitors 
(inhibiting MEK, p38, MEK1/2) in chondrocyte monolayer cultures, demonstrating that 
MAPK pathways are activated by S100A8 and S100A9 in chondrocytes. 
8. S100A8- and S100A9-induced gene regulation of MMPs and ADAMTS was blocked by TLR4 
inhibitors in chondrocyte monolayer culture, whereas aggrecan and collagen type II down-
regulation was not affected, demonstrating that the TLR4 signalling pathway is activated by 
S100A8 and S100A9 in chondrocytes, but may not be involved in regulation of biosynthesis. 
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9. DMSO had a toxic effect on chondrocytes in cartilage explant cultures at concentrations 
>2.5%. 
10. Determining signalling pathways using small molecule synthetic inhibitors in cartilage was 
problematic; however, similar trends were shown in cartilage explant cultures as were seen 
in chondrocytes using MAPK inhibitors for MEK and MEK1/2, suggesting that the same 
signalling pathways were activated by S100A8 and S100A9 in cartilage explant cultures as in 
chondrocyte monolayer cultures.   
11. Co-treatment with S100A8, S100A9 or S100A8/A9 and IL-1α on cartilage explant cultures 
caused similar results to treatment with IL-1α alone, with no additive effect when both 
molecules were used at usual concentrations. 
12. Co-treatment with S100A8, S100A9 or S100A8/A9 and IL-1α on cartilage explant cultures did 
not differ from treatment with S100A8, S100A9 or S100A8/A9 alone when sub-optimal 
doses of IL-1α are used. 
13. Co-culturing synovium explants with cartilage explants caused an increase in catabolic gene 
expression, MMP protein expression and activation, and biochemical matrix breakdown. Co-
cultures treated with S100A9 enhanced up-regulation of MMP-2 mRNA, down-regulation of 
TIMP-3 mRNA, activation of pro-MMP-9 and -MMP-13, and degradation of aggrecan. 
14. Human OA cartilage explants treated with S100A8, S100A9 or S100A8/A9 showed similar 
trends to healthy ovine cartilage explants, with changes in gene expression levels of MMPs 
and ADAMTS. 
15. S100A8 and S100A9 alone were not capable of causing an increase in pro-MMP-2, -MMP-9 
or -MMP-13 production, activation of pro-MMP-2 or -MMP-9, or aggrecan breakdown, 
however S100A9 treatment caused activation of pro-MMP-13 and collagen breakdown in 
human OA cartilage explants. 
16. S100A8 and S100A9 do not play prominent roles in non-inflammatory murine models of OA: 
S100A8 and S100A9 protein levels were increased one day after surgery only in DMM mice 
representing post-traumatic OA; no differences were seen in S100A8 or S100A9 staining in 
mice genetically modified to spontaneously undergo OA pathology. 
17. In human OA joints, chondrocytes, bone marrow cells, bone lining cells and cells located in 
osteophytes and at joint margins stained positive for S100A8, with occasional cells positive 
for S100A9 at joint margins. 
18. S100A8 mRNA was up-regulated during chondrogenic differentiation, but not osteogenic or 
adipogenic differentiation, whereas S100A9 mRNA was decreased during all three 
differentiation processes. 
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19. Addition of S100A8 to chondrogenic pellet cultures had variable effects on differentiation 
potential of bone marrow-derived MSCs from OA patients, either having no effect or 
decreasing/slowing chondrogenic potential. 
 
The studies outlined in this thesis have provided information about a novel two-message system in 
which S100A8 and S100A9 “prime” the cartilage by up-regulating catabolic genes, with a second 
message required to facilitate MMP activation and subsequent biochemical degradation. S100A8 is 
present in multiple joint tissues in human OA; however its role appears to be restricted to murine 
models of OA that have a prominent inflammatory component. Based on the findings outlined 
above, it seems unlikely that targeting of S100A8 and/or S100A9 would form the basis of an effective 
therapy for OA, however; perhaps targeting these proteins in combination with other therapies that 
target the second messenger may be worth considering. Figure 8.1 shows a schematic summary of 
the results obtained in this thesis. 
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Figure 8.1: Schematic representation of the results obtained in this thesis, showing mechanisms of action in 
cartilage explant culture systems, expression of S100A8 and S100A9 in OA, and the role of S100A8 and S100A9 
in chondrogenic differentiation. 
 
8.2 Questions arising from the research 
Some of the key questions unanswered and/or arising from this research include: 
1. How are S100A8 and S100A9 priming the cartilage for degradation and what is the second 
messenger: 
a. Why doesn’t the heterodimer have any effect on cartilage degradation? 
b. Are S100A8 and/or S100A9 binding to TLR4, and is there another binding partner 
that is activating MAPK pathways?  
c. Are synovial cells directly participating with chondrocytes via physical cues or cross-
talk, or are soluble factors acting in concert with S100A8 and S100A9? Is this 
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restricted to synovial tissue or would co-culture with other joint tissues have the 
same outcome? 
d. What is in human OA cartilage that is working synergistically with S100A9? 
e. Would other cytokines prevalent in OA work synergistically with S100A8 and 
S100A9? 
2. Are S100A8 and S100A9 only involved in the inflammatory component of arthritis, or is this 
only true in murine models of OA? 
3. Do S100A8 and S100A9 have an inhibitory or an enhancing effect on chondrogenesis?  Could 
this information be used in cartilage regeneration? 
a. Why is S100A8 present in cells in osteophytes and joint margins? 
b. Why were there large differences in the effect of S100A8 on bone marrow MSCs 
from different patients? 
 
8.3 Future Directions 
In order to answer the questions raised in response to the findings in this thesis, further work needs 
to be conducted. 
 
Firstly, to explore the reason why the heterodimer doesn’t have any effect on cartilage degradation 
where S100A8 and S100A9 homodimers do, it would be beneficial to study the protein configuration 
and binding sites; it is plausible to suggest that specific binding sites are exposed in the homodimers 
that are then hidden in heterodimer formation. One study suggests that formation of a 
heterotetramer is essential for activity in tubule formation [209], suggesting that the heterodimer is 
not active unless it is in a higher order oligomer. This could be explored by comparing the effect of 
the heterodimer and the heterotetramer on cartilage degradation in vitro. To further explore the 
signalling pathways activated by S100A8 and S100A9 in cartilage, further optimisation of the use of 
synthetic inhibitors in cartilage explants is required in order to obtain definitive outcomes. It would 
also be pertinent to explore RAGE as a binding partner for S100A8 and S100A9 in cartilage, despite 
controversial reports of its binding to S100A8 and S100A9. Of interest in this thesis was that S100-
induced down-regulation of aggrecan and collagen type II mRNA was inhibited by MAPK inhibitors 
but not TLR4 inhibitors, suggesting there may be a secondary binding partner other than TLR4 at play 
in cartilage. Other experiments to further explore the activation of MAPK, NF-κB and downstream 
signalling of TLR4 could be performed to examine if these pathways are activated. Lysates could be 
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collected from chondrocytes stimulated with S100A8 or S100A9 and immunoblotting experiments 
could be utilised to examine phosphorylation of different signalling proteins. Based on the evidence 
presented in Chapter 1 that S100A8 and S100A9 may bind to heparan sulphates, this could also be 
explored in more detail, perhaps using immunocytochecmistry techniques or co-
immunoprecipitation experiments to see if these proteins are binding. 
 
In Chapter 5, it was found that S100A9 had an additive effect on biochemical cartilage breakdown in 
co-cultures of synovium and cartilage, which raises the questions of whether S100A9 was 
synergistically working with a soluble factor secreted from synovium, or whether it was due to cross-
talk or physical cues directly from the synovium. This could be explored using transwell culture 
techniques to separate the two tissues, or by adding conditioned media from synovial cultures to 
cartilage explant cultures. Similarly, in the case of human OA explants, conditioned media could be 
added to healthy cartilage to determine if the factors present in the local environment are 
influencing the effect of S100A9, or whether the enhanced biochemical breakdown induced by 
S100A9 is due to the process of cartilage breakdown having already started in OA cartilage. In both 
cases, if conditioned media is found to be sufficient to cause biochemical cartilage breakdown in the 
presence of S100A9, techniques such as ELISA may be used to study the contents of the conditioned 
media and to determine exactly what is causing this effect. Alternative methods of searching for a 
second messenger would include co-treating cartilage with S100 and other cytokines such as TNFα, 
or with other molecules known to be MMP activators such as APC, or co-culturing cartilage with 
other joint tissues such as subchondral bone or infrapatellar fat pad. 
 
To explore whether S100A8 and S100A9 are only involved in more inflammatory sub-types of OA, or 
whether this is species-dependant, it would be useful to study animal models other than murine, as 
there seems to be little or no role for S100A8 and S100A9 in murine non-inflammatory OA. Post-
traumatic OA could be studied in animals such as dogs or sheep, and could provide evidence for or 
against this theory. Studies could involve anti-S100A8 or anti-S100A9 injection after induction of OA 
to determine whether this would be protective or not, as knockout models are obviously not 
possible in these species. A transgenic S100A9 mouse has now been developed [356], so this mouse 
could be used to study cartilage damage in various models of arthritis (AIA, CIA, DMM etc.). 
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Chapter 7 of this thesis explored the role of S100A8 and S100A9 in chondrogenic differentiation of 
bone marrow-derived MSCs from OA patients. Only three patients’ MSCs were able to be analysed, 
so it would firstly be of benefit to obtain cells from more patients in order to find a trend, and to 
culture these cells in chondrogenic culture for longer time points, looking at multiple time points. 
Longer culture periods and multiple time points would help to evaluate exactly which stages (if any) 
of differentiation are affected by S100A8 and/or S100A9. It would also be of interest to compare OA 
cells to healthy cells, to see if S100A8 and S100A9 have the same effect in both cases. The original 
plan for this study was to transfect MSCs with S100A8 or S100A9 using recombinant adeno-
associated retrovirus; however, this could not be achieved in the time frame available. This would be 
a good avenue to pursue, as the results would likely be less variable than adding exogenous S100 to 
the culture media, and the effect of intra-cellular versus extra-cellular S100 proteins may be 
different. Osteophytes are likely formed from MSCs from the periosteum and synovial lining, so it 
would be beneficial to obtain MSCs from these tissues and perform the same experiments to see if 
they respond differently to S100A8 and S100A9 treatment. 
 
In summary, the experiments performed in this thesis shed light on the role of S100A8 and S100A9 
in cartilage degradation and formation, furthering our limited understanding of why these immune-
related proteins are present in cartilage. The experiments performed in this thesis also raised more 
questions on the mechanisms of action of S100A8 and S100A9 in cartilage in vitro, and the roles of 
S100A8 and S100A9 in animal models of OA and in human disease, which may be answered by 
following the above suggestions. 
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